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“…view the lengthening odds with disdain and bloody well get 
on with it. You know it’s not easy, but it’s a challenge. Those that 
win for a living like a challenge.” 
Sir Steve Redgrave CBE, 5 Time Consecutive Olympic Gold Medallist, Diabetic. 
 
 
 
 
 
 
 ABSTRACT 
For patients with type 1 diabetes, a fear of hypoglycaemia and a concern over a loss of control 
with wider diabetes management are the most salient barriers to exercise participation and 
adherence. A large proportion of patients report a lack of advice for preventing post-exercise 
hypoglycaemia, and many feel largely uninformed about insulin administration and 
carbohydrate intake around aerobic-based exercise. Presently, recommendations within the 
literature are based predominantly on anecdotal and observational, but not empirical or 
interventional data. Therefore, this thesis aimed to develop a strategy that enables patients to 
effectively self-manage glycaemia following exercise, supported by evidence pertaining to the 
deeper physiological implications and consequences. 
Study one (chapter 3) revealed that under conditions of reduced pre-exercise rapid-acting 
insulin dose, it is also necessary to reduce post-exercise rapid-acting insulin administration by 
50% to prevent early-onset hypoglycaemia (≤ 8 hours post-exercise). Consequently, some 
patients experienced post-prandial hyperglycaemia with this intervention, although this was 
not associated with any other metabolic, counter-regulatory hormonal, or inflammatory 
disturbances. The results of study two (chapter 4) demonstrate that post-exercise meal 
composition, under conditions of reduced pre- and post-exercise rapid-acting insulin dose, 
carry important implications for post-prandial glycaemia. Specifically, consumption of low GI 
post-exercise carbohydrates normalise post-prandial hyperglycaemia, whilst protection from 
early onset hypoglycaemia is maintained. In addition, post-exercise meal composition heavily 
influences inflammatory markers; a high GI meal results in a pronounced inflammatory 
response, but a low GI meal completely prevented any rise in measured inflammatory markers. 
Lastly, study three (chapter 5) assessed the efficacy of a combined basal-bolus insulin 
reduction and low GI carbohydrate post-exercise feeding strategy. A 20% reduction in basal 
insulin provided full protection from hypoglycaemia for a total of 24 hours after exercise. 
Furthermore, ketonaemia did not increase to clinically meaningful levels, nor did inflammatory 
 markers rise above concentrations seen at rest or when exercising under usual basal dose. No 
other metabolic or counter-regulatory hormonal disturbances were observed following a 
combined dose reduction to basal-bolus insulin and low GI carbohydrate post-exercise feeding. 
Collectively, this thesis has shown that acute prandial adjustments in rapid-acting insulin and 
carbohydrate feeding, in combination with alterations in basal dose, are effective for managing 
post-exercise glycaemia and protecting patients from hypoglycaemia for a total of 24 hours 
after exercise. Moreover, this strategy aims to maintain euglycaemia by reducing post-prandial 
hyperglycaemia. This is not associated with clinically significant rises in ketonaemia, nor does 
it induce inflammatory, counter-regulatory hormonal, or other metabolic disturbances. 
Clinicians are advised to tailor these recommendations to a patient’s individual exercise 
preferences, fitness and exercise ability, level of diabetes management, and treatment regimen. 
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1.0 Introduction 
Somewhat simplistically, blood glucose concentrations are a function of the rate at which 
glucose enters the circulation (glucose appearance) and the rate at which glucose is removed 
from the circulation (glucose disappearance). If the rate of glucose disappearance exceeds the 
rate at which glucose appears, blood glucose concentrations will fall, and hypoglycaemia 
(blood glucose concentration <3.9 mmol.l-1) will ensue (Cryer 1997). Although blood glucose 
naturally fluctuates during the day, concentrations are maintained within tight physiological 
limits (3.9-7.9 mmol.l-1), achieved through the regulation of insulin release from the pancreatic 
β-cells. Defects in insulin secretion, insulin action, or both, consequently result in blood 
glucose excursions outside of these physiological ranges. The clinical classification of this is 
Diabetes Mellitus, a heterogeneous group of diseases with the common feature of glycaemic 
dysregulation. Whereas Type 2 is generally characterised by insulin resistance, Type 1 
diabetes results from an absolute deficiency of insulin secretion due to an autoimmune 
destruction of the insulin secreting pancreatic β-cells. This is, at present, irreversible, and 
means that patients are ultimately dependent upon exogenous insulin replacement.  
Adjunct to conventional insulin therapy, exercise may also be an important component of a 
patient’s therapeutic regimen (Lehmann et al. 1997, Wiesinger et al. 2001, Stettler et al. 2006, 
Rachmiel et al. 2007, Gulve 2008, Maahs et al. 2009), providing numerous physiological 
benefits (Wasserman and Zinman 1994, Choi and Chisholm 1996, Praet et al. 2006, Manders 
et al. 2010, Maarbjerg et al. 2011, Van Dijk et al. 2012)  associated with preventing and 
regressing diabetes related complications (Wasserman and Zinman 1994, Kulenovic et al. 
2006, Fowler 2008). In spite of these benefits, exercise induces vast metabolic disturbances, 
often predisposing patients to hypoglycaemia (blood glucose ≤3.9 mmol.l-1) for as long as 24 
hours after exercise (Macdonald 1987, Steppel and Horton 2003, Tsalikian et al. 2005), and 
particularly at night (Mcmahon et al. 2007). Compared to their type 2 counterparts, patients 
with type 1 diabetes often want to exercise, but unfortunately have the highest risk of 
developing hypoglycaemia. Presently, incorporating exercise into the lives of type 1 diabetes 
3 
 
Figure 1.0 A-C. Islet of Langerhans during type 1 diabetes progression. A depicts healthy β-cells with 
abundant insulin content (β-cells, green) with α-cells (yellow), purple (ducts) and cyan (vasculature). B 
depict healthy β-cells as well as exhausted β-cells with empty granules, infiltration of leukocytes and β-
cell phagocytosis. C end stage diabetes consists primarily of α-cells, with reduced leukocyte count. 
Images reproduced with permission from Ravelli (2013). 
A B C 
patients is confounded by a lack of evidence-based recommendations for self-managing post-
exercise glycaemia. In light of this, there is a need to develop comprehensive strategies which 
enable type 1 diabetes patients to effectively manage glycaemia after exercise. 
1.1 Type 1 diabetes mellitus 
The immune system is equipped with T cells (or T lymphocytes), which, under normal 
circumstances play an integral role in cell-mediated immunity by controlling or eliminating 
autoantigens (Van Parijs and Abbas 1998, Morran et al. 2008). In type 1 diabetes, self-reactive 
T cells, specifically CD4+ and CD8+ T cells (Knip and Siljander 2008), destroy the insulin 
secreting pancreatic β-cells, whereby the immune system’s ability to recognise self-pancreatic 
tissue is lost (Morran et al. 2008). The T cells expand and migrate from local draining lymph 
nodes and infiltrate the islets (Figure 1.0 A-C) causing chronic inflammation (insulitis), 
followed by the gradual deterioration of the β-cells and a reduction in insulin content (Figure 
1.0 B) (Foulis et al. 1991). As the disease progresses the immunoreactivity spreads, such that 
by the time that symptoms present and diagnosis is made, 90-95% of β-cells have been 
destroyed (Daaboul and Schatz 2003, Atkinson 2005) (Figure 1.0 C). At this point endogenous 
insulin production is severely diminished or completely undetectable (Figure 1.0 C) (Daaboul 
and Schatz 2003). Patients are now in metabolic dysregualtion and require exogenous insulin 
therapy to control blood glucose concentrations. 
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1.1.1 Aetiology of type 1 diabetes mellitus 
Type 1 diabetes is a complex disease in which there is a strong genetic component, but also 
non-genetic factors including environmental exposure and stochastic events play part (Knip 
and Åkerblom 2009). To an extent, genetic risk can be estimated from family history and the 
presence of particular alleles of genes, so much so that the disease is partially predictable in 
genetically susceptible individuals more than any other common autoimmune disease (Anaya 
et al. 2006). Present in most patients are two characteristics, namely at least one susceptible 
human leukocyte antigen (HLA) class II haplotype (Ziegler and Nepom 2010), and islet 
autoantibodies (Ziegler et al. 1999). Indeed, the vast majority of genetic susceptibility is 
accounted for by loci within the HLA, however meta-analyses and genone-wide association 
studies indicate that over 40 HLA and non-HLA loci are involved (Ziegler and Nepom 2010). 
More than 85% of newly diagnosed patients have islet autoantibodies (Van Belle et al. 2011), 
the development of which is sequential (Ziegler et al. 1999) and arguably the most important 
change in the risk status of type 1 diabetes. Importantly, the appearance of autoantibodies at an 
early stage is positively related to the rate of disease progression (Hummel et al. 2004) (Figure 
1.1), with a high risk of developing autoantibodies early in life (Bingley 1996). Interestingly, 
autoantibodies are unlikely to present in individuals younger than 6 months, and even in those 
with familial autoantibody appearance, concentrations do not peak until 18 months (Naserke et 
al. 1999, Hummel et al. 2004, Achenbach et al. 2006) suggesting that islet autoimmunity is 
triggered by events after birth and therefore influenced by environmental exposure. 
The role of environmental exposure in the pathogenesis of type 1 diabetes is further supported 
by the rate at which the incidence of the disease is increasing, a rate at which genetic change 
alone cannot be solely accountable (Ma and Chan 2009, Patterson et al. 2009, Patterson et al. 
2012, Roche et al. 2013). Within the literature, there are a number of environmental factors 
believed to be involved which could act in utero and thereafter, including: dietary factors 
(consumption of cereal proteins and cow milk proteins, low vitamin D and zinc) (Knip et al. 
2010, Marjamäki et al. 2010, Samuelsson et al. 2011, Virtanen et al. 2012, Chiu and Beyan 
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2013, Atkinson et al. 2014), enteroviruses (Tracy et al. 2010, Atkinson et al. 2014, Dunne et 
al. 2014), changes in the composition of gut microbiota (Atkinson and Chervonsky 2012), 
seasonal changes (Svensson et al. 2009, Haynes et al. 2012; Dunne et al. 2014), the “hygiene 
hypothesis” (Okada et al. 2010, Virk et al. 2010), and even traumatic life events. 
1.1.2 Clinical presentation of type 1 diabetes mellitus 
Commonly, the disease occurs during childhood or adolescence and was therefore aptly named 
“juvenile diabetes”; it can in fact occur at any age. This is likely due to the variability in the 
progression of the disease, which is dependent upon the rate of β-cell deterioration (Von 
Herrath et al. 2007, American Diabetes Association 2011) although this tends to occur more 
rapidly in younger individuals. The pre-clinical phase, in which the disease starts and matures, 
typically occurs over a period of at least 2 years (Thrower and Bingley 2011). During this time 
there is gradual decline in stimulated C-peptide levels (a hallmark of endogenous insulin 
production) and a deterioration in glucose tolerance (Thrower and Bingley 2011), although 
patients are largely asymptomatic (Sosenko et al. 2006). Indeed, diagnosis is typically made 
when symptoms surface (hyperglycaemia and / or ketoacidosis) (Sosenko et al. 2006) at which 
point 90-95% of β-cells have been destroyed (Daaboul and Schatz 2003, Atkinson 2005). 
Although some residual β-cell function may be retained following diagnosis, and some insulin 
secretion may persist even in long-standing type 1 diabetes (Oram et al. 2014), usually ~99% 
of cells have been destroyed after a further 2 years (Meier et al. 2005). Ultimately, patients are 
dependent upon daily exogenous insulin administration and remain bound to this for the 
remainder of their lives.  
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1.1.3 Treatment of type 1 diabetes mellitus with exogenous insulin therapy 
The purpose of insulin therapy is to mimic normal physiological insulin secretion by providing 
a basal insulin replacement together with insulin boluses to control post-prandial glucose 
excursions. Amino acid modification to the structure of the insulin molecule produces 
alterations in its biological properties (Drejer et al. 1991) which affect its absorption from the 
site of injection (Dimarchi et al. 1994, Lepore et al. 2000). Modern insulin analogues with 
improved pharmacodynamic and pharmacokinetic properties have allowed for an 
intensification in insulin therapy in recent years, with insulin regimens closer emulating 
physiological action-time profiles with lower within-subject variability (Heise et al. 2004), 
fewer glycaemic fluctuations (Gerich et al. 2006), and improved glycated haemoglobin 
(HbA1c; gold standard marker of diabetes control) (Siebenhofer et al. 2006) than longer 
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established exogenous insulins (Ratner et al. 2000, Vague et al. 2003, Ashwell et al. 2006, 
Kølendorf et al. 2006). 
In the UK, patients are predominantly treated with a basal-bolus regimen, injecting two types 
of insulin analogues (Mcintyre et al. 2010). The basal replacement aims to provide a 
continuous, reproducible and stable supply of insulin into the circulation to suppress excessive 
post-absorptive hepatic glucose production (Vajo and Duckworth 2000) and prevent excessive 
lipolysis (Rahn et al. 1994) and ketogenesis (Laffel 2000). This is achieved by injecting 
insulin, such as insulin Glargine (Lantus, Sanofi-Aventis), or Detemir (Levemir, Novo 
Nordisk), which is slowly absorbed from subcutaneous tissue and has a protracted action time-
course. Although Glargine and Detemir are different chemical and structural entities (Bolli et 
al. 1999), a single dose carries similar metabolic effects over the initial 12 hours following 
administration (Porcellati et al. 2007), reaching a metabolic plateau 3-6 hours after injection 
(Heinemann et al. 2000, Lepore et al. 2000, Rave et al. 2003, Klein et al. 2007).  
 
 
 
 
 
 
Beyond this time, pharmacodynamic and pharmacokinetic properties differ between these two 
long-acting insulins, with Glargine remaining in a steady state activity close to 100% for 24 
Figure 1.2. Representation of acute glycaemic control in a type 1 diabetes patient under treatment with 
a basal-bolus regimen. Light blue trace = basal insulin, dark blue trace = bolus insulin, red trace = 
glycaemia (interstitial glucose). CGM trace taken from an individual with type 1 diabetes during data 
collection. 
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hours, and possibly longer (Porcellati et al. 2007), whereas Detemir exhibits a progressive 
decrease in activity to ~55% by 24 hours post-administration (Porcellati et al. 2007). 
Therefore, basal dose and timing is an important clinical consideration for patients.  
Prandial insulin requirements are provided by injecting a bolus of a readily absorbed, rapid-
acting insulin analogue (insulin Lispro or Aspart) that controls post-prandial glucose 
excursions. However, maintaining insulin levels at a concentration that keeps blood glucose 
close to euglycaemia without necessarily increasing the risk of hypoglycaemia is the most 
challenging aspect of insulin therapy. Bolus insulin titration is based on estimation of 
carbohydrate amount (DAFNE Study Group 2002; Mcintyre et al. 2010) with patients using an 
individualised carbohydrate-to-insulin ratio to determine meal-time insulin doses. However, 
this method does not take into consideration the composition of carbohydrate. As such, there is 
often a mismatch between the absorption of bolus insulin and the appearance of carbohydrate 
into the circulation. Therefore, patients still struggle to adequately control blood glucose and 
the risk of hypoglycaemia remains, despite the intensification of insulin therapy. 
1.1.4 Epidemiology of type 1 diabetes mellitus 
Today, an estimated 366 million people worldwide are affected by Diabetes (Diabetes UK 
2012). Of those, ~40 million (10% to 20%) of patients have type 1 diabetes (Rewers 2012). 
With the prevalence in the UK expected to rise up to 1 million by 2015 (Quality of Outcomes 
Framework 2011). Type 1 diabetes is associated with higher relative morbidity and mortality 
rates and health care costs than type 2 diabetes. At present, it is estimated that diabetes care 
alone costs the National Health Service (NHS) an estimated £25 million per day, which 
equates to £1 million per hour, or £286 per minute. This excludes social service costs such as 
residential home help services and nursing care. Clearly, diabetes is a huge burden upon public 
spending.  
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1.1.5 Complications arising from type 1 diabetes mellitus: implications for glycaemic control 
Diabetes is the fifth most common cause of mortality in the world (Roglic and Unwin 2010) 
accounting for an estimated 15% of all deaths occurring in England (National Diabetes Audit 
2011). Life expectancy is reduced by more than 20 years in individuals with type 1 diabetes 
(Diabetes UK 2012), and patients are exposed to a host of co-morbidities. For example, within 
20 years of diagnosis, almost all patients with type 1 diabetes have a degree of retinopathy, 
over 44% of diabetics die from cardiovascular disease, and 21% from renal disease (Diabetes 
UK 2012). Approximately 50% of patients have neuropathy, with one in twenty developing 
foot ulcers, of which one in ten ulcers require amputation of the foot or leg (Diabetes UK 
2012); up to 70% of these patients die within five years as a result of diabetes (Bate and 
Jerums 2003). In addition, patients are susceptible to other autoimmune disorders such as 
Graves’ disease, Hashimoto’s thryoditis, and Addison’s disease (Anaya et al. 2006), and 
depression and sexual dysfunction are twice as high in this population (Tagliabue et al. 2011, 
Morgan et al. 2014). 
1.2 Exercise and type 1 diabetes 
The American Diabetes Association (ADA) and Diabetes UK encourage patients to engage in 
physical activity of all levels, including leisure activities, recreational exercise and competitive 
sports. General guidelines advocate patients perform ~150 minutes per week of moderate 
intensity aerobic exercise, 90 minutes of vigorous aerobic exercise, or a combination of the 
two (Thompson et al. 2009). This roughly translates to 20-45 minutes of moderate-to-high 
intensity aerobic exercise 5-7 days per week (Thompson et al. 2009).  
1.2.1 Benefits of exercise to type 1 diabetes patients 
Regular exercise plays an important role in maintaining a “healthy” lifestyle as well as 
preventing and treating diseases. Indeed, there is a strong negative correlation between 
exercise and the risk of disease and premature death in both healthy individuals (Warburton et 
10 
 
al. 2006), and those with type 1 diabetes (Moy et al. 1993). This is because exercise is strongly 
associated with improvements in a range of health outcomes; to name but a few, exercise 
results in increased levels of aerobic fitness (Komatsu et al. 2005), increased lean mass 
(Wasserman and Zinman 1994, Choi and Chisholm 1996), reductions in blood pressure 
(Whelton et al. 2002), improved autonomic tone and augmented cardiac function (Davison et 
al. 2002, Petersen and Pedersen 2005), reduced blood coagulation (Kupchak et al. 2013), 
improved coronary blood flow (Sonnenschein et al. 2011), improvements in lipid profiles 
(Kelley et al. 2012), enhanced endothelial function (Sonnenschein et al. 2011, Dubé et al. 
2012), and reduced systemic inflammation (Loimaala et al. 2003, Lucini et al. 2012). 
Potentially, these benefits may be of great importance to those with type 1 diabetes as 
macrovascular (coronary artery disease, peripheral arterial disease, and stroke) and 
microvascular complications (diabetic nephropathy, neuropathy, and retinopathy) are a major 
cause of morbidity and mortality (Wasserman and Zinman 1994, Kulenovic et al. 2006, 
Fowler 2008). In addition, exercise has profound effects on insulin sensitivity and glucose 
metabolism (Praet et al. 2006, Manders et al. 2010, Van Dijk et al. 2012), with studies 
indicating less daily insulin requirements and a need to reduce the insulin-to-carbohydrate ratio 
(Ebeling et al. 1995, Fuchsjäger-Mayrl et al. 2002, Sideravičiūtė et al. 2006). Thus, exercise 
has the capacity to improve quality of life in patients, and potentially aid in diabetes 
management. 
1.2.2 Exercise and glycaemic control 
Unfortunately, the benefits of exercise on long-term glycaemic control are less clear. Two 
recent meta-analyses provide conflicting conclusions, either a beneficial effect (Tonoli et al. 
2012), or no effect at all (Kennedy et al. 2013) (when measured by absolute change in HbA1c 
values). In addition, a number of stand-alone studies demonstrate worsening glycaemic control 
with exercise training (Huttunen et al. 1989, Ebeling et al. 1995, Ramalho et al. 2006). This 
may, at least in part, be explained by variation in the exercise intervention employed in studies. 
Indeed, mixed study methodologies (type of exercise, diet, insulin administration, length of 
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intervention, patient characteristics) hampers the ability to draw conclusions from this body of 
evidence. However, when data are pooled, there is a trend, albeit not statistically significant, 
for a reduction in HbA1c (%HbA1c:  0.3, 95%CI = -0.59-0.09, p =0.144) when exercise of an 
aerobic nature is performed, and interventions are carried out over longer periods of time 
(Tonoli et al. 2012, Kennedy et al. 2013).  
The majority of these studies report an increase in calorie intake. Although this may be due to 
changes in appetite (Dubé et al. 2014), most of the authors report additional carbohydrate 
consumption to avoid post-exercise hypoglycaemia (for review see Kennedy, Nirantharakumar 
et al. (2013)). This is unsurprising considering patients with type 1 diabetes experience severe 
blood glucose variability around the time of exercise (Gordin et al. 2008, Kapitza et al. 2010). 
Glycaemic variability occurs because of an inability to manage hypoglycaemia, a condition 
which is now considered an independent risk factor for diabetes related complications (Jaiswal 
et al. 2012). If exercise-induced hypoglycaemia can be managed, then euglycaemia would be 
more easily achievable, and patients would have near normal HbA1c (Cryer 2010). 
However, HbA1c may not be the most appropriate marker of glycaemic control, especially in 
patients who lead an active lifestyle. HbA1c is the gold standard for assessing long-term 
glycaemic control; the method uses the enzymatic glycation pathway by which circulating 
blood glucose is bound to haemoglobin. Erythrocytes, which are rich in haemoglobin, are 
present in the blood for ~100 days (Shemin and Rittenberg 1946), therefore the amount of 
glucose bound to haemoglobin offers a good clinical bio-marker of the average blood glucose 
concentration over a ~3 month period. However, this measure does not reflect daily glycaemic 
variability (Figure 1.3), specifically the severity of glycaemic excursions (Nalysnyk et al. 
2010). This has prompted the use of a range of glycaemic variability indices (Rodbard 2009). 
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Glycaemic variability is suggested to exhibit a greater effect on oxidative stress (Monnier et al. 
2006), and also acute and chronic changes in inflammation (Erbağci et al. 2001, De Rekeneire 
et al. 2006) opposed to exposure to chronically-sustained hyperglycaemia. This is important 
because changes in these parameters are heavily associated with vascular complications 
(Giugliano et al. 1996, Saraheimo et al. 2003, Devaraj et al. 2007, Wentholt et al. 2008). 
Although exercise training has been demonstrated to reduce systemic inflammation (Petersen 
and Pedersen 2005), and increase protection against oxidative stress (Cooper et al. 2002), 
somewhat paradoxically, these long-term adaptations occur despite opposing acute effects in 
which there is a pronounced increase in inflammatory cytokines early after exercise (Sprenger 
et al. 1992, Drenth et al. 1995, Nehlsen-Cannarella et al. 1997, Ostrowski et al. 1998, 
Ostrowski et al. 1999, Nemet et al. 2002, Turner et al. 2014). Thus, an inability to effectively 
manage post-exercise glycaemia may in fact offset a number of associated health benefits and 
precipitate deeper metabolic, hormonal and inflammatory disturbances. This may offer some 
Figure 1.3. Representation of glycaemic variability over a 24 hour period in a type 1 diabetes patient. 
Red trace = interstitial glucose. CGM trace taken from a type 1 diabetes patient during data collection. 
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explanation towards the divergent opinion surrounding the efficacy of exercise on long-term 
glycaemic control and progression of diabetes complications in active type 1 diabetes patients 
(Rosa et al. 2010, Padgett et al. 2013). 
1.3 Hypoglycaemia and exercise 
The physical symptoms of hypoglycaemia (blood glucose <3.9 mmol.l-1) range from 
unpleasant feelings such as anxiety, hunger, palpitations, tremor, and paraesthesia, to 
neurological impairments including changes in behaviour, cognitive dysfunction, seizures, 
coma and death. Hypoglycaemia, which is widely acknowledged as the limiting factor in the 
management of type 1 diabetes (Davis et al. 1997, Cryer 1999, Cryer 2008, Cryer 2010), is a 
frequent and dangerous occurrence which is long associated with exercise (Macdonald 1987, 
Malik and Taplin 2014). So much so, exercise is the most frequently identified specific cause 
of severe hypoglycaemia (Bhatia and Wolfsdorf 1991), that which is not only debilitating, but 
life threatening. In addition, the threat of hypoglycaemia is not only limited to during exercise, 
but may persist for many hours after (Macdonald 1987, Steppel and Horton 2003, Tsalikian et 
al. 2005, Mcmahon et al. 2007) particularly at night (Mcmahon et al. 2007, Taplin et al. 2010). 
Unsurprisingly, patients often avoid exercise due to a fear of hypoglycaemia (Dubé et al. 2006, 
Brazeau et al. 2008, Cryer 2008); two thirds of patients currently fail to achieve the minimal 
amount of exercise needed for good health (Plotnikoff et al. 2006). It is therefore important 
that patients feel empowered to exercise, and providing strategies that enable patients to 
engage in exercise without fear of hypoglycaemia may aid in this endeavour. 
1.3.1 Physiological mechanisms preventing exercise-induced hypoglycaemia in individuals 
without diabetes 
Skeletal muscles are tissues that convert chemical energy to mechanical work through 
muscular contractions. To perform muscular contractions, a vast increase in energy turnover is 
required, such that during exercise, the metabolic demands of skeletal muscle can increase 
100-fold (Sahlin et al. 1998). Generally, this energetic challenge is met by the oxidation of 
14 
 
carbohydrates and lipids (Holloszy and Kohrt 1996, Richter et al. 2001, Kiens 2006), with 
carbohydrate, in the form of glucose derived from the circulation and intramuscular glycogen 
stores, becoming the predominant fuel source with increasing exercise intensity. 
Exercise of a moderate intensity (~55-75% V̇O2max), involving the rhythmical contraction and 
relaxation of large muscle masses performed over a prolonged period of time is considered 
“aerobic” exercise. This is because fuels are hydrolysed and metabolised in the presence of 
oxygen in the mitochondria of muscle cells for subsequent resynthesis to adenosine 
triphosphate (ATP). Initially, aerobic exercise is fuelled predominantly by muscle glycogen 
before non-esterified fatty acids (NEFA) and blood glucose become the major fuel sources. 
The reliance upon NEFA and circulating blood glucose increases with exercise duration, as 
does gluconeogenesis and the breakdown of hepatic glycogen for uptake and use by the 
exercising musculature and maintenance of blood glucose. As exercise duration lengthens, 
relative exercise intensity increases despite a constant absolute workload. Thus, with 
prolonged continuous moderate-to-high intensity exercise, muscle glycogen is predominantly 
utilised (Jeukendrup 2014).  
As muscle glycogen concentrations begin to deplete, overall contribution of carbohydrate to 
fuel metabolism is maintained by increasing glucose extraction from the circulation for uptake 
into musculature, via an increase in insulin-independent translocation of glucose transporter 
proteins (GLUT 4) to the surface of the muscle cell (Wojtaszewski et al. 2002). As the central 
nervous system relies heavily upon a continuous blood glucose supply to meet its energy 
requirements (Longo and Cryer 2013), it is important that blood glucose concentrations are 
maintained within normal physiological limits to ensure a constant supply. To do this, high 
levels of glucose production are necessary (Wasserman 2009). This is achieved by 
orchestrating a complex and well-coordinated neuroendocrine and autonomic nervous system 
response (Figure 1.4) that facilitates counteractive responses to decrements in blood glucose, 
and ultimately prevents hypoglycaemia. 
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In the post-absorptive state, liver release of glucose (hepatic output), through glycogenolysis 
and gluconeogenesis, is the primary means by which blood glucose is sustained during 
exercise (Wahren et al. 1971, Bergeron et al. 1999). Although the kidneys also produce 
glucose during exercise, renal output is negligible (Wahren et al. 1971) meaning maintenance 
of blood glucose is largely determined by the control of hepatic output which occurs through a 
change in the insulin-to-glucose output ratio (Battezzati et al. 2009). The normal physiological 
response to falling blood glucose includes a decrease in insulin concentrations, and an increase 
in glucagon, release of catecholamines from the adrenal medulla and sympathetic nerve fibres, 
cortisol from the adrenal cortex, and anterior pituitary release of growth hormone, which, 
collectively counteract falling blood glucose (Figure 1.4, Table 1.0) (Cryer and Gerich 1985, 
Cryer 2012). A reduction in insulin concentrations and an increase in counter-regulatory 
hormones also act to combat stimulation of muscle glucose uptake during exercise. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Normal physiological hierarchic counter-regulatory hormonal responses to falling blood 
glucose. Data taken from Cryer (Cryer 2002) and presented as mean. Note: Samples were taken from 
arterialised-venous blood. 
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1.3.2 Pathophysiological mechanisms of exercise-induced hypoglycaemia in type 1 diabetes 
For patients with type 1 diabetes, circulating insulin concentrations are the result of the 
previously administered insulin dose, and are therefore unregulated and do not decrease in 
response to falling blood glucose concentrations or exercise. As such, patients are likely to be 
exercising under relatively hyperinsulinaemic conditions, with insulin levels well in excess of 
those seen in non-diabetic individuals (Chokkalingam et al. 2007). Additionally, exercise 
causes marked hypereamia (Sjøberg et al. 2011) and increases in temperature (Koivisto 1980). 
This results in an increased delivery of glucose to the working muscle (Wasserman et al. 2011, 
Richter and Hargreaves 2013) and an increased permeability of the muscle to glucose (Hamrin 
et al. 2011, Wasserman et al. 2011) which collectively enhance the capacity for glucose 
exchange (Hamrin et al. 2011). This heamo- and thermodynamic effect not only increases the 
delivery of glucose, but of all blood constituents including insulin, and causes an accelerated 
absorption of the previously administered dose from subcutaneous tissue (Koivisto and Felig 
1978, Koivisto 1980, Lauritzen et al. 1980, Wojtaszewski et al. 2002). Furthermore, skeletal 
muscle, which represents approximately 40-45% of total body mass (Hargreaves and Hawley 
2003), comprises the bulk of insulin-sensitive tissue (Galbo et al. 1975) and is a site of 
enhanced sensitivity to insulin, resulting from muscular contraction induced (and insulin 
independent) GLUT-4 recruitment (Galassetti et al. 2001). Therefore, patients are likely to 
experience an increase in potency of the previously administered insulin dose during exercise. 
Together, the superimposition of hyperinsulinaemia and muscle contraction exert a synergistic 
stimulatory effect on glucose uptake and carbohydrate metabolism (Galbo et al. 1975, 
Wasserman et al. 1991, Chokkalingam et al. 2007).  
Insulin inhibits the counter-regulatory response to falling blood glucose even in healthy 
individuals (Hirsch et al. 1991) through suppression of both net hepatic glycogenolysis 
(through an increase in GSK3-mediated activation of glycogen synthase activity) and 
gluconeogenesis (by decreasing the delivery and extraction of gluconeogenic precursors and 
supressing lipolysis in adipose tissue) (DCCT Research Group 1994, Nathan et al. 2005), 
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although the former effect is more potent (Reichard et al. 1993, Fisher et al. 2002). Insulin 
reduces the liver’s sensitivity to glucagon, and supresses glucagon release itself (Cooperberg 
and Cryer 2010). In non-diabetic individuals, glucagon exerts a rapid and potent increase in 
hepatic glucose production (potentially through an AMPK-mediated increase in the hepatic 
glycogen phosphorylase to glycogen synthase activity ratio), thus favouring an increase in net 
hepatic glycogenolysis (UKPDS Group 1998). Additionally, the hormone serves to increase 
gluconeogenesis through increasing hepatic gluconeogenesis precursor extraction and 
conversion to glucose (Wasserman et al. 1989, Davis et al. 2000). Although only a small 
increase in glucagon is needed to increase hepatic glucose output (Wasserman 1995), the 
progressive destruction of the pancreatic -cells results in a concomitant and temporal 
disturbance of intra-islet signalling (Taborsky et al. 1998, Banarer et al. 2002, Raju and Cryer 
2005, Briscoe et al. 2007) resulting in diminished α-cell function in response to decrements in 
glycaemia (Xu et al. 2006, Cooperberg and Cryer 2010). Hence, glucagon secretion in 
response to falling blood glucose concentrations is typically attenuated in type 1 diabetes.  
When the intra-islet hormone response is disturbed, other counter-regulatory responses play a 
more important role to counteract hypoglycaemia (Gilbertson et al. 2001). Catecholamines 
(adrenaline and noradrenaline) increase during hypoglycaemia, and also exercise in direct 
response to intensity and duration (Cryer and Gerich 1985, Schwartz et al. 1987, Wasserman et 
al. 1989, Heller and Cryer 1991, Mitrakou et al. 1991, Mcaulay et al. 2001, Brand-Miller et al. 
2003, Battezzati et al. 2009). These responses coincide with increased hepatic output, although 
a direct causal relationship is yet to be fully established. Catecholamines (although primarily 
adrenaline (Davey et al. 2013)) stimulate glycogen phosphorylase and activate hormone-
sensitive lipase, which in turn, enhance hepatic glycogenolysis and lipolysis, respectively 
(Brand-Miller et al. 2003, Thomas et al. 2007, Nansel et al. 2008). Although the 
catecholamine response to exercise is intact in patients (Petersen et al. 2004), the impact of 
acute hormonal responses on glycaemia are likely to be short lasting (Yardley et al. 2013). 
Moreover, catecholamine responses during hypoglycaemia are often attenuated in type 1 
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diabetes patients (Amiel et al. 1988, Dagago-Jack et al. 1993, Cryer 2006, Cryer 2008, Cryer 
2009, 2010, Parillo et al. 2011) and under hyperinsulinemic conditions are likely to be reduced 
even further (Hirsch et al. 1991).  
Growth hormone which is secreted from the anterior pituitary gland, and cortisol from the 
adrenal cortex increase glucose production and reduce glucose utilisation by insulin sensitive 
tissues (Davis et al. 2000, Khani and Tayek 2001, Jorgensen et al. 2004). Both are increased 
during exercise and hypoglycaemia, but play only minor roles in regulating glucose 
homeostasis (Parillo and Riccardi 1995). Therefore, increases in the appearance of these 
hormones are not necessarily related to declines in glycaemia per se (Galbo et al. 1975, 
Jenkins et al. 1981, Bantle et al. 2008) and are heavily influenced by sex, maturation and 
circadian rhythm (Knutsson et al. 1997).  
 
Table 1.0 Counter-regulatory hormones affecting blood glucose homeostasis 
Hormone Origin Action Healthy control Type 1 diabetes 
Glucagon Pancreatic α-cell  glycogenolysis  gluconeogenesis 
 
  
Adrenaline Adrenal medulla and 
sympathetic nerve 
fibres 
 glycogenolysis  lipolysis 
 
 ≠ 
Noradrenaline Adrenal medulla and 
sympathetic nerve 
fibres 
 lipolysis 
 
 ≠ 
Cortisol Adrenal cortex  gluconeogenesis  lipolysis  
 
 ≠ 
Growth hormone Anterior pituitary 
gland 
 lipolysis  
 
 
 ≠ 
Note:  = present or functioning,  = absent or dysfunctioning, ≠ = attenuated. Information taken from  Cryer and 
Gerich (1985) and Mitrakou, Ryan et al (1991). 
 
Many other hormones are released during hypoglycaemia (Cryer 1997), potentially counter-
regulatory neurotransmitters (sympathetic neural noradrenaline and parasympathetic neural 
acetylcholine) (Cryer 1997, Chu et al. 1998) as well as an array of neuropeptides (Cryer 2012). 
In addition glucose auto-regulation, a phenomenon in which ambient glucose levels, 
19 
 
 
independent of hormonal and neural regulation, increases hepatic glucose production, may 
play a role (Cryer 2012). However, these mechanisms are only triggered at very low 
circulating glucose concentrations (Cryer 2012) and with a lack of conclusive evidence, it is 
yet to be established whether these mechanisms are active, ineffective or redundant in type 1 
diabetes (Cryer 2002). 
Another important consideration is exposure to antecedent hypoglycaemia, sleep or indeed 
prior exercise (Cryer et al. 2003, Cryer 2009, Cryer 2012, Longo and Cryer 2013). 
Hypoglycaemia, exercise and sleep have all been shown to blunt the counter-regulatory 
hormone response to subsequent hypoglycaemia (Davis et al. 2000, Galassetti et al. 2001, 
Galassetti et al. 2003, Sandoval et al. 2006). Unfortunately, the exact mechanisms are yet to be 
described within the literature, however, clinical presentation is quite clear. An attenuation of 
autonomic, sympathetic neural and adrenomedullary responses following exposure to 
hypoglycaemia, exercise and / or sleep cause a loss of symptomatic awareness for falling blood 
glucose concentrations (Cryer et al. 2003, Cryer 2009, Cryer 2012, Longo and Cryer 2013). 
The glycaemic threshold for counter-regulatory hormone release is lowered, and behavioural 
defences, such as carbohydrate ingestion prompted by symptoms such as hunger, tiredness and 
irritability (Mcaulay et al. 2001), are compromised; the clinical classification of this has been 
aptly coined “hypoglycaemia unawareness” (Heller and Cryer 1991). Those patients with 
hypoglycaemia unawareness face a 25-fold greater risk of severe hypoglycaemia, and it is 
likely to develop in those who are regularly active (Cryer 2010). 
1.3.3 Post-exercise hypoglycaemia in type 1 diabetes 
In type 1 diabetes, the post-exercise period is characterised by an increase in glucose 
requirements to maintain euglycaemia. Indeed, research indicates that the requirement to 
maintain glucose in the period after exercise is increased in a biphasic manner, early after 
exercise and again 7-11 hours later (Mcmahon et al. 2007), meaning the threat of developing 
hypoglycaemia exists not only during exercise, but remains for many hours after (Macdonald 
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1987). Following exercise, the glucose disappearance is increased because of two phenomena: 
(1) the residual effect of previously contracted musculature, independent of insulin action, and 
(2) increased sensitivity towards insulin (Garetto et al. 1984, Richter et al. 1984). Contraction-
stimulated glucose uptake usually reverses completely within the first few hours after exercise, 
whereas increased insulin sensitivity persists for longer, and in some situations has been 
observed to last as long as 48 hours (Mikines et al. 1988, Cartee et al. 1989). Current opinion 
suggests that increased glucose uptake and enhanced insulin sensitivity following exercise 
occur to replenish depleted glycogen stores induced by exercise (Jentjens and Jeukendrup 
2003). Glycogen restoration is a high metabolic priority (Jentjens and Jeukendrup 2003), and 
in a state of defective hormonal counter-regulation it is a challenge for patients to maintain 
euglycaemia during this time. 
Mechanisms of glycogen replenishment have received notable attention within the literature 
(Maæhlum et al. 1977, Garetto et al. 1984, Blom et al. 1987, Ivy et al. 1988, Price et al. 1994, 
Aulin et al. 2000), mainly because restoration rates are strongly associated with post-exercise 
recovery and subsequent exercise performance (Jentjens and Jeukendrup 2003). Muscular 
contraction and insulin increase glycogen synthase activity (Danforth 1965, Friedman et al. 
1991, Ivy 1991, Nielsen et al. 2004), more so when muscle glycogen concentrations are low or 
depleted (Zachwieja et al. 1991, Montell et al. 1999, Nielsen et al. 2004). Initially following 
exercise, there is a rapid phase of muscle glycogen synthesis which lasts for ~60 minutes, and 
occurs independently from the actions of insulin. Increased membrane GLUT4 protein 
expression is enhanced during this time, which leads to an increased permeability of the 
muscle cell membrane to glucose (Lund et al. 1995, Kuo et al. 1999, Richter and Hargreaves 
2013). During this time, hyperaemia-induced increased glucose supply to the muscle and an 
enhanced capacity to convert glucose to glycogen promotes the rapid restoration of muscle 
glycogen. Following this period, insulin sensitivity is increased. Increased insulin sensitivity 
has been associated with increased activity of the serine/threorine kinase (PKB/Akt), although 
this is not the only mechanism suggested to play a part (Gao et al. 1994, Goodyear and Kahn 
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1998, Hansen et al. 1998, Wojtaszewski et al. 2000, Fisher et al. 2002, Thong et al. 2003) and 
the exact physiology behind this remains to be fully elucidated. Irrelevant of the exact 
mechanisms at play, patients are likely to experience an increase in the potency of 
administered insulin in the post-exercise period. 
1.4 Influence of exercise type on blood glucose in type 1 diabetes patients  
Prolonged continuous aerobic exercise generally has glucose lowering effects and therefore 
carries a risk of hypoglycaemia in patients with type 1 diabetes (Macdonald 1987, Tuominen et 
al. 1995, Riddell et al. 1999, Rabasa-Lhoret et al. 2001, Francescato et al. 2004, Tansey et al. 
2006, West et al. 2010). However, not all forms of exercise acutely lower blood glucose, 
meaning some types of exercise may confer a lower risk of hypoglycaemia (Fahey et al. 2012). 
High-intensity exercise (such as sprinting) often results in an acute increase in blood glucose 
concentrations in patients with type 1 diabetes (Marliss and Vranic 2002, Fahey et al. 2012). 
This form of exercise induces a substantial increase in catecholamine release (≥ +Δ500% from 
rest (Fahey et al. 2012, Davey et al. 2013, Davey et al. 2014)) which can increase hepatic 
glucose output (Kjaer et al. 1986) at a greater rate than glucose clearance (Sigal et al. 1996). 
Exercise in intermittent form, short bursts of high intensity exercise interspersed with moderate 
intensity aerobic exercise, has been demonstrated to reduce the risk of hypoglycaemia early 
after exercise (Guelfi et al. 2005, Bussau et al. 2006, Bussau et al. 2007, Guelfi et al. 2007, 
Maran et al. 2010).  
From a practical perspective the vast majority of studies suffer from short observation periods, 
which means it is difficult to assess the effectiveness of manipulating exercise for the 
prevention of late-onset hypoglycaemia (Guelfi et al. 2005, Bussau et al. 2006, Bussau et al. 
2007, Guelfi et al. 2007, Maran et al. 2010, Campbell et al. 2014). Indeed, much of the work 
in this area was designed to simulate the demands of team games such as soccer, rugby and 
hockey (Guelfi et al. 2005, Guelfi et al. 2007, Maran et al. 2010, Campbell et al. 2014), rather 
than strategies to prevent hypoglycaemia per se. Much of this existing literature has focused 
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predominantly upon cycling (Guelfi et al. 2005, Bussau et al. 2006, Bussau et al. 2007, Guelfi 
et al. 2007, Iscoe and Riddell 2011, Fahey et al. 2012, Davey et al. 2013, Davey et al. 2013), 
however cycling fails to adequately replicate the physiological demands of games-type 
activities, in which repeated changes in speed and direction are a major component. Cycling 
involves primarily concentric muscle actions (Bijker et al. 2002) meaning that the muscle 
shortens as it contracts, whereas in the majority of intermittent game-type activities, which 
typically involve running, a significant proportion of eccentric muscle action occurs, where the 
muscle lengthens during the contraction phase. This is a particularly important consideration in 
type 1 diabetes, as eccentric muscle actions have the potential to down-regulate the insulin 
receptor, thus hindering insulin action and glucose uptake following exercise (Asp et al. 1995). 
Moreover, weight bearing exercise, which typically requires greater muscle mass involvement 
(running versus cycling), has a greater energy demand (Robertson et al. 2009). Thus, the 
ecological validity of these studies is somewhat questionable, and the impact of exercise 
modality on late-onset hypoglycaemia has been under researched. 
A recent investigation which I conducted outside of this series of studies (2014) aimed to 
address the limitations of these former studies, by comparing the 24 hour glycaemic responses 
to continuous versus intermittent running exercise, which was designed to closely simulate 
games-play. The results from this study indicate that the preservation in blood glucose early 
after exercise is only marginally greater following intermittent running, compared to 
continuous running exercise at a similar intensity (matched %V̇O2peak). Moreover, there was an 
equal incidence of late-onset hypoglycaemia in this dataset, indicating that falls in glycaemia 
are likely to occur irrelevant of exercise modality.  
Recently, resistance exercise in type 1 diabetes has received notable attention within the 
literature because this form of exercise also elicits similar hormonal and metabolic responses 
to that of intermittent and high-intensity running or cycling (Kraemer and Ratamess 2005). 
Resistance exercise results in a lesser decline in blood glucose immediately after exercise 
(Yardley et al. 2010), however, the risk of late-onset hypoglycaemia remains (Yardley et al. 
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2013), irrelevant of exercise intensity (Silveira et al. 2014) or duration (Turner et al. 2013, 
Turner et al. 2014), whether this is incorporated into aerobic exercise or not (Yardley et al. 
2010), and regardless of the order exercise is performed (Yardley et al. 2012).  
Manipulating an acute hormonal response through altering exercise type, is likely to carry only 
short lasting effects on glycaemia (Yardley et al. 2013). Thus, it would appear that 
manipulating exercise modality alone is not a completely protective strategy against exercise-
induced hypoglycaemia. Moreover, the majority of studies utilising high-intensity work in 
intermittent (Guelfi et al. 2005, Guelfi et al. 2005, Bussau et al. 2006, Bussau et al. 2007, 
Guelfi et al. 2007, Maran et al. 2010, Iscoe and Riddell 2011, Fahey et al. 2012, Davey et al. 
2013) or resistance form (Yardley et al. 2010, Yardley et al. 2012, Turner et al. 2013, Yardley 
et al. 2013, Silveira et al. 2014), have typically recruited patients young in age (mean ~26 
years, range 18-30 years), in good glycaemic control (HbA1c ~7.4%), and are already regularly 
engaged in exercise; three studies include competitive athletes in their cohort (Iscoe and 
Riddell 2011, Yardley et al. 2012, Yardley et al. 2013). Results in these studies, may not 
necessarily be generalised to the wider population of type 1 diabetes patients, and may be 
inappropriate or even unachievable for many individuals considering not all studies 
demonstrate good adherence rates for novices (~62% adherence rate to exercise in type 1 
diabetes (Plotnikoff et al. 2006)). Eccentric-based intermittent shuttle running exercise can 
induce severe muscle soreness and muscular dysfunction (Bailey et al. 2007), and has been 
observed as a primary mechanism of injury (Hawkins et al. 2001, Woods et al. 2004); the 
frequency of speed changes places greater emphasis on the acceleration and deceleration 
phases of the running cycle applying more eccentric load than conventional cycling based 
sprinting protocols (Greig and Siegler 2009). An increased risk of muscle soreness, fatigue, 
and injury are likely to deter older patients or those unaccustomed to such movement patterns. 
Additionally, research suggests that the performance of prolonged lower-intensity exercise 
confers similar gains in cardiovascular fitness (Wenger and Bell 1986) and carries greater 
long-term adherence rates (Perri et al. 2002) compared to shorter-duration, higher intensity 
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training. In addition, aerobic exercises which are weight-baring, such as running and jogging, 
are likely to offer similar improvements in bone mineral density (Welsh and Rutherford 1996, 
Kelley et al. 2001) and deliver greater improvements in stability and maintenance of gait in 
older individuals (Sauvage Jr et al. 1992). 
1.5 Influence of exercise on markers of inflammation 
Type 1 diabetes is, by large, an inflammatory disease (Rosa et al. 2010). However, diabetes-
related inflammation is complex and multifactorial. Whilst low grade systemic inflammation is 
present due to hyperactivation of specific leukocyte subtypes pertinent to autoimmune events, 
diabetes control also acutely and chronically influences inflammatory exacerbations (Schram 
et al. 2003;Yamagishi and Imaizumi 2005). In healthy individuals free of diabetes, regular 
exercise training results in a chronic reduction in systemic inflammation (Robertson et al. 
2008). Somewhat paradoxically however, this occurs following acute exacerbations in 
inflammatory status, with increased pro-inflammatory cytokines such as interleukin-1 beta (IL-
1β), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α) (Ludbrook 1998; 
Galassetti et al. 2006; Pedersen et al. 2007). Importantly, hypoinsulinaemia and/or 
hyperglycaemia can acutely increase these inflammatory markers. Under such conditions, 
inflammation may be compounded by the performance of exercise Galassetti et al. 2005; this 
may result in a dampening or even loss of the long-term anti-inflammatory effects of exercise 
(Cooper et al. 2004). Thus, exercise, hyperglycaemia, and insulin administration all have the 
capacity to heavily influence inflammation status in type 1 diabetes patients. This is important 
because a change in inflammation status is good proxy marker for the development of long 
term diabetes related complications (Yamagishi and Imaizumi 2005). 
1.6 Strategies for preventing hypoglycaemia during and after aerobic exercise 
1.6.1 Carbohydrate intake for type 1 diabetes patients 
1.6.1.1 Daily macronutrient recommendations 
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The provision of exogenous fuels for exercise is important not only for performance (Wright et 
al. 1991, Below et al. 1995), but also for the avoidance of hypoglycaemia in type 1 diabetes 
(Gallen 2003, Hibbert-Jones and Regan 2005, De Feo et al. 2006, Maahs et al. 2009, Perry and 
Gallen 2009). Thus, it is important that energy and macronutrient needs, especially 
carbohydrate, are met to maximise training effects and avoid hypoglycaemia. Despite this, 
there are no specific guidelines pertaining to macronutrient intake for regularly exercising type 
1 diabetes patients. Instead, recommendations have been taken from research investigating 
athletic performance in non-diabetic individuals, and then tailored using anecdotal evidence 
and experience. A number of review articles suggest active type 1 diabetes patients should 
consume ~5g carbohydrate.kg-1 BM daily (Gallen 2003, Lumb and Gallen 2009, Perry and 
Gallen 2009, Robertson et al. 2009) constituting ~60-80% of total daily energy intake (Burke 
2006, Riddell and Perkins 2006, Inge and Sutherland 2007, Sedlock 2008), with 5-10% 
protein, and less than 30% fat (Inge and Sutherland 2007). If patients maintain their usual 
insulin-to-carbohydrate ratio however (i.e. increasing total daily insulin administration to 
match increased carbohydrate ingestion), then simply consuming large quantities of 
carbohydrate is unlikely to negate hypoglycaemia. Moreover, increased carbohydrate 
consumption may neutralise any gains from the glycaemic lowering effects of exercise 
(Mckewen et al. 1999), and disrupt energy balance. Patients are therefore recommended to 
adopt a two-point strategy before engaging in exercise: 1) ingest carbohydrate (Ramires et al. 
1997, Gallen 2003, Steppel and Horton 2003, De Feo et al. 2006, Riddell and Iscoe 2006, 
Perry and Gallen 2009), and 2) reduce the amount of rapid-acting insulin administered with it 
(Rabasa-Lhoret et al. 2001, West et al. 2010, West et al. 2011, West et al. 2011).  
1.6.1.2 Carbohydrate requirements for exercise  
Recommendations for carbohydrate ingestion for exercise have been based upon exercise 
duration (Gallen 2003, Perry and Gallen 2009) as well as patient characteristics such as body 
mass (Ramires et al. 1997, Riddell and Iscoe 2006) or blood glucose concentrations prior to 
exercise (Steppel and Horton 2003, De Feo et al. 2006). Unsurprisingly, the amount of 
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carbohydrate recommended for patients to ingest varies greatly (Hernandez et al. 2000, Dubé 
et al. 2005, Iafusco 2006), although ~60g carbohydrate per hour of moderate-to-high intensity 
exercise is generally advised (Gallen et al. 2011). This is based on the assumption that glucose 
disposal from the circulation occurs at a rate of ~1g glucose.kg.h-1 in type 1 diabetes patients 
(Francescato et al. 2004). This amount of carbohydrate can be consumed either as a single 
bolus before exercise, or split into equal portions and consumed throughout (Hernandez et al. 
2000, Dubé et al. 2005, Iafusco 2006). However, consuming carbohydrates throughout 
exercise is often impractical and may cause gastric distress. Moreover, ingesting large 
quantities of carbohydrate as a single bolus (~1-2g carbohydrate.kg-1 BM) (Robertson et al. 
2009) will require administration of insulin to avoid post-prandial hyperglycaemia. If insulin 
adjustments are not made with the carbohydrate ingested before exercise, then hypoglycaemia 
will ensue (Rabasa-Lhoret et al. 2001). In one study, where pre-exercise insulin dose was not 
adjusted, administering additional carbohydrate (15 grams of carbohydrates, ~60 kcal) in 
frequent amounts was insufficient to restore euglycaemia (Tansey et al. 2006), and in another 
study, patients required an additional 70g (~280 kcal) of carbohydrate throughout exercise to 
prevent hypoglycaemia (Riddell et al. 1999). 
The composition of the carbohydrate is also important. Meals containing identical 
macronutrient compositions are digested and absorbed at varying rates producing a range of 
glycaemic responses in type 1 diabetes patients (Parillo et al. 2011). Whereas the type, amount 
and concentration of carbohydrates determine the rate of gastric emptying, meal viscosity, 
osmolality, temperature, pH, ambient blood glucose concentrations as well as long term 
glycaemic control are also influential (Davis et al. 1990, Schvarcz et al. 1993, Murray et al. 
1997, Schvarcz et al. 1997, Maughan and Leiper 1999, Ma et al. 2009, Jeukendrup and 
Moseley 2010). Beyond gastric emptying, it is the type of carbohydrate that largely influences 
subsequent absorption and systemic appearance. This is predicted, at least in part, using the 
glycaemic index (GI), a method originally developed to assist diabetes patients in controlling 
glycaemia, but now predominantly used as a tool in exercise nutrition to aid in carbohydrate 
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selection for sport performance. This method which expresses time-course changes in blood 
glucose resulting from the consumption of specific carbohydrate-containing foods, relative to 
that of a standardised reference food of equivalent available carbohydrate content (Jenkins et 
al. 1981). Carbohydrate foodstuffs with a low GI elicit a more gradual rise and decline in 
blood glucose in comparison to their high GI equivalents. Studies in both healthy individuals 
(Demarco et al. 1999, Kawai et al. 2003, Achten et al. 2007, Kawamura 2007, Stevenson et al. 
2006) and those with type 1 diabetes (Nansel et al. 2008, Rovner et al. 2009, Parillo et al. 
2011) demonstrate that low GI diets impart more favourable post-prandial blood glucose 
profiles. In the longer term, this is associated with a reduction in HbA1c, less daily insulin 
requirements, and a reduced risk of hypoglycaemia in type 1 diabetes patients (Gilbertson et 
al. 2001, Brand-Miller et al. 2003, Nansel et al. 2008). Although, some factors such as 
cooking methods, taste preferences, and the co-ingestion of other foodstuffs may partially limit 
the translation of GI into clinical practice. 
GI also has important implications for pre-exercise blood glucose concentrations. In one study, 
where pre-exercise insulin dose was not adjusted, 86% of patients developed hypoglycaemia 
when blood glucose concentrations before exercise were less than 6.6 mmol.l-1 (Tansey et al. 
2006). Typically, patients attempt to increase blood glucose before exercise, often via 
ingestion of high GI carbohydrate-based beverages that result in pre-exercise hyperglycaemia. 
However, Jenni et al (2008) observed that under hyperglycaemic conditions, exercising 
carbohydrate oxidation rates were significantly greater, compared to when exercise is 
performed under euglycaemic conditions. Increased glucose availability, thus increased 
glycolytic flux and ultimately greater rates of carbohydrate oxidation directly supresses lipid 
metabolism (Coyle et al. 1997). Importantly, increased combustion of exogenous carbohydrate 
occurs without sparing of muscle or hepatic glycogen stores in type 1 diabetes (Chokkalingam 
et al. 2007). Based on the premise that GI heavily influences pre-exercise blood glucose 
concentrations (Parillo et al. 2011) and thus the rate of glucose availability, potentially, 
manipulating the GI of foods consumed before exercise could alter exercising substrate 
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metabolism. Data in individuals without diabetes (Coyle et al. 1997, Demarco et al. 1999, 
Stevenson et al. 2006, Achten et al. 2007), and in those with type 1 (West et al. 2011) indicate 
that compared to high GI carbohydrate ingestion, carbohydrate utilisation is decreased and 
lipid oxidation increased during exercise when low GI carbohydrates are consumed before 
exercise. Thus the ingestion of low GI carbohydrates before exercise, may spare endogenous 
and exogenous carbohydrate utilisation, resulting in a greater preservation of blood glucose, 
and potentially lower rates of post-exercise hypoglycaemia.  
1.6.2 Pre-exercise reductions in insulin-to-carbohydrate ratio 
Hypoglycaemia during exercise is largely attributed to iatrogenic causes, whereby patients 
exercise during times of peak insulin absorption (Tuominen et al. 1995). Typically, patients 
are recommended to abstain from exercise during times of peak-absorption, because of 
increased risk of hypoglycaemia (Dandona et al. 1980, Tuominen et al. 1995); for rapid-acting 
insulin this is generally ~60 minutes following administration (Plank et al. 2002). This means 
delaying exercise for ~90-120 minutes. However, recent data indicates that when only small 
amounts of rapid-acting insulin is administered, exercise can be performed within 30-60 
minutes following administration without increasing the risk of post-exercise hypoglycaemia 
(West et al. 2011). However, insufficient insulin administration, or indeed an omission of 
insulin, will induce hyperglycaemia and potentially raise ketone concentrations (Laffel 2000, 
Wallace and Matthews 2004). Exposure to severe hyperglycaemia before exercise may negate 
any beneficial glycaemic-lowering effect of the exercise and induce metabolic and / or 
inflammatory disturbances (Laffel 2000, Devaraj et al. 2005, Galassetti et al. 2006, Rosa et al. 
2008, 2010, Rosa et al. 2011). Thus, an appropriate dose-reduction strategy is important. 
Recommendations for reducing the amount of insulin administered before exercise vary within 
the literature, ranging from 10 up to a 90% reduction in dose (Campaigne et al. 1987, Rabasa-
Lhoret et al. 2001, Mauvais-Jarvis et al. 2003, Grimm 2005, De Feo et al. 2006, West et al. 
2010), although much of this variation can be attributed to differences in insulin type and 
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exercise intensity (Table 1.1). With current insulin regimens, patients are recommended to 
reduce the amount of rapid-acting insulin administered before exercise (Rabasa-Lhoret et al. 
2001), with current opinion suggesting a reduction in dose by 75% when undertaking exercise 
of a moderate-to-high intensity (75% V̇O2max) (Rabasa-Lhoret et al. 2001, West et al. 2010, 
West et al. 2011). Importantly, when a large reduction is applied to rapid-acting insulin, 
patients are able to inject as little as 30 minutes before exercise (West et al. 2011) without 
increased risk of hypoglycaemia. Moreover, West and colleagues (2011) demonstrated that the 
composition of the pre-exercise meal consumed with this rapid-acting insulin reduction, does 
not seem to influence risk of hypoglycaemia during or immediately after exercise. It is 
noteworthy that in this study the authors used a carbohydrate beverage (10% solution) as the 
pre-exercise meal, which although not reported, may have caused gastro-intestinal discomfort 
in some patients, especially if ingested as little as 30 minutes before exercise (Peters et al. 
1995). As it is important to integrate these strategies into a patient’s habitual diet, 
incorporating the pre-exercise carbohydrate bolus into a meal format would make this strategy 
more applicable to patients normal exercising patterns.  
Despite the importance of reducing pre-exercise rapid-acting insulin dose, current 
recommendations alone are inadequate at fully protecting patients from exercise-induced 
hypoglycaemia. Beyond 180 minutes post-exercise, patients are susceptible to hypoglycaemia 
irrelevant of pre-exercise rapid-acting insulin dose, meal composition, or insulin / meal timing 
(West et al. 2010, West et al. 2011, West et al. 2011).  
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Table 1.1 Summary of literature investigating pre-exercise reductions in insulin-to-carbohydrate ratio 
Reference Design Main outcomes and Implications 
Campaigne et al. 
(1987) 
9 T1DM males treated with bi-daily pre-mixed NPH and Soluble insulin. 50% 
reduction of NPH vs. 50% reduction of soluble insulin vs. Full dose with 45 
minutes of cycling at 60%V̇O2max Under treatment with NPH and Soluble Human insulin the risk of early and late-onset hypoglycaemia remains, particularly at night. 
Rabasa-Lhoret et 
al. (2001) 
8 T1DM males treated with Basal Ultralente and bolus Lispro. Full dose vs. 
50% reduction vs. 75% reduction before 60 minutes cycling at 25%V̇O2max, 30 
or 60 minutes at 50% V̇O2max, and 30 minutes at 75%V̇O2max Increased risk of hypoglycaemia during exercise, irrelevant of exercise intensity when a reduction is not performed. A 75% reduction is needed when exercise of a moderate intensity is 
performed. Hypoglycaemia occurred over the course of 18 hours 
post-exercise. 
Mauvais-Jarvis et 
al. (2003) 
12 T1DM males treated on NPH and Regular insulin either bi-daily (n=6) or 
tri-daily (n=6). 50% reduction for bi-daily patients, 90% reduction for tri-
daily patients with 60 minutes cycling at 70%V̇O2max Increased risk (66%) of hypoglycaemia when reductions are not employed. Reductions serve to maintain glycaemia during exercise and in early recovery. Implications late after exercise were not 
reported. 
West at al. (2010) 1 female and 6 T1DM males treated on basal Glargine, and bolus Aspart or 
Lispro. Full dose vs. 75% reduction vs. 50% reduction vs. 25% reduction 120 
minutes before 45 minutes of treadmill running at 70%V̇O2max Hypoglycaemia was noted immediately after exercise when insulin was not reduced. Patients under all reduction trials were protected from hypoglycaemia for 180 minutes post-exercise. 
West et al. (2011) 1 female and 7 T1DM males treated on basal Glargine or Detemir, and bolus 
Aspart or Lispro. Low vs. high GI pre-exercise meal with 75% reduced rapid-
acting insulin dose, 120 minutes prior to 45 minutes of treadmill running at 
70%V̇O2max 
Low GI pre-exercise meal improved glycaemia before and after 
exercise, but did not influence risk of early onset hypoglycaemia. 
Implications late after exercise were not reported. 
West et al. (2011) 7 T1DM males treated on basal Glargine and bolus Aspart or Lispro. Low GI 
meal and 75% rapid-acting insulin reduction taken 120, 90, 60, or 30 minutes 
prior to 45 minutes of treadmill running at 70%V̇O2max No cases of hypoglycaemia during exercise, or for 180 minutes after exercise, despite insulin administration 30 minutes before exercise. 
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1.6.3 Post-exercise strategies for preventing hypoglycaemia 
Existing strategies have focused on actions taken before and during exercise, yet the real 
challenge is managing glycaemia after exercise. Indeed, risk of late-onset post-exercise 
hypoglycaemia still remains (West et al. 2010). Despite this, there is a lack of available 
information for managing post-exercise glycaemia. There are currently no standard guidelines 
regarding carbohydrate amount, type, or timing of feeding for minimising post-exercise 
hypoglycaemia, with most advice centred on fluid replacement for avoidance of 
hyperglycaemia-induced dehydration (Sigal et al. 2006). However, carbohydrate consumption 
early after exercise is important, as studies using euglycaemic clamp techniques demonstrate 
an increased requirement for exogenous carbohydrate to maintain blood glucose 
concentrations early after exercise (Mcmahon et al. 2007). In addition, carbohydrate ingestion 
soon after exercise is also important for replenishing muscle and / or hepatic glycogen stores 
(Jentjens and Jeukendrup 2003) and delaying this could increase the risk of hypoglycaemia 
later in the day (Mcmahon et al. 2007, Gallen et al. 2011). Robertson et al. (2009) also 
recommends adjusting the insulin dose administered with this post-exercise meal to 
compensate for increased insulin sensitivity. However there is a lack of empirical evidence to 
support this at present, especially when following current recommendations for reducing pre-
exercise rapid-acting insulin dose. Studies investigating alterations in pre-exercise insulin 
administration and carbohydrate consumption are limited by the extended observation period 
in which food was withheld after exercise (West et al. 2010, West et al. 2011, West et al. 
2011).  
1.6.3.1 Post-exercise reductions in rapid-acting insulin dose 
Clearly, current pre-exercise recommendations carry only short-lasting protective effects from 
hypoglycaemia, yet there is no information for patients regarding insulin dosage with the meal 
after exercise. It is unknown whether administering unchanged insulin with the meal consumed 
after exercise, when employing pre-exercise insulin dose reductions, would increase the risk of 
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early post-exercise hypoglycaemia, whether reductions in dose could be a preventative action, 
or what the glycaemic implications are for late-onset hypoglycaemia. Conversely, reducing 
post-exercise rapid-acting insulin, under conditions of a pre-exercise reduction, may induce 
hyperglycaemia. Furthermore, it would be reasonable to speculate that low levels of circulating 
insulin and elevated concentrations of post-exercise counter-regulatory hormones could 
precipitate a metabolic milieu promoting increased lipolysis (Khani and Tayek 2001) and 
ketogenesis (Laffel 2000). Collectively and also independently, hyperglycaemia (Targher et al. 
2001, Esposito et al. 2002, De Rekeneire et al. 2006, Rosa et al. 2008), lipid oxidation 
(Febbraio and Pedersen 2005), hyperketonaemia (Stouthard et al. 1995, Karavanaki et al. 
2011, Karavanaki et al. 2012) and under-insulinisation (Rosa, Flores et al. 2008) could 
exacerbate inflammatory disturbances already evident following acute exercise (Sprenger et al. 
1992, Drenth et al. 1995, Nehlsen-Cannarella et al. 1997, Ostrowski et al. 1999, Pedersen and 
Hoffman-Goetz 2000, Nemet et al. 2002). At present, the deeper metabolic, hormonal and 
inflammatory consequences of reducing pre- and post-exercise rapid-acting insulin dose are 
also unknown. 
1.6.3.2 Post-exercise feeding 
As discussed previously, the composition of carbohydrates is a particularly important 
consideration for type 1 diabetes patients. Carbohydrates with a high GI promote accelerated 
muscle glycogen restoration compared to lower GI equivalents (Jentjens and Jeukendrup 2003, 
Jensen and Richter 2012). Therefore, manipulating post-exercise carbohydrate composition 
could have implications for reducing post-exercise hypoglycaemia. However, under conditions 
of reduced pre- and post-exercise rapid-acting insulin dose, this may induce hyperglycaemia 
(Nansel et al. 2008, Rovner et al. 2009, Parillo et al. 2011) and increase ketoneamia (Koeslag 
et al. 1980, Laffel 2000, Wallace and Matthews 2004). On the contrary, glycaemic excursions 
resulting from a reduced pre- and post-exercise insulin-to-carbohydrate ratio may be avoided 
by simply consuming carbohydrates with a low GI (Qi et al. 2006, Nansel et al. 2008). 
However, a slower delivery of carbohydrate to exercised muscle tissue following low GI 
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ingestion, may result in reduced rates of muscle glycogen replenishment (Jentjens and 
Jeukendrup 2003), which could increase late-onset hypoglycaemia (Macdonald 1987, Riddell 
and Perkins 2006). At present there are no recommendations regarding the composition of the 
meal consumed after exercise for the avoidance of post-exercise hypoglycaemia 
1.7 Influence of evening-time exercise 
Many individuals prefer to exercise in the evening due to study or work commitments or even 
for social reasons. Research indicates that patients experience a delayed risk of hypoglycaemia 
7-11 hours after exercise (Mcmahon et al. 2007), with exercise in the evening associated with 
a greater risk of post-exercise hypoglycaemia (Mcmahon et al. 2007, Davey et al. 2013), as 
these falls in blood glucose are likely to occur nocturnally (Taplin et al. 2010). Current 
recommendations for the avoidance of nocturnal hypoglycaemia following evening exercise 
consist of consuming a bedtime snack (Hernandez et al. 2000) to supply adequate 
carbohydrate availability during the night. Current opinion suggests a snack equating to ~0.4 
g.carbohydrate.kg-1 BM, but there is little information pertaining to the composition of this 
snack, nor whether a snack is required at all if adjustments in post-exercise rapid-acting insulin 
and meal composition are made.   
1.8 Application of basal insulin reductions 
Although alterations in basal insulin administration are promoted in both clinical practice and 
within the literature (Tsalikian et al. 2005, Robertson et al. 2009), reductions in basal dose 
have been trialled predominantly in individuals treated with continuous subcutaneous insulin 
infusion therapy (CSII) (Edelmann et al. 1986, Sonnenberg et al. 1990, Admon et al. 2005, 
Tsalikian et al. 2006). This form of treatment involves continuous infusion of rapid-acting 
insulin delivered subcutaneously at a variable rate controlled via an electronically controlled 
pump. CSII adjustment strategies have focused on a reduction or suspension in the insulin 
infusion rate before and during exercise (Table 1.2), whereby 50% - 100% reductions have 
been shown to reduce rates of hypoglycaemia. However, when insulin infusion rates are 
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returned to full following exercise, it would seem patients are exposed to hypoglycaemia later 
in the day (Table 1.2), suggesting it may be necessary to reduce basal insulin rates over a 
longer period of time. In the UK, patients are predominantly treated using a basal-bolus 
regimen, which is associated with greater rates of post-exercise hypoglycaemia than CSII 
(Yardley et al. 2013). The basal component consists of a slowly-absorbed long-acting insulin 
analogue (insulin glargine [Lantus], Sanofi-Aventis; determir [Levemir], Novo Nordisk) that is 
self-administered once or twice per day. This is a far less flexible method of insulin delivery 
than CSII, meaning, manipulation of self-administered basal dose is likely to carry long lasting 
effects.  
Interestingly, late falls in glycaemia following exercise typically coincide with glucose nadirs 
occurring 4-14 hours after administration of basal insulin on non-exercise days (Ashwell et al. 
2006, Thomas et al. 2007). Potentially, reducing basal insulin over the course of an exercise 
day could be a strategy to combat late-onset hypoglycaemia, whereby hepatic glucose output is 
increased to supplement greater rates of glucose uptake and counteract anticipated glucose 
nadirs following exercise.  
However, there is currently no investigative data exploring the glycaemic effects of reducing 
basal insulin as part of a basal-bolus regimen. In addition, there is no information pertaining to 
the glycaemic effects of applying a basal dose reduction under conditions of acute prandial 
adjustments in rapid-acting insulin and carbohydrate intake. Reducing basal dose under such 
conditions could expose patients to severe and / or prolonged hyperglycaemia. Moreover, 
considering basal insulin is important for restricting ketogenesis (Mcgarry and Foster 1980, 
Nosadini et al. 1994, Laffel 2000, Keller et al. 2009), such a strategy may precipitate a 
metabolic state of increased ketonaemia (Nosadini et al. 1994, Keller et al. 2009), which could 
augment an increased inflammatory response (Jain et al. 2003). There is a need for research to 
confirm or refute this, so that current clinical recommendations for reducing basal dose can be 
validated for use in conjunction with acute prandial adjustments.  
35 
 
Table 1.2 Summary of literature investigating alterations to basal insulin  
Reference Design Main outcomes and Implications 
Edelmann et al. 
(1986) 
7 T1DM males performed 45 minutes of cycling at 60%V̇O2max 30 minutes after 
insulin infusion was suspended, or during full insulin infusion. In the 
suspension trial, insulin infusion rate remained discontinued for a further 95 
minutes 
Despite a suspension in insulin infusion rate 30 minute before 
exercise, throughout exercise, and for a further 95 minutes 
afterwards, hypoglycaemia was still encountered by patients 
Sonnenberg et al. 
(1990) 
7 T1DM males treated on Actrpid (purified porcine regular insulin) performed 
60 minutes of low-to-moderate intensity (80 watts) cycling 90 minutes after a 
carbohydrate meal and either a fully or 50% reduced bolus insulin. Basal 
insulin infusion was maintained or reduced by 25%, 50% or 100% during 
exercise 
Hypoglycaemia during exercise was preventable when the pre-meal 
insulin bolus was reduced by 50% in concert with a reduction in 
basal insulin infusion rate by25%. Larger reductions were 
associated with hyperglycaemia. Late-onset hypoglycaemia was not 
reported 
Admon et al. (2005) 6 female and 4 T1DM males treated with rapid-acting insulin Lispro performed 
40-45 minutes of cycling exercise at 60%V̇O2max during either a suspension in 
insulin infusion, or a reduction in infusion rate by 50%. A carbohydrate bolus 
were provided before and after exercise 
This was the first study to utilise rapid-acting insulin analogues. No 
advantage found under either condition, but late-onset 
hypoglycaemia was more common than hypoglycaemia induced 
during exercise 
Tsalikian et al. 
(2006 
49 children with T1DM performed four 15 minute treadmill walking / jogging 
intervals at a heart rate of 140 bpm interspersed with three 5 minute rest breaks 
over 75 minutes. Basal insulin was either suspended during exercise, or 
continued. Glycaemia was monitored for 45 minutes after exercise 
Suspending insulin infusion was associated with a reduction in the 
rate of hypoglycaemia from 43% to 16%. However, high rates of 
hyperglycaemia were evident. Late onset hypoglycaemia was not 
reported 
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1.9 Summary of literature 
Current guidelines for preventing exercise-induced hypoglycaemia are not fully protective, 
leaving patients exposed to falls in glycaemia late after exercise. Moreover, if exercise is 
performed in the evening, hypoglycaemia is likely to occur nocturnally. There are at present, 
few guidelines which inform patients how to manage blood glucose after exercise, and these 
are based largely on opinion and experience rather than to empirical evidence.  
1.10 Summary of experimental aims 
The work in this thesis adds to the existing literature by investigating strategies to manage 
post-exercise glycaemia, and determine the effects of these strategies on wider markers of 
diabetes management in type 1 diabetes patients. Specifically, this thesis has examined: 
1. The acute and 24 hour glycaemic effects of reducing post-exercise rapid-acting insulin 
dose whilst employing current recommendations for reducing pre-exercise rapid-
acting insulin dose. 
2. The acute metabolic, inflammatory, and counter-regulatory hormonal effects of 
reducing post-exercise rapid-acting insulin dose under conditions of reduced pre-
exercise rapid-acting insulin dose. 
3. The acute and 24 hour glycaemic effects of manipulating the glycaemic index of 
carbohydrates consumed following evening exercise, under conditions of reduced pre- 
and post-exercise rapid-acting insulin dose. 
4. The metabolic, inflammatory, and counter-regulatory hormonal effects of  
manipulating the glycaemic index of post-exercise carbohydrates consumed following 
evening exercise, under conditions of reduced pre- and post-exercise rapid-acting 
insulin dose. 
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5. The appetite responses following the manipulation of the glycaemic index of 
carbohydrates consumed following evening exercise, under conditions of reduced pre- 
and post-exercise rapid-acting insulin dose. 
6. The acute and 24 hour glycaemic effects of a combined basal-bolus insulin reduction 
and carbohydrate feeding strategy for evening exercise. 
7. The metabolic, counter-regulatory hormonal, and inflammatory responses following a 
combined basal-bolus insulin reduction and carbohydrate feeding strategy for evening 
exercise. 
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CHAPTER 2 
 
 
 
 
 
GENERAL METHODOLOGY 
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2.0 Project approval 
Favourable ethical opinion was received from Sunderland National Health Service (NHS) 
Research Ethics Committee, and project approval was gained from Newcastle upon Tyne 
Hospitals NHS Foundation Trust Research and Development for carrying out this series of 
studies (Appendix A1-3). All patients provided written informed consent (Appendix A4). 
2.1 Participants 
2.1.1 Recruitment of patients 
Type 1 diabetes volunteers were sought from Newcastle upon Tyne and the surrounding areas. 
Potential participants were approached in clinic (Newcastle Primary Care Trust Diabetes 
Centre) by their Diabetes Specialist Nurse / Clinician, or recruited through The Diabetes 
Research Network following a database search for eligible patients. In addition, advertisements 
were placed in local newspapers, on Northumbria University’s webpage, on regional and 
national Diabetes UK and JDRF websites, and a Facebook® networking page was created to 
increase awareness. Interested participants were issued a study information pack. Those who 
were willing to participate were subsequently screened against inclusion / exclusion criteria 
(Table 2.0), and invited to attend an interest meeting to discuss the study further. 
2.1.2 Health screening 
Patients attended the Newcastle NIHR Clinical Research Facility exercise laboratory for a pre-
participation health screening between the hours of 09:00AM and 17:00PM. The screening 
visit was conducted in accordance with the American College of Sports Medicine’s (ACSM) 
guidelines for exercise testing (Thompson et al. 2009), and administered by a certified ACSM 
Clinical Exercise Specialist. Patients completed a medical history and physical examination, 
including an assessment of hypoglycaemia awareness (Clarke et al. 1995) (Appendix B) before 
a resting and exercise stress test was conducted. 
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Table 2.0 Inclusion / exclusion criteria for patients across all experimental chapters 
Males aged 18-50 years 
Regularly and consistently physically active (aerobic-based physical activities ≥ 3 per week) 
Free of diabetes complications (excluding background diabetic retinopathy), including impaired awareness to 
hypoglycaemia 
Diagnosed for of minimum of one year 
HbA1c < 10% / 86 mmol/mol 
Treated with a basal-bolus regimen composed of either insulin Glargine or Detemir, and Aspart of Lispro (stable for 
≥ 6 month) 
Receiving no other medication 
Free of muscular-skeletal or orthopaedic contraindications 
No abnormalities in cardiac function (assessed using a resting and exercise electrocardiogram stress test) 
 
2.1.2.1 Resting and exercise electrocardiogram 
A modified Mason-Likar 12 lead ECG configuration was used to assess real-time cardiac 
function during rest and throughout the exercise stress test. Blood pressure was measured at 
rest, during the last minute of each stage of exercise, and for 15 minutes after the cessation of 
exercise. The exercise test was terminated if a patient demonstrated an abnormal response to 
exercise. Contraindications to exercise were derived from criteria established by ACSM 
(Thompson et al. 2009). Clinical cover and an on-call physician were available during all 
testing procedures in the event of an adverse reaction to exercise. 
2.1.2.2 Referral from unsuccessful screening 
If a participant failed the screening process or showed resting or exercise-induced cardiac 
abnormalities they were referred to their general physician. A screening report was provided, 
and the patient was advised to avoid exercise until cleared to do so. All patients who 
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participated in this series of studies demonstrated a normal cardiopulmonary response to 
exercise. 
2.2 Experimental procedures 
2.2.1 Preliminary testing 
Patients arrived to the laboratory in a fed and hydrated state to perform an incremental exercise 
test to determine peak oxygen uptake (V̇O2peak) and peak heart rate (HRpeak); peak cardio-
respiratory parameters of patients participating in chapters 3-5 are provided in Table 2.1. 
Individual peak cardiorespiratory parameters of patients are presented in respective chapters. 
To avoid time of peak circulating insulin concentrations, visits were organised such that 
exercise commenced a minimum of 3 hours following prandial insulin administration (Homko 
et al. 2003). Having established stature and mass (Seca 220, Seca, Germany), capillary blood 
glucose concentrations were taken (Glucomen Lx+, A. Menarini diagnostics, UK). Participants 
with a blood glucose concentration < 6.5 mmol.l-1 (De Feo et al. 2006) consumed a 20g 
carbohydrate-based hypertonic drink (117ml Lucozade®, GlaxoSmithKline, UK). Patients 
commenced exercise when blood glucose was ≥ 6.5 mmol.l-1 for a minimum of 15 minutes.  
Following completion of a standardised warm-up (3 minutes at 6 km.hr-1), patients performed 
a continuous incremental running protocol on a motorised treadmill (Woodway ELG, 
Woodway Inc, USA), as per West et al (2010). The protocol comprised of a series of 3 minute 
stages of steady-state exercise, starting at a speed of 8 km.hr-1 and increasing by 1 km.hr-1 per 
stage. A gradient was set at 1% to reflect the running cost of outdoor running (Jones and Doust 
1996). Expired air was measured using an online gas analyser (Metalyser 3B, Cortex, 
Germany), and HR via online telemetry (RS400, Polar, Polar Global, Finland). Strong verbal 
encouragement was given throughout. The test was terminated upon volitional exhaustion. It 
was considered a maximal effort if patients met any two of the following criteria: a respiratory 
exchange ratio (RER) of 1.12 or greater, ≥ 90% age predicted maximum HR (220-age), a 
rating of perceived exertion (RPE) of 18 and / or a distinct plateau in oxygen consumption 
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(Day et al. 2003, Midgley et al. 2007). Patients were monitored closely during and after 
exercise by observation for symptoms of hypoglycaemia (pallor, confusion, or presyncope). 
Patients were discharged following completion of the exercise test if blood glucose was ≥ 6.5 
mmol.l-1 for a minimum of 15 minutes. 
2.2.1.1 Quantification of peak aerobic capacity and trial running speed 
The peak rate of O2 consumption (V̇O2peak) was defined as the greatest volume of O2 attained 
during the last stage of the test. The speed at which this occurred was defined as absolute 
vV̇O2peak. A linear regression equation was used plotting V̇O2 against running speed (km.h-1) to 
determine relative vV̇O2peak. This value represents the estimated speed at which V̇O2peak would 
be attained if treadmill speed was not limited by the protocol stage speed (Jones and Doust 
1996, Bishop et al. 1998). This value was then used to calculate a treadmill running speed 
which would elicit 70% V̇O2peak: 
+ ( * V̇O2) = Relative vV̇O2peak  
Note:  = the slope of the regression line,  = the point of intercept of the regression line and � 
axis.  
Trial velocity = Relative vV̇O2peak  * 0.7. 
Table 2.1 Patient peak cardiorespiratory characteristics across experimental chapters 
 Chapter 3 Chapter 4 Chapter 5 �̇O2peak (l.min-1) 3.5  0.5 3.4  0.6 3.6  0.9 �̇O2peak (ml.kg.min-1) 53.1  1.1 51.9  1.2 51.3  2.1 ��̇O2peak (km.hr-1) 13.2  0.5 14.4  0.3 14.1  0.4 
HRpeak (bpm) 199  2 192  2 201  2 
Note: Data presented as mean  SEM. 
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2.2.2 General study design  
All studies were a randomised, counterbalanced, cross-over design. Randomisation and 
counterbalancing was determined via simulated computer programme. Prior to main trials, 
patients recorded and replicated their diets and activity patterns for a total of 24 hours prior to 
their laboratory visit. During this time glycaemia was monitored using subcutaneous 
continuous interstitial glucose monitoring (CGM). All main trials were conducted at the 
Newcastle NIHR Clinical Research Facility, separated by a minimum of 7 days. Glycaemia 
was further monitored following discharge from the laboratory, so that glycaemic responses 
were captured for a minimum of 24 hours after the performance of exercise. Diet and activity 
were recorded during this time. 
2.2.3 Continuous interstitial glucose monitoring systems 
Patients were fitted with CGM (Figure 2.2) a minimum of 48 hours before attending the 
laboratory on each occasion, so that data during the 24 hours prior to laboratory attendance 
was not influenced by the initialisation period of the sensor. Across chapters, patients wore 
either an iPro2 (chapter 3; Medtronic Diabetes, Medtronic Minimed, USA) CGM which was 
blinded, or a Paradigm Veo (chapter 4 and 5; Medtronic Diabetes, Medtronic Minimed, USA) 
CGM which was unblinded and reported interstitial glucose in real-time. Enlite sensors (Enlite, 
Medtronic Diabetes, Medtronic Minimed, USA) were used for both CGM. The sensor is a 
glucose-oxidase based platinum electrode, which, enclosed in a waterproof casing, is secured 
by applying a dressing. Enzyme-mediated oxidation of glucose in the interstitial fluid 
generates an electrical current that is transmitted to the CGM. Sensor readings are acquired 
every 10 seconds, and averaged values are reported every 5 minutes. 
The sensor was inserted into the subcutaneous tissue of the anterior-superior abdomen (Figure 
2.2) to minimise the physiological time-lag between blood and interstitial concentrations 
(Keenan et al. 2012). The insertion site was taken as equidistant between the most medial 
portion of the iliac crest and navel which was marked with indelible ink, so that initial 
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placement was replicated on subsequent insertions. Sensor fit was checked upon arrival and 
discharge from the laboratory. During CGM wear, patients were provided with a glucose 
testing meter (GlucoMen Lx+, A. Menarini diagnostics, UK; see 2.4) and lancets to obtain 
blood glucose values for calibration purposes. Data was captured for a total of 24 hours after 
exercise, at which point the CGM and sensor was removed. A new sensor was used for each 
experimental trial. Reliability and validity were established for both CGM devices and the 
glucose testing meter against venous blood glucose (Appendix C); measures were comparable 
to findings in previous literature (Kubiak et al. 2004).  
 
 
 
 
 
 
 
 
 
2.2.3.1 The Medtronic iPro2 CGM 
Patients used the iPro2 CGM during study 1. The iPro2 consists of a recording device that is 
attached to the indwelling sensor (Figure 2.0). The sensor outputs are stored in the device’s 
memory for download and analysis after removal. Real-time interstitial glucose readings are 
not available to patients, therefore ensuring blinded continuous interstitial glucose readings. 
Figure 2.0 Insertion and fitting of the Enlite sensor and Medtronic transmitter. A Enlight sensor in 
protective casing (left) and automated insertion device (right). B Enlight sensor inserted into anterior-
superior abdomen on a site with sufficient adiposity to minimise discomfort. Insertion site was 
replicated between trials. C Removal of insertion device leaving imbedded sensor in subcutaneous 
tissue. D Fitting of either Ipro2, or CGM transmitter. E Fully fitted sensor and transmitter. 
A B 
C D 
E 
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For calibration purposes, patients were required to record a minimum of 4 blood glucose 
readings per day, which were retrospectively entered into the CGM software (CareLink, 
Medtronic Diabetes, Medtronic Minimed, USA) for automatic calibration through modified 
linear regression. Following processing, an average interstitial glucose value was attained for 
each 5 minute period over the duration of wear. Raw data was transferred to Microsoft® excel 
(Microsoft, USA) for analysis.  
2.2.3.2 The Medtronic Paradigm Veo Real Time CGM 
Real-time CGM (Paradigm Veo; Figure 2.1) was used during studies 2 and 3 as a safety 
precaution to falling blood glucose concentrations at night, a concern raised by the Research 
Ethics Committee. Glucose alerts were set at ≤3.5 and ≥16 mmol.l-1 during the pre-trial period, 
the upper alert was discontinued once patients left the laboratory after experimental trials. The 
Paradigm Veo system is primarily used for subcutaneous insulin infusion with an in-built 
CGM. Patients did not use the insulin infusion facility, and maintained their usual basal-bolus 
regimen. A transmitter is attached to the sensor which signals the sensor readings to a portable 
device that displays interstitial glucose concentrations on-screen (Figure 2.1). For calibration 
purposes, patients were required to input blood glucose values 4 times per day. Patients were 
informed to take calibration blood glucose values at standardised times which were replicated 
between trials; alarms were set to remind patients.  
 
 
 
 
Figure 2.1 Medtronic Paradigm Veo Real Time CGM. Receiver, transmitter and sensor. 
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2.2.4 Diet and activity replication 
In the 24 hours preceding their arrival to the laboratory, patients were required to replicate 
their diet and eating patterns, which were assessed using weighed dietary recording sheets 
(Appendix D). Patients were required to weigh individual foodstuffs consumed during this 
time and describe items in as much detail as possible, retaining packaging and nutritional 
information. Patients were required to note down meal times and additional carbohydrate 
intake to correct falling blood glucose concentrations. In addition, patients recorded their 
insulin regimen noting injection time and dose of basal and bolus insulin administration, 
detailing additional rapid-acting insulin units administered to correct high blood glucose 
concentrations. Online programs and nutrition analysis software (Microdiet, Downlee systems 
LTD, UK) were used to determine the composition and nutritional content of individual foods. 
Raw data was transferred to Microsoft® excel (Microsoft, USA) for dietary analysis. During 
this time patients were instructed to avoid caffeine, and strenuous activity. Activity patterns 
were recorded using a pedometer (Walking style pro, Omron,Omron Healthcare Europe B.V., 
Hoofddrop, The Netherlands) adjusted for individual stride length. Pedometer placement was 
standardised (attached onto the belt loop of trousers). The pedometer was tested for 
repeatability over different speeds (Appendix E). 
2.2.5 Standardised meals 
For chapter 4A-C and chapter 5A-B patients consumed a total ~5.0 g.carbohydrate.kg-1BM 
over the course of each trial day. This was estimated to provide enough carbohydrate to cover 
the cost of the exercise bout, providing a positive energy balance post-exercise. This was 
chosen so that an assessment of: GI (chapter 4A), and basal dose (chapter 5A), on post-
prandial glycaemia could be made without being influenced by inadequate carbohydrate 
intake. This was achieved by providing patients with standardised meals. The combined 
macronutrient content for all meals collectively was: carbohydrate = ~77%, fat = ~12%, and 
protein = ~11%. Carbohydrate intake and macronutrient content aimed to match current 
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recommendations for exercising type 1 diabetes patients (Riddell and Perkins 2006, Perry and 
Gallen 2009). The glycaemic index (GI) was determined for all meals. 
2.2.5.1 Glycaemic index testing 
The GI of all test meals were calculated using the methods described by Wolever and Jenkins 
et al (1986) (refer to Calculation of blood and interstitial glucose area under the curve; see 
2.6). Testing was conducted using non-diabetic controls, following the procedures outlined by 
Brouns et al (2005). In a randomised and counterbalanced fashion, either a test food or a 
standard was administered on each separate occasion, so that the test food and the standard 
were repeated three times by each participant. The standard comprised of a ~10% glucose 
solution dissolved in still water (75g Dextrose, 750ml water). The standard and test meal were 
both adjusted relative to body mass (1.0 g.carbohydrate.kg-1BM). A baseline blood sample (1 
ml venous blood) was taken, with further periodic sampling at 15 minute intervals up to 135 
minutes. All blood samples were analysed for blood glucose using a Biosen (EKF Diagnostic 
GmbH, Germany; see 2.2.8.1). Following the baseline blood sample, participants consumed 
either the test food or standard within a 5 minute period.  
The area under the glycaemic-response curve (see 2.6) for each food was expressed as a 
percentage of the mean response to the standard food for each participant, and then averaged to 
obtain the GI value for the food. If an individual’s value was > 2 standard deviations from the 
mean, it was considered an outlier. If individuals demonstrated an unrepresentative response to 
a test food, their results were cross-checked with their response to the standard. If their 
response to the standard was normal, the test meal was repeated. If a participant’s response to 
the standard was idiosyncratic, their data were removed from analysis. A GI value was 
obtained and classified as either low (<55), moderate (56-75), or high (>76) (Kirpitch and 
Maryniuk 2011). A summary of the composition of each standardised, experimental meal is 
provided in table 2.2. 
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2.2.5.2 Pre-laboratory standardised meals (Chapter 4 and Chapter 5) 
In studies 2 and 3 patients received two standardised meals that were consumed on the day of 
the trial, and before arrival. The composition of the meals was based on the habitual dietary 
patterns of type 1 diabetes patients (assessed from weighed food diaries from chapter 3 and an 
online questionnaire). Both meals were tested for palatability. Participants were required to 
replicate eating times (breakfast ~08:00, lunch ~13:00).  
2.2.5.3 Pre-trial meal 1: MEAL 1 
The first meal was a cereal-based breakfast meal (frosted flakes, semi-skimmed milk, and 
peaches) equating to 1.3 g.carbohydrate.kg-1 BM (Table 2.2). Fibre content was negligible 
across studies.  
2.2.5.4 Pre-trial meal 2: MEAL 2 
The second meal was a pasta-based lunch (pasta, tomato-based sauce, cheddar cheese, olive 
oil) equating to 1.3 g.carbohydrate.kg-1 BM (Table 2.2). Fibre content was negligible across 
studies.   
2.2.5.5 Laboratory test meals 
Meals consumed in the laboratory were designed to cover the estimated energy cost of the 
exercise bout. Patients drank water ad libitum. 
2.2.5.6 Pre-exercise meal: MEAL 3 
The pre-exercise meal was consistent across all three studies. The pre-exercise meal was 
cereal-based (frosted flakes, semi-skimmed milk, and peaches) equating to 1.0 
g.carbohydrate.kg-1BM (Table 2.2). Fibre content was negligible across studies. 
2.2.5.7 Post-exercise meal (Chapter 3): MEAL 4 
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The post-exercise meal for chapter 3 was a pasta-based lunch (pasta, tomato-based sauce, 
cheddar cheese, olive oil) equating to 1.0 g.carbohydrate.kg-1 BM (Table 2.2). Fibre content 
was negligible across studies. 
2.2.5.8 Post-exercise meals (Chapter 4): MEAL 5 and 6 
Each meal was designed to be isoenergetic and was matched for macronutrient content, 
equating to 1.0 g.carbohydrate.kg-1 BM, but differing in GI (low versus high).  
The low GI meal consisted of basmati rice, tomato-based sauce, turkey breast and a 
isomaltulose orange flavoured drink [10% solution] (Table 2.2). Fibre content was negligible 
across studies.  Food provided 29.8% of carbohydrates, and the drink 70.2%. 
The high GI meal (jasmine rice, tomato-based sauce, turkey breast; maltodextrin orange 
flavoured drink [10% solution]) (Table 2.2). Fibre content was negligible across studies. Food 
provided 29.8% of carbohydrates, and the drink 70.2%. 
2.2.5.8 Post-exercise meal (Chapter 5): MEAL 7 
The low GI post-exercise meal from chapter 5 was adopted in this study. The meal (basmati 
rice, tomato-based sauce, turkey breast; isomaltulose orange flavoured drink [10% solution]) 
(Table 2.2). Fibre content was negligible across studies. Food provided 29.8% of 
carbohydrates, and the drink 70.2%. 
2.2.5.9 Bedtime snack (Chapter 4): MEAL 8 and 9 
Each snack was designed to be isoenergetic and was matched for macronutrient content, 
equating to 0.4 g.carbohydrate.kg-1 BM as per current recommendations for patients exercising 
in the evening (Hernandez et al. 2000). However, each meal differed in GI (low versus high).  
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The low GI snack (burgen sliced bread [soya and linseed]; isomaltulose orange flavoured drink 
[10% solution]) (Table 2.2). Fibre content was negligible across studies. Food provided 47.3% 
of carbohydrates, and the drink 32.9%. 
The high GI snack (white sliced bread; maltodextrin orange flavoured drink [10% solution]) 
was calculated to have a GI of 86. (Table 2.2). Fibre content was negligible across studies. 
Food provided 47.3% of carbohydrates, and the drink 52.7%. 
2.2.5.10 Bedtime snacks (Chapter 5): MEAL10 
The bedtime snack in chapter 5 was adopted from the low GI snack in chapter 4 (burgen sliced 
bread [soya and linseed]; isomaltulose orange flavoured drink [10% solution]) (Table 2.2). 
Fibre content was negligible across studies. Food provided 47.3% of carbohydrates, and the 
drink 52.7%. 
2.2.5.11 Subsequent morning meal: MEAL 11 
The subsequent morning breakfast meal for chapter 5 was a cereal-based meal (frosted flakes, 
semi-skimmed milk, and peaches) equating to 1.0 g.carbohydrate.kg-1 (Table 2.2). Fibre 
content was negligible across studies. 
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Table 2.2 Macronutrient composition of experimental meals 
Meal Meal code Macronutrient composition (%) Glycaemic index (GI) Ingredients and manufacturer 
CHO FAT PRO 
Pre-trial meal 1 MEAL 1 87.1 2.8 10.1 57 
Milk (semi-skimmed; Tesco), Frosted flakes (sugar 
coated corn flakes, Tesco), Peaches (peach halves, 
Tesco). 
Pre-trial meal 2 MEAL 2 60.3 21.8 17.9 57 
Pasta (penne pasta, Tesco), Tomato-based sauce 
(bolognaise sauce, Tesco), Cheese (Cheddar, Tesco), 
Olive oil (refined virgin olive oil, Tesco). 
Pre-exercise meal MEAL 3 87.1 2.8 10.1 57 
Milk (semi-skimmed; Tesco), Frosted flakes (sugar 
coated corn flakes, Tesco), Peaches (peach halves, 
Tesco). 
Post-exercise meal 
(chapter 3) 
MEAL 4 60.3 21.8 17.9 57 
Pasta (penne pasta, Tesco), Tomato-based sauce 
(bolognaise sauce, Tesco), Cheese (Cheddar, Tesco), 
Olive oil (refined virgin olive oil, Tesco). 
LGI Post-exercise meal 
(chapter 4) 
MEAL 5 85.8 2.4 11.8 37 
Basmati rice (Tesco), Tomato-based sauce (bolognaise 
sauce, Tesco), Turkey breast (Turkey breast pieces, 
Tesco), Isomaltulose powder (supplied by Beneo™). 
HGI Post-exercise meal 
(chapter 4) 
MEAL 6 85.8 2.4 11.8 92 
Jasmine rice (Tesco), Tomato-based sauce (bolognaise 
sauce, Tesco), Turkey breast (Turkey breast pieces, 
Tesco), Dextrose powder (supplied by Beneo™). 
Post-exercise meal 
(chapter 5) 
MEAL 7 85.8 2.4 11.8 37 
Basmati rice (Tesco), Tomato-based sauce (bolognaise 
sauce, Tesco), Turkey breast (Turkey breast pieces, 
Tesco), Isomaltulose powder (supplied by Beneo™). 
LGI Bedtime snack 
(chapter 4) 
MEAL 8 86.8 2.5 9.5 86 
Burgan bread (sliced soya and linseed burgan loaf, 
Tesco), Isomaltulose powder (supplied by Beneo™). 
HGI Bedtime snack 
(chapter 4) 
MEAL 9 86.8 0.3 12.9 86 
White bread (sliced white loaf, Tesco), Dextrose powder 
(supplied by Beneo™). 
Bedtime snack (chapter 
5) 
MEAL 10 86.8 2.5 9.5 86 
Burgan bread (sliced soya and linseed burgan loaf, 
Tesco), Isomaltulose powder (supplied by Beneo™). 
Subsequent morning 
meal 
MEAL 11 87.1 2.8 10.1 57 
Milk (semi-skimmed; Tesco), Frosted flakes (sugar 
coated corn flakes, Tesco), Peaches (peach halves, 
Tesco). 
Note: Cooking methods and times were standardised. 
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2.2.6 Self-administered insulin 
2.2.6.1 Insulin regimen of patients  
The insulin regimen of patients across studies is presented in Table 2.2. All patients were 
treated on a stable basal-bolus regimen for a minimum of 6 months prior to enlistment. The 
basal component consisted of insulin Detemir (Levemir, NovoNordisk, Denmark) or Glargine 
(Lantus, Sanofi Aventis, France), and the bolus component consisted of rapid-acting insulin 
Lispro (Humalog, Lilly, USA) or Aspart (Novorapid, NovoNordisk, Denmark). Although 
insulin Glargine and Detemir carry different pharmacodynamic properties (Porcellati et al. 
2007), they both exhibit a peak-less action-time profile over a 24 hour period (Gulve 2008), 
are unaffected by exercise (Peter et al. 2005), and are promoted as equal in clinic, despite 
different metabolic effects in the 12 hours after administration (Heller et al. 2009). Insulin 
Lispro and Aspart have been demonstrated to have similar action-time profiles (Plank et al. 
2002), and metabolic effects (Homko et al. 2003).  
In chapter 3, all patients treated with insulin Detemir (n=3) administered bi-daily, injecting on 
a morning and on an evening / before bed. All patients treated with insulin Glargine (n=8) 
administered once daily, with 50% administering on a morning and 50% administering on an 
evening / before bed. In chapter 4, all patients were treated on insulin Glargine and Aspart 
only, administering insulin Glargine once daily either on a morning (50%) or on an evening / 
before bed (50%). In chapter 5, patients were treated on insulin Glargine (n=8) or Detemir 
(n=2), and Aspart only, administering insulin Glargine once daily either on a morning (50%) 
or on an evening / before bed (50%). Patients treated with insulin Detemir administered bi-
daily.  
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Table 2.3 Patients’ insulin regimen across experimental chapters 
  Patient ID  
Chapter Insulin 
IU 
1 2 3 4 5 6 7 8 9 10 11 MeanSEM 
3 A-B Basal 38GM 20
D
B 22
G
M 26
D
B 34
G
E 18
D
B 20
G
E 31
G
M 24
G
M 30
G
E 20
G
E 26  2 
 Bolus 1L 1A 1A 1A 1A 0.8A  1A 1 A 1A 1A 1A 1.0  0.0 
4 A-B Basal 20GE 30
G
M 38
G
M 20
G
E 24
G
E 26
G
M 14
G
M 20
G
E 34
G
M 43
G
E - 27  3 
 Bolus 1A 1A 1A 0.8A 1A 1A 1A 1.3A 0.8A 1A - 1.0  0.0 
5 A-B Basal 26GM 30
G
M 38
D
B 20
G
E 26
G
M 14
G
M 44
D
B 31
G
E 43
 G
E 52
G
E - 32  4 
 Bolus 1A 1A 1A 0.8A 1A 0.5A 1.5A 1A 1A 1A - 1.0  0.0 
Note: G = Glargine, D = Detemir, A = Aspart, L = Lispro, M = once daily (morning), E = once daily evening , B = 
bi-daily; bolus insulin calculated per 10g CHO. Patients administered bolus insulin based on their individual 
carbohydrate-insulin ratio. 
 
2.2.6.2 Bolus dose administration  
Patients self-administered all rapid-acting insulin into abdominal sites to avoid exercising 
musculature, injecting on the contralateral site of the previously administered dose at each 
injection time. In an attempt to minimise the influence of injection location on insulin 
absorption kinetics, the site of bolus injection was standardised using prominent anatomical 
landmarks (equidistant from the most medial portion of iliac crest and navel) which was 
marked with indelible ink. Particular care was taken to avoid potential sites of insulin 
lipoatrophy (Kiivisto and Felig 1980, Young et al. 1984). Bolus dose was calculated using the 
carbohydrate counting method of rapid-acting insulin units per 10g carbohydrate consumed. 
Across chapters patients administered a 25% (75% reduced) dose of rapid-acting insulin with 
the pre-exercise meal, as per current recommendations (West et al. 2010, West et al. 2011). 
2.2.7 Exercise protocol 
Patients performed 45 minutes of treadmill running at a speed calculated to elicit 70% �̇O2peak 
(see 2.2.3.1) on each visit across chapters. The exercise intensity and duration was chosen such 
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that the bout of exercise fell within the recommendations of the ACSM for exercising type 1 
diabetes patients (see 1.2). 
2.2.8 Cannulation and blood sampling 
All participants were instructed to arrive to the laboratory in a hydrated state to aid in vein 
palpability and blood draws. In a seated or supine position, a 20-gauge cannula (Vasofix®, 
B.Braun Melsungen AG, Germany) was inserted into the antecubital vein of the non-dominant 
arm and secured with a dressing (Tegadrern™ I.V., 3M Health Care , Germany). For comfort 
and ease of use, a Stylet (Madrin/Stylet Introcan®, B Braun, Germany) was used to keep the 
cannula patent during exercise and rest periods. Periodic infusion of saline during rest was 
used to flush the cannula at regular intervals.  
Blood was sampled via the cannula by connecting a multi-sample leur encased in a sampling 
barrel to the leur connection. A total 12 ml of whole blood was collected using 2 vacutainers®, 
a Lithium-Heparin tube (6 ml), and a serum separation tube (6 ml) during each sample point. 
Two ml of blood were used to determine blood glucose and lactate concentrations (see 2.2.8.1) 
and determine plasma volume (see 2.2.8.2) before both vacutainers were held on ice and 
centrifuged for 15 minutes at 3000 rev.min-1 at 4˚C; samples were centrifuged within 5 
minutes from being drawn. Plasma and serum were extracted, and stored in 5 ml aliquot tubes 
at -80˚C. On one visit, an additional 5 ml of whole blood was sampled at rest using a K+ 
EDTA vacuainer®. This was analysed for glycosylated haemoglobin (HbA1c) via standard 
routine of the Clinical Biochemistry Department of the Royal Victoria Infirmary, Newcastle-
upon-Tyne. 
2.2.9 Quantification of blood, serum and plasma analytes 
2.2.9.1 Blood glucose and lactate - Biosen C-line blood glucose and lactate analyser  
The Biosen C-line (EKF Diagnostic GmbH, Germany; Figure 2.2) system is designed to 
quantitatively determine blood glucose and lactate concentrations. Concentrations are 
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determined by comparison to a calibration standard (a known concentration of a glucose and 
lactate), which are run through two measurement channels for each metabolite. The system 
operates using microchip sensors which transforms the sample concentration (glucose and 
lactate) into an evaluable electrical signal, producing an on-screen reading. The blood sample 
is collected via an 20 μL end-to-end capillary tube which is sodium heparinised for 
anticoagulation, then hemolysed in a 1 mL micro test tube. The tube is then placed into a 
sample tray which is automatically recognized and processed. Tests of reliability were 
conducted on blood glucose samples ranging from hypoglycaemia to severe hyperglycaemia 
(Appendix F), and blood lactate over a range of concentrations (Appendix G). 
 
 
 
 
 
 
2.2.9.2 Haematocrit, haemoglobin and the calculation of plasma volume  
Haematocrit and haemoglobin were determined using the HemoCue Hb 201+ (EKF Diagnostic 
GmbH, Germany). Whole blood is collected in a microcuvettte that is analysed using a 
modified azidemethemoglobin reaction. Erythrocyte membranes are disintegrated by sodium 
deoxycholate that release haemoglobin, and sodium nitrate converts the haemoglobin iron 
from the ferrous to the ferric state to form methemoglobin, this then combines with azide to 
form azidemthemoglobin. Once a steady state has been reached following the reaction, 
haematocrit and haemoglobin concentrations are displayed on screen. Plasma volume, and 
Figure 2.2 Biosen C_Line, determination of blood glucose and lactate. 
Waste bottle 
System solution 
Glucose sensor chip 
Lactate sensor chip 
Control sample 
Pivot arm for sample 
processing 
Sample drum 
Online display 
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changes in plasma volume were determined using the methods of Dill and Costill (1974) 
(Appendix H). 
2.3 Determination of hypoglycaemia and hyperglycaemia 
Hypoglycaemia was defined as a blood or interstitial glucose concentration of ≤ 3.9 mmol.l-1, 
and hyperglycaemia defined at glucose ≥ 8.0 mmol.l-1. A duration of 10 minutes at or below 
each threshold, which equated to three consecutive interstitial glucose readings, were required 
for the determination of hypo- or hyperglycaemia. If patients demonstrated a symptomatic 
hypoglycaemic episode within 24 hours prior to a main experimental trial, their visit was 
rescheduled. Patients were monitored closely during the post-exercise period by observation 
for symptoms of hypoglycaemia (pallor, confusion, or presyncope). If blood glucose dropped < 
3.5 mmol.l-1 (Rabasa-Lhoret et al. 2001) patients received a bolus of carbohydrate (20 g 
carbohydrate; Lucozade®, GlaxoSmithKline, UK).  
2.4 Self-recorded capillary blood glucose and ketone measurements 
Patients used the Glucomen LX capillary blood glucose and ketone meter (GlucoMen Lx+, A. 
Menarini diagnostics, UK). Tests of reliability were conducted on capillary blood glucose 
(ranging from hypoglycaemia to severe hyperglycaemia) and a range of blood ketone samples 
(Appendix C). 
2.5 Serum and plasma analytes 
All biochemical analysis was conducted first hand, and in-house. All samples were thawed at 
room temperature, and placed on a vortex before analysis. All reagents were prepared to 
manufacturer’s specifications. All assays composed of standards and quality controls (QC) in 
duplicate, with samples in singlet.  For calculation of concentrations, a standard curve was 
constructed and results from QCs and samples were calculated from the curve using a 
computer software package (Multicalc®; PerkinElmer, Wallac OY; Finland). The standard 
curve was calculated by plotting the mean absorbance for each standard on the linear y-axis 
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against the concentrations on a logarithmic x-axis, a line of best fit was applied to the curve, 
and sample concentrations determined from the mean absorbance for the standard curve: 
whereby percentage absorbance = (B – blank OD)/(Bo – blank OD), B = OD of sample or 
standard, and Bo = OD of zero standard (total binding). Concentrations were presented as per 
standard convention. Optical density was determined using a plate illuminometer (Microplate 
illuminometer LB 96P, EG&G Berthold, Germany). The coefficient of variance for all assays 
conducted was < 10%, as determined from standards on each plate. A summary of the assays 
used to determine hormones, metabolites and cytokines measured across studies is provided in 
Appendix I. Concentrations derived as a molarity (g.mol-1) then converted to mass (pg.ml-1) by 
multiplication of the molecular mass of the peptide by the peptide molarity; the reverse was 
performed for concentrations derived in molecular mass and typically presented as a molarity 
(Appendix J). 
2.5.1 Insulin 
The Invitron insulin assay (Invitron Ltd, Monmouth, UK) was used to analysis serum insulin. 
The insulin assay is a two-site immunoassay, which employs a solid base phase insulin 
antibody immobilised on microtitre wells, and a soluble insulin antibody labelled with a 
chemiluminescent acridinium ester. Labelled insulin antibody is added to each well followed 
by either a standard, QC or sample. Following an incubation period and a wash, optical density 
was determined. Concentrations were established in pmol.l-1. 
The Invitron assay is 100% cross-reactive with insulin Lispro, Aspart, and Glargine, and 300% 
cross reactive with Determir (Pennartz et al. 2011). Therefore, all patients treated with insulin 
Determir were excluded from the analysis of serum insulin. In addition, the insulin assay is 
also 100% cross reactive with human insulin, however, all patients in this series of studies had 
long-standing type 1 diabetes and were solely dependent upon exogenous insulin 
administration, thus, the influence of any residual β-cell function was considered negligible 
(Wang et al. 2012). When basal dose was maintained (chapters 3 and 4), changes in insulin 
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concentrations detected by this assay were considered to be due to the appearance / 
disappearance of rapid-acting insulin analogues. Conversely, where bolus administration was 
matched in trials (chapter 5), changes were considered to be due to the appearance / 
disappearance of insulin Glargine. The coefficient of variance for all insulin assays conducted 
was 7.4 ± 1.1%, as determined from standards on each plate.  
2.5.2 Glucagon 
Plasma glucagon was analysed using a competitive enzyme immunoassay (Glucagon EIA 
RAB0202; Sigma Aldrich, MD, USA). The microplate kit is pre-coated with anti-rabbit 
secondary antibody. After a blocking step and incubation of the plate with anti-glucagon 
antibody, both biotinylated glucagon peptide and peptide standard or targeted peptide in 
samples interacts competitively with the glucagon antibody. Uncompleted, or bound, 
biotinylated glucagon peptide then interacts with streptavidin-horseradish peroxidase (SA-
HRP), which catalyses a colour development reaction. The intensity of colorimetric signal is 
directly proportional to the amount of biotinylated peptide-SA-HRP complex and inversely 
proportional to the amount of glucagon peptide in the standard or samples. This is due to the 
competitive binding to glucagon antibody between biotinylated glucagon peptide and peptides 
in standard or samples. The coefficient of variance for all glucagon assays conducted was 6.9 ± 
2.1%, as determined from standards on each plate. 
2.5.3 Catecholamines (Adrenaline and Noradrenaline) 
Plasma adrenaline and noradrenaline were analysed using the CatCombi enzyme-linked 
immunosorbent assay (ELISA) kit (IBL, Europe Ltd). The test consists of 2 stages, an 
extraction phase and an assay phase. The extraction phase consists of an extraction plate to 
which standards, QC or samples are added. Deionised water is added to all wells to correct for 
differences in volume. The extraction plate then undergoes a number of incubations and 
washes, in which an acetylation reaction occurs producing an “extracted sample”. The 
samples, standards ad QCs are then ready for assay. Adrenaline and noradrenaline anti-serum 
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is added before a further incubation. Optical density was immediately determined. 
Concentrations were derived as a mass (pg.ml-1) then converted to molarity (nmol-1) by 
division of the molecular mass of the peptide by the peptide molarity (Appendix J). The 
coefficient of variance for all insulin assays conducted was 9.1 ± 0.8%, as determined from 
standards on each plate. 
2.5.4 Cortisol 
Serum cortisol concentrations were determined using the Parameter™ Cortisol Assay (R&D 
Systems, Minneapolis, USA). For this assay, serum samples require a 20-fold dilution; 
therefore, 20μl of the serum sample was mixed with 380μl of calibrator diluent. The assay uses 
a cortisol conjugate (horseradish peroxidase with red dye and preservatives). To which a 
primary antibody solution (mouse monoclonal antibody to cortisol in buffer with blue dye with 
preservatives) is added followed by a series of incubation periods and washes before two 
colour regents (stabilised hydrogen peroxide and stabilised chromogen (tetramethylbenzidine)) 
are added. Following a further incubation period optical density is determined. The 
concentrations read from the standard curve were multiplied by the dilution factor to account 
for dilution. Concentrations were derived as a mass (pg.ml-1) then converted to molarity 
(nmol.l-1) by division of the molecular mass of the peptide by the peptide molarity (Appendix 
J). The coefficient of variance for all insulin assays conducted was 9.0 ± 0.7%, as determined 
from standards on each plate. 
2.5.5 Non-esterified fatty acids (NEFA) 
The enzymatic non-esterified fatty acids (NEFA) assay (NEFA, Randox Laboratories, UK) 
was used in accordance with the Randox Daytona Plus (Randox Daytona Plus, Randox 
Laboratories, UK) for the determination of NEFA concentrations. The assay uses direct 
photometry to measure a coloured endpoint from the following reaction: 
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1) NEFA + ATP + COA 
Acyl CoA Synthetase Acyl CoA + AMP + PPi 
2) Acyl CoA + AMP + PPi 
Acyl CoA Oxidase   2,3,-trans-Enoyl-CoA +H2O2 
2)  2,3,-trans-Enoyl-CoA +H2O2Peroxidase        Purple adduct + 4H2O 
Concentrations are automatically determined using Randox Daytona Plus computer software 
(Randox Daytona Plus, Randox Laboratories, UK), and derived in mmol.l-1. The coefficient of 
variance for all insulin assays conducted was 8.3 ± 1.2 %, as determined from standards on 
each plate. 
2.5.6 -Hydroxybutyrate 
Serum β-hydroxybutyrate was chosen as the primary marker of ketone body formation. β-
hydroxybutyrate is the most abundant ketone body and is more sensitive to changes in acid-
base balance than acetoacetate (3:1 or greater) (Laffel 2000). As ketoacidosis normalises, there 
is a coincidental conversion of β-hydroxybutyrate to acetoacetate, driven by an oxidized state 
in the hepatocytes, meaning that whilst acetoacetate levels plateau, β-hydroxybutyrate and 
overall ketone body levels are decreasing (Davidson 1998). In addition, urinary ketone tests 
which utilise acetoacetate are unreliable for monitoring recovery due to differing and 
unpredictable reabsorption rates of ketone-bodies in the kidneys (Sulway and Malins 1970). 
Moreover, acetoacetate is likely to be detected in urine long after blood concentrations have 
returned to normal levels (Sulway and Malins 1970). 
The enzymatic β-hydroxybutyrate assay (β-hydroxybutyrate, Randox Laboratories, UK) was 
used in accordance with the ILab300 Plus (ILab 300 Plus Chemistry Analyser, Instrumentation 
Laboratory, Werfen Group, Spain) for the determination of β-hydroxybutyrate concentrations. 
The assay uses direct photometry to measure a coloured endpoint from the following reaction: 
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β -3-Hydroxybutyrate + NAD+  
3 − HydroxybutyrateDehydrogenase  Acetoacetate + NADA + H+ 
Concentrations are automatically determined using ILab300 Plus computer software (ILab 300 
Plus Chemistry Analyser, Instrumentation Laboratory, Werfen Group, Spain), and derived in 
mmol.l-1. The coefficient of variance for all insulin assays conducted was 8.8 ± 1.1%, as 
determined from standards on each plate. 
2.5.7 Markers of Inflammation 
Several studies report chronically, and permanently, elevated levels of inflammatory cytokines 
at rest in type 1 diabetes patients (Erbağci et al. 2001, Targher et al. 2001, Galassetti et al. 
2006). Elevations are influenced by metabolic alterations such as high insulin concentrations, 
hyperglycaemia and also glycaemic fluctuations, as well as exercise (Brownlee 2001, Esposito 
et al. 2002, Fishel et al. 2005, Pedersen and Febbraio 2005). These metabolic disturbances 
may induce inappropriately elevated levels of inflammatory cytokines, which could potentially 
carry negative implications on the onset and progression of diabetic complications (Mohamed-
Ali et al. 2001). Interlukin-6 (IL-6) and Tumour Necrosis Factor alpha (TNF-α) were chosen 
because amongst all other cytokines, they consistently display the most robust and greatest 
quantitative changes (Nemet et al. 2002, Galassetti et al. 2006, Rosa et al. 2011). 
2.5.7.1 Interlukin-6 (IL-6) 
IL-6 was determined via immunoassay (Quantikine HS ELISA Human IL-6 Immunoassay, 
R&D Systems, Minneapolis, USA). A monoclonal antibody specific for IL-6 is pre-coated 
onto a microplate. Standards and samples are pipetted into the wells and IL-6 which is present 
is bound by the immobilised antibody. A wash removes unbound substances before an 
enzyme-linked polyclonal antibody specific for IL-6 is added. A further wash removes any 
unbound antibody-enzyme reagent, before a substrate solution is added. Following an 
incubation period, an amplifier solution is added to the wells. Colour develops in proportion to 
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the amount of IL-6 bound in the initial step. The colour development is stopped and optical 
density is determined. Concentrations are derived and presented as pg.ml-1. The coefficient of 
variance for all insulin assays conducted was 4.3 ± 3.2%, as determined from standards on 
each plate. 
2.5.7.2 Tumour Necrosis factor alpha (TNF-α)  
TNF-α was determined via immunoassay (ELISA Human TNF-α Immunoassay, R&D 
Systems, Minneapolis, USA). A monoclonal antibody specific for TNF-α is pre-coated onto a 
microplate. Standards and samples are pipetted into the wells and any TNF-α present is bound 
by the immobilised antibody. After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific reagent, a substrate solution is added to the wells and colour 
develops in proportion to the amount of TNF-α bound in the initial step. The colour 
development is stopped and optical density is determined. Concentrations are derived and 
presented as pg.ml-1. The coefficient of variance for all insulin assays conducted was 4.9 ± 
2.3%, as determined from standards on each plate. 
2.5.8 Glucagon-Like Peptide-1 total (GLP-1) 
Total GLP-1 was determined via immunoassay (GLP-1 active ELISA, IBL International 
GmbH, Hamburg, Germany). Streptavidin is pre-coated onto a microplate. Standards and 
samples are pipetted into the wells. Subsequently, a mixture of biotinylated GLP-1 specific 
antibody and a horseradish peroxidate conjugated GLP-1 specific antibody is added. Following 
the first incubation, a “sandwich” immunocomplex of Streptavidin – Biotin-antibody – GLP-1 
– HRP conjugated antibody is formed. After washing away any unbound substances, a 
substrate solution was added which acts in a timed reaction. The colour development is 
stopped and the optical density is determined. Concentrations are derived and presented as 
pmol.l-1. The coefficient of variance for all insulin assays conducted was 9.3 ± 0.5%, as 
determined from standards on each plate. 
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2.6 Calculation of blood and interstitial glucose area under the curve 
Area under the curve (AUC) was calculated using the methods described by Wolever and 
Jenkins (1986) and was time-averaged. In order to account for both an increase and decrease 
above or below baseline concentrations, respectively, the total area under the response curve 
was taken. The formula is as follows: 
Total AUC = At + Bt + Ct 
At = [((B – A)/2) + A) * Time (min)] + 
Bt = [((C – B)/2) + B) * Time (min)] + 
Ct = [((D – C)/2) + C) * Time (min)] + 
Time average AUC = Total AUC (mmol.l-1.hour-1) / (total hours * 60) 
Note: Capital letters correspond to respective time points, e.g. A = time point 1. t = time between 
respective time points.  
 
2.7 Calculation of glycaemic variability 
Several measures were chosen to characterise multiple aspects of glycaemic variability. 
Measures include: median, mean and standard deviation, percentage coefficient of variation 
(CV%), mean amplitude of glycaemic excursions (MAGE), mean of daily differences 
(MODD), and continuous overall net glycaemic action (CONGA), weighted average of 
glucose values (MR), and J index, as per current recommendations (Rodbard 2009) (Table 2.6). 
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Table 2.4 Measures of glycaemic variability 
Measure Description Calculation 
Median 
Identifies the most common value within a 
data set 
The middle values from a data set arranged in 
numerical order 
Mean 
Describes the average value over a set period 
of time for a certain number of individuals 
The sum of each value in the data set divided 
by the number of values in the data set 
SD 
Simplest tool for assessment of glycaemic 
variability (Garg et al. 2006). Provides 
information for both minor and major 
fluctuations but does not distinguish them 
(Rodbard 2009, 2009) 
The sum of each value in the data set 
subtracted from the mean of all values in the 
data set, squared, and then divided by the 
number of values in the data set. The final 
value is produced from the square root of this 
CV% 
A description of the magnitude sample values 
and the variation within them whilst allowing 
for standardised comparison between patients 
with different levels of mean glycaemia 
=100 X SD / Mean 
MAGE 
Most popular parameter for assessing 
glycaemic variability. Designed to assess 
major glucose changes and exclude minor 
changes (Molnar et al. 1970) 
Average amplitude of peaks or nadirs with 
magnitude greater than 1 SD 
MODD 
Provides an estimation of inter-day glycaemic 
variability (Molnar et al. 1972) 
Absolute mean difference between glucose 
values obtained at the same time on two 
consecutive days 
CONGA 
Assess glucose variability within a 
predetermined time window (Mcdonnell et al. 
2005) 
The SD of differences in data points 
measured at regular time intervals 
MR 
Provides a measure of stability of glycaemia 
in comparison with an arbitrary assigned 
“ideal” glucose value (Wójcicki 1995) 
(1000 x (LOG10(glucose/100))3 X 18 
J index 
A measure of quality of glycaemic control 
(Wojcicki 1995, Sun et al. 2010) 
= 0.001 x (mean + SD) 
Note: SD = standard deviation, CV% coefficient of variation, MAGE = mean amplitude of glycaemic excursions, 
MODD = mean of daily differences, CONGA = continuous overall net glycaemic action. 
 
2.8 Gas analysis 
Expired air was analysed using the Metalyser 3B (Metalyser 3B, Cortex, Germany). The 
system was turned on a minimum of 30 minutes before calibration to ensure the stabilisation of 
oxygen and carbon dioxide sensors. Calibration used gases of certified concentrations (17.1% 
O2, 5.0% CO2: BOC, Industrial Gases, Linde AG, Munich, Germany), and a 3 litre syringe 
(Series 5530, Hans-Rudolph Inc, Kansas City, Missouri, USA) to check sample volume. 
Expired air samples were collected using a facemask (model 7940, Hans-Rudolph Inc, Kansas 
City, Missouri, USA), which was connected directly to the breath-by-breath system. Ambient 
temperature, humidity and pressure were recorded, and expired gas samples corrected to 
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standard temperature and pressure. Metasoft software (Cortex Biophysik GmbH, Leipzig, 
Germany) was used to calculate the volume of oxygen and carbon dioxide. The software 
package uses the Haldane Transformation method. 
2.8.1 Estimation of substrate oxidation rates and energy expenditure 
Substrate oxidation rates during exercise were estimated from oxygen and carbon dioxide 
values using stoichiometric equations as described by Frayn (1983):  
Carbohydrate oxidation (g.min-1)  = 4.55 V̇CO2 – 3.21 V̇O2 
Lipid oxidation (g.min-1)    = 1.67 V̇O2 - 1.67 V̇CO2 
Calculations for carbohydrate utalisation during rest were determined using updated methods 
of Frayn (1983) by (Jeukendrup and Wallis 2004). The calculations for carbohydrate during 
exercise are based upon the oxidation of blood glucose only. During exercise at ~70-80% V̇ O2peak in non-diabetic individuals, carbohydrate metabolism is met predominantly by 
oxidation of glucose (80%) and to a lesser extent muscle glycogen (20%) (Jeukendrup and 
Wallis 2004). Thus, it is possible that carbohydrate oxidation during exercise was over 
estimated by applying the equations of Frayn (1983). However, it is unknown whether 
assumptions of substrate utilisation in non-diabetic controls can be applied to individuals with 
type 1 diabetes. Furthermore, patients in this series of studies heavily reduced rapid-acting 
insulin dose prior to exercise. As such, patients were typically hyperglycaemic before and at 
least in part, during exercise, resulting in a greater availability of glucose for oxidation. 
Correct calculation of lipid oxidation was important due to the influence of ketonaemia on 
RER (Frayn 1983). Differences in fat oxidation between equations in the literature are 
negligible, and ketogenesis was minimised before experimental trials by patients maintaining 
their usual basal insulin regimen. The equations for lipid oxidation during exercise followed 
those proposed by Frayn (1983), and those at rest based on the weighted-average of 99% of the 
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fatty acid composition of human adipose tissue (Péronnet and Massicotte 1991); 1.70 V̇O2 - 
1.70 V̇CO2. 
Calculations were based on negligible protein oxidation. Protein oxidation is minimal at rest 
and contributes least to total energy expenditure. In addition, protein oxidation stimulated 
above basal rates is unusual and only occurs when large quantities of protein are ingested (40 
g) or exercise is vastly increased in duration (~6 hours). All studies in this thesis employed 
test-meals / drinks containing less than 40g protein.  
In further support of these methods, recent studies in type 1 diabetes patients have followed 
these assumptions (West et al. 2010, West et al. 2011, West et al. 2011). The examination of 
indirect calorimetry was not underpinning to the outcome measures in any of the studies in this 
thesis. 
2.9 Measurement of appetite sensations using Visual Analogue Scales (VAS) 
Subjective appetite ratings were measured using previously validated Visual Analogue Scales 
(VAS) (Flint et al. 2000). Two commonly used scales were used in which patients answer a 
question relating to their perceived feelings of fullness or satiety (Appendix K). The questions 
asked were “how full do you feel?”, and “how satisfied do you feel?”. Patients marked a 
vertical line on a 100mm scale, which was anchored at either end by opposing extreme states 
to indicate how close to each extreme they felt. Previously made markings were not made 
visible to patients. Scales were analysed by measuring the distance in mm from the left-hand 
extreme of the scale to the point at which the participant had marked. 
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2.10 Sample size calculation 
Sample size requirement was estimated using the methods described by Hopkins (2000). The 
calculation is provided below: 
n = 8s2 / d2 
Note: n is the sample size, s is the typical error in measurement and d is the meaningful effect size. 
Considering large effect sizes are generally reported for changes in blood glucose 
concentrations following exercise and the manipulation of diet within patients with type 1 
diabetes (Rabasa-Lhoret et al. 2001, West et al. 2010, West et al. 2011, West et al. 2011), the 
magnitude of d was derived from 0.8 of the between subject variation (Cohen 1988), which 
was calculated using mean baseline data collected during four repeated trials, presented in 
West et al. (2011). In this study, the mean resting blood glucose concentrations were 7.9 
mmol.l-1 with the between subject standard deviation of 2.8 mmol.l-1. Therefore d was 
calculated at 2.2 mmol.l-1. The typical error in measurement was derived at 3.1 mmol.l-1. These 
data indicate a recommended sample size of 11 participants to detect 80% power (Hopkins 
2000). However, due to strict inclusion criteria and the time commitment required to complete 
each study, it was not possible to recruit the number of patients required for 80% power in all 
studies (chapters 4 and 5). Therefore a sample of sufficient size to perform parametric statistics 
was attained.  
2.11 Statistical analysis 
All data is presented as mean ± SEM. Data described as a change from rest, or pre-meal were 
calculated by subtracting resting values (e.g. mean blood glucose) away from all subsequent 
sample time-points. A statistical software package (PASW; IBM PASW version 18; IBM, 
Armonk NY) was used to analyse all data with statistical significance set at p ≤ 0.05. Data 
were tested from normality and parametricity prior to statistical analysis. 
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All variables were examined for interactions of time and condition using repeated measures 
ANOVA. Where significant p-values were identified for interaction effects (time*condition), p 
values, F value, and effect size (partial-eta2) were reported. Significant within (time) effects 
were analysed using post-hoc Bonferroni adjusted pairwise comparisons. Significant between 
(condition) effects were analysed using a One-way repeated ANOVA or Bonferroni adjusted 
pairwise comparisons. Relationships were explored using Pearson’s product moment 
correlation coefficient and reported with r and p values. 
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CHAPTER 3A 
 
 
 
 
 
 
 
 
THE GLYCAEMIC EFFECTS OF REDUCING POST-EXERCISE 
RAPID-ACTING INSULIN IN TYPE 1 DIABETES 
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3.0 Introduction 
Exercise-induced hypoglycaemia is a frequent (Briscoe et al. 2007) and dangerous (Cryer 
2008) occurrence, which is widely feared by type 1 diabetes patients (Brazeau et al. 2008). 
Research suggests that falls in glycaemia during exercise occur due to a synergistic effect of 
both muscular contraction and unregulated circulating insulin promoting blood glucose uptake 
(Rabasa-Lhoret et al. 2001, Mauvais-Jarvis et al. 2003, West et al. 2010). To combat this, 
patients are recommended to reduce the dose of rapid-acting insulin which they administer 
with the meal before exercise (Rabasa-Lhoret et al. 2001, Mauvais-Jarvis et al. 2003, Grimm 
2005, De Feo et al. 2006, West et al. 2010, West et al. 2011). However, this current strategy is 
not fully protective and patients may still be exposed to hypoglycaemia later in the day. This 
has, at least in part, been attributed to iatrogenic causes (West et al. 2010), whereby patients 
administer their usual doses of rapid-acting insulin in a heightened insulin-sensitive state.  
During exercise at moderate to high-intensities, the predominant energy substrate is glucose 
derived from the circulation and intramuscular glycogen stores (Hargreaves and Richter 1988, 
Jentjens and Jeukendrup 2003, Jensen and Richter 2012). The replenishment of these stores is 
a high metabolic priority, and is accelerated early after exercise (Price et al. 1994). This is 
facilitated by increased glycogen synthesis (Mikines et al. 1988, Nielsen et al. 2004), and an 
up-regulation of insulin signalling pathways (Maarbjerg et al. 2011). Thus, early after exercise, 
patients are faced with a window of increased glucose uptake and an enhanced sensitivity to 
insulin. With this in mind, the dose of rapid-acting insulin administered with the meal during 
this time is of particular importance and may warrant adjustment (Robertson et al. 2009). In 
light of this, it may be intuitive to reduce the amount of rapid-acting insulin taken with the 
meal early after exercise. Although this has been previously proposed (Hiatt et al. 1994, 
Rabasa-Lhoret et al. 2001, Gallen 2003, Riddell and Perkins 2006), suggestions are largely 
anecdotal and there is little experimental data to support. Indeed, there is limited information 
examining adjustments in post-exercise rapid-acting insulin when following current 
recommendations for reducing pre-exercise dose. The subsequent glycaemic effects of 
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reducing pre and also post-exercise rapid-acting insulin dose are yet to be determined, and the 
implications of this for preventing hypoglycaemia early and also late after exercise are 
unknown.  
Therefore, this study examined the glycaemic responses to reductions in post-exercise rapid-
acting insulin dose, for 24 hours following running exercise in type 1 diabetes patients 
employing current pre-exercise rapid-acting insulin dose recommendations. 
3.1 Methods 
Patient demographic information is presented in Table 3.0. A schematic of the trial design is 
presented in Figure 3.0; this study was a randomised, counterbalanced, cross-over design. 
Patients arrived to the exercise laboratory on three separate mornings (~08:00 AM) having 
fasted overnight.. Following a resting sample, patients self-administered a 25% dose of rapid-
acting insulin (1.8 ± 0.1 IU, see 2.2.6) into the abdomen (West et al. 2010). Patients consumed 
a pre-exercise carbohydrate meal equating to 1.0 g.carbohydrate.kg-1 BM (1.6 ± 0.04 MJ, see 
2.2.5.6, Table 2.3, MEAL 3) within a 5 minute period. Patients remained at rest for 60 minutes 
following consumption of the pre-exercise carbohydrate bolus / rapid-acting insulin injection. 
Immediately after a blood draw at 60 minutes, patients commenced 45 minutes of treadmill 
running at a speed calculated to elicit 70% of their V̇O2peak. Immediately following exercise, a 
blood sample was taken, with further interval samples at 15, 30, and 60 minutes post-exercise. 
At 60 minutes, patients administered one of three rapid-acting insulin doses, either a Full 
(unchanged dose; 7.5 ± 0.3 IU), a 75% dose (i.e. a 25% reduction: 5.6 ± 0.2 IU), or a 50% 
(i.e. a 50% reduction: 3.7 ± 0.1 IU) dose (see 2.2.6) and consumed a standardised post-exercise 
meal equating to 1.0 g.carbohydrate.kg-1 BM (2.8 ± 0.04 MJ, see 2.2.5.7, Table 2.3, MEAL 4) 
within a 5 minute period. Patients remained rested for a further 180 minutes with periodic 
blood samples taken every 30 minutes (Figure 3.0). At 180 minutes, patients were discharged 
from the laboratory. CGM captured interstitial glucose responses for a further 21 hours (see 
2.2.3.1) and patients self-recorded β-hydroxybutyrate (see 2.4). 
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Table 3.0 Patients demographic information  
  Patient ID  
  1 2 3 4 5 6 7 8 9 10 11 MeanSEM 
Insulin 
(IU) 
Basal 38GM 20
D
B 22
G
M 26
D
B 34
G
E 18
D
B 20
G
E 31
G
M 24
G
M 30
G
E 20
G
E 26  2 
Bolus 1L 1A 1A 1A 1A 0.8A 1A 1 A 1A 1A 1A 1.0  0.0 
HbA1c                      
(%) 
7.9 7.7 7.8 7.8 6.3 7.7 7.9 8 7.9 7.2 7.7 7.7 ± 0.4 
BMI                    
(kg.m2) 
22.9 21.2 20.3 23.1 25.4 22.8 22.9 21.1 22.1 27.2 22.9 22.9  0.7 
Diabetes duration 
(years) 
13 14 16 14 12 4 25 12 13 15 9 13  2 
�̇O2peak  
(ml.kg.min-1)      
53.1 54.3 55.4 56.3 53.2 54.3 55.4 54.3 45.3 51.2 50.4  53.1  1.1 
Age 
(years) 
29 24 26 24 23 34 27 19 26 21 19 24  2 
Note: G = Glargine, D = Detemir, A = Aspart, L = Lispro, M = once daily (morning), E = once daily evening , B 
= bi-daily; bolus insulin calculated per 10g CHO. 
 
 
 
 
 
Rest Exercise 60 30 150 30 0 15 60 60 90 120 180 -24hr +21hr 
CGM 
Bolus         
insulin 
 Bolus         
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 Blood       
glucose 
HR and         
respiration 
Diet 
Activity 
Figure 3.0. Schematic of experimental trial design. Note: Bold text indicates post-exercise 
intervention period. 
Serum      
insulin 
Self-recorded       
β-hydroxybutyrate 
73 
 
3.2 Results  
3.2.1 Pre-laboratory phase 
3.2.1.1 Pre-laboratory dietary intake, insulin administration and activity 
Dietary intake was similar between conditions in the 24 hours before trials; there were no 
differences in total energy consumed (Full 9.4  0.5, 75% 9.6  0.8, 50% 8.9  0.6 MJ; p = 
0.750), with contribution from carbohydrate (Full 53.5, 75% 49.7, 50% 48.9 %; p = 0.844), 
fat (Full 29.7, 75% 30.4, 50% 33.2 %; p = 0.958), and protein (Full 17.8, 75% 19.9, 50% 
17.9 %; p = 0.843) similar between conditions. There were no differences in the amount of 
carbohydrate ingested to correct blood glucose (Full 10  7, 75% 13  5, 50% 11  8 g; p = 
0.750) nor were there differences found in the total amount of rapid-acting insulin 
administrated (Full 24  4, 75% 27  5, 50% 24  5 IU; p = 0.632) or in the carbohydrate-to-
insulin ratio (p = 0.588) between conditions. There were no differences observed in activity 
patterns during the 24 hours prior to main trials with similar steps recorded (Full 5125  75, 
75% 5211  101, 50% 5253  92 steps; p = 0.693). 
3.2.1.2 Pre-laboratory glycaemia 
Patients displayed similar glycaemic control during the 24 hours prior to experimental trials 
with similar mean (Full 8.6  0.4, 75% 7.7  0.5, 50% 8.1  0.6 mmol.l-1; p = 0.451) and total 
interstitial glucose area under the curve (Full 12389  705, 75% 10986  765, 50% 11385  
791 mmol.l-1.min-1; p = 0.400) across trials with the majority of time in euglycaemic ranges 
(Full 949  130, 75% 1044  101, 50% 1053  125 minutes; p = 0.451). Total time spent 
hypoglycaemic (Full 117  43, 75% 155  49, 50% 128  58 minutes; p = 0.722) and 
hyperglycaemic (Full 375  74, 75% 242  73, 50% 245  77 minutes; p = 0.575) were 
similar.  
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3.2.2 Laboratory phase 
3.2.2.1 Serum insulin responses 
The serum insulin responses are presented in Figure 3.1. There was a significant 
condition*time interaction (F(22,154) = 2.566, p < 0.001, partial-eta
2 = 0.391), and a significant 
time (F(11,77) = 4.934, p = 0.046, partial-eta
2 = 0.552) and condition effect (F(2,14) = 6.586, p = 
0.020, partial-eta2 = 0.622) when examining insulin concentrations. No conditional differences 
were noted at rest (Full 67  22, 75% 69  17, 50% 66  16 pmol.l-1; p = 0.989; figure 3.1) or 
before the post-exercise meal (Full 68  21, 75% 73  19, 50% 64  20 pmol.l-1; p = 0.648; 
Figure 3.1). Following the post-exercise meal, serum insulin peaked at 60 minutes under all 
conditions, with concentrations greatest under Full and lowest under 50% (Full 199  47, 
75% 182  38, 50% 109  28 mmol.l-1; p = 0.009; Figure 3.1). Concentrations remained 
significantly greater under Full throughout the post-meal period (p < 0.05; Figure 3.1). 
 
 
 
 
 
 Figure 3.1. Time-course changes in serum insulin from rest. Data presented as mean ± SEM (n = 8). 
Black squares = Full, blue triangles = 75%, red diamonds = 50%. Transparent sample point within a 
condition indicates a significant difference from pre-meal concentrations (p ≤ 0.05). * indicates 
significantly different from Full (p ≤ 0.05). ** indicates significantly different from Full and 75% (p 
≤ 0.05). Thatched area indicates exercise. Vertical dashed line break indicates carbohydrate meal and 
insulin administration. Note: Test meal and insulin were administered immediately following 60 
minutes post-exercise sample point. 
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3.2.2.2 Blood glucose responses 
The absolute blood glucose responses are presented in Figure 3.2. There was a significant 
condition*time interaction (F(22,154) = 4.085, p = 0.003, partial-eta
2 = 0.290), and a significant 
time effect (F(11,77) = 18.030, p < 0.001, partial-eta
2 = 0.643) for absolute blood glucose 
concentrations. There were no conditional differences at rest (Full 7.2  0.9, 75% 7.1  0.7, 
50% 7.1  0.6 mmol.l-1; p = 0.594) or immediately before exercise (Full 13.9  0.6, 75% 15.0 
 0.6, 50% 13.1  0.8 mmol.l-1; p = 0.352).  
3.2.2.3 Exercise and recovery period 
On average, individuals ran at a velocity of 9.3  0.3 km.h-1 and completed 7.0  0.2 km. 
Patients exercised at a similar intensity (%V̇O2peak: Full 73.8 ± 0.0, 75% 72.8 ± 0.0, 50% 70.8 
± 0.0; p = 0.575; %HRpeak: Full 80 ± 2, 75% 79 ± 3, 50% 79 ± 1; p = 0.631), resulting in a 
similar decrease in blood glucose from pre-exercise concentrations (Full Δ-6.8  0.0; 75% Δ-
6.9  0.0; 50% Δ-6.2  0.0 mmol.l-1, p = 0.891), such that immediately following the cessation 
of exercise glycaemia was similar to baseline under all conditions (p > 0.05; Figure 3.2). Blood 
glucose concentrations remained similar between conditions for 60 minutes post-exercise (p > 
0.05; Figure 3.2) meaning concentrations immediately before the administration of the post-
exercise meal were comparable (Full 7.6  1.0, 75% 8.20  1.2, 50% 8.5  1.3 mmol.l-1; p = 
0.822). There were no incidences of hypoglycaemia during the exercise bout, or over the 
course of the 60 minute post-exercise recovery period. 
3.2.2.4 Post-exercise intervention period 
Following the consumption of the post-exercise meal, blood glucose declined under Full and 
75%, whereas glycaemia was preserved under 50% (Figure 3.2). Following the post-exercise 
meal, 5 patients under Full, and 2 under 75% experienced hypoglycaemia; whilst under 50%, 
all patients remained protected. Furthermore, some participants under Full and 75% 
experienced multiple bouts of hypoglycaemia, with total episodes across each trial greatest 
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under Full (Full n = 9 vs. 75% n = 6, 50% n = 0). On average, blood glucose concentrations 
were 2.8  0.2 mmol.l-1 before receiving carbohydrate supplementation. Inversely, more 
patients experienced hyperglycaemia under 50% compared to 75% and Full (50% n = 9 vs. 
75% n = 5, Full n = 4).  
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Post-laboratory phase 
3.2.3.1 Late evening glycaemia 
There was a significant condition*time interaction (F(2,33) = 1.214: p = 0.046, partial eta
2 = 
0.148), and a significant time (F(2,13) = 6.583: p < 0.001, partial eta
2 = 0.485) and condition 
Figure 3.2. Time-course changes in blood glucose from rest. Data presented as mean ± SEM. Black 
squares = Full, blue triangles = 75%, red diamonds = 50%. Transparent sample point within a 
condition indicates a significant difference from pre-meal concentrations (p ≤ 0.05). * indicates 
significantly different from Full (p ≤ 0.05). ** indicates significantly different from Full and 75% (p 
≤ 0.05). Thatched area indicates exercise. Vertical dashed line break indicates carbohydrate meal and 
insulin administration. Note: Test meal and insulin were administered immediately following 60 
minutes post-exercise sample point. 
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effect (F(2,13) = 4.213: p = 0.037, partial eta
2 = 0.376) and when examining the interstitial 
glucose concentrations during the post-laboratory period (Figure 3.3). 
During the evening total interstitial glucose area under the curve was significantly greater 
under 50% (2709  245 mmol.l-1.min-1) compared to Full (1706  247 mmol.l-1.min-1; p < 
0.001) and 75% (1860  244 mmol.l-1.min-1; p < 0.001). Patients under 50% remained 
protected for a further 4 hours, meaning that the first hypoglycaemic episode occurred at 8 
hours post-exercise. No patient administered additional insulin to correct blood glucose 
concentrations during this time. 
3.2.3.2 Nocturnal glycaemia  
Beyond 8 hours post-exercise, declines in glycaemia were evident under all conditions and 
coincidental with sleep (Figure 3.3). Interstitial glucose nadir occurred during the night 
irrespective of condition (Figure 3.3) with similar total nocturnal interstitial glucose area under 
the curve (Full 3201  401, 75% 2519  222, 50% 3262  330 mmol.l-1.min-1; p = 0.240). 
Across trials, 82% of all hypoglycaemic episodes occurred nocturnally (Figure 3.3, Table 3.1). 
Moreover, those patients experiencing a hypoglycaemic episode during their laboratory stay 
also developed nocturnal hypoglycaemia. However, fewer patients under 50% experienced 
nocturnal hypoglycaemia (50% n = 2 vs. Full n = 6, 75% n = 6; Figure 3.3, Table 3.1). In 
addition, total time spent in hypoglycaemic ranges across the whole post-laboratory period was 
significantly less under 50% (50% 82  23 vs. Full 113  27, 75% 126  17, minutes; p = 
0.042). Conversely, total time spent in hyperglycaemic ranges was significantly greater under 
50% (50% 418  67 vs. Full 266  62, 75% 210  54, minutes; p = 0.041). Patients on 
average corrected blood glucose at an interstitial glucose concentration of 4.5  0.3 mmol.l-1; 
however, this was typically performed following their CGM calibration routine. Morning 
glycaemia was also similar across trials (p > 0.05; Figure 3.3). 
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Table 3.1. The total number of patients experiencing hypoglycaemia and the total number of 
hypoglycaemic episodes during the post-laboratory period. 
  Full 75% 50% 
Evening 
No. patients 2 1 1 
Total episodes 2 1 1 
Nocturnal 
No. patients 4 5 2 
Total episodes 7 8 4 
Morning 
No. patients 0 0 0 
Total episodes 0 0 0 
Total 
No. patients 6 6 3 
Total episodes 9 9 5 
Figure 3.3. Time-course changes in interstitial glucose throughout the post-laboratory period. Data 
presented as mean ± SEM. Black solid trace = Full, blue dashed trace = 75%, red broken trace = 50%. 
** indicates interstitial glucose area under the curve is significantly different from Full and 75% (p ≤ 
0.05). Open circles represent hypoglycaemic episodes, as determined from CGM data. Vertical dashed 
line breaks indicate daytime, nocturnal, or morning periods.  
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3.2.3.3 Post-laboratory dietary intake, insulin administration, activity, and self-recorded 
blood β-hydroxybutyrate 
Self-recorded β-hydroxybutryate concentrations were undetectable in all patients throughout 
the post-laboratory period. During this time, total energy consumed (Full 6.6  1.0, 75% 7.5  
1.2, 50% 7.3  0.6 MJ; p = 0.836), with contribution from carbohydrate (Full 55  4, 75% 47 
 5, 50% 48  4 %; p = 0.516), fat (Full 30  4, 75% 31  4, 50% 34  4 %; p = 0.916), and 
protein (Full 16  2, 75% 22  6, 50% 18  2 %; p = 0.827) similar between conditions. 
Moreover, there were no differences in the total amount of insulin administered, or in the 
carbohydrate-to-insulin ratio (p > 0.05). No differences were observed in activity patterns for 
24 hours after exercise, with similar steps recorded across conditions (Full 5341  95, 75% 
4786  87, 50% 5543  108 steps; p = 0.877).  
3.3 Discussion 
The aim of this study was to examine the glycaemic responses to reductions in post-exercise 
rapid-acting insulin dose following running exercise in type 1 diabetes patients adopting 
current recommendations for reducing pre-exercise rapid-acting insulin dose. This study 
demonstrates for the first time that despite a large reduction in pre-exercise rapid-acting insulin 
dose, it is important that post-exercise dose is also heavily reduced. Such a strategy is 
necessary so that glycaemia is preserved, and hypoglycaemia prevented early after exercise (≤ 
8 hours). However, during this time patients may experience periods of post-prandial 
hyperglycaemia, and beyond this time, may still be at risk from late-onset hypoglycaemia. 
All patients completed a bout of intensive aerobic exercise (~73% V̇O2peak), running at an 
average velocity of ~9 km.h
-1
 and expending ~ 3.0 MJ (708 kcal). During exercise, patients 
exhibited a respiratory exchange ratio of ~0.97, which is typical of exercise of an intense 
nature (Marliss and Vranic 2002) and reflects the utilisation of carbohydrate as the primary 
fuel source. Despite this, there were no incidences of hypoglycaemia during exercise, 
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complimenting previous literature (Rabasa-Lhoret et al. 2001, Mauvais-Jarvis et al. 2003, 
West et al. 2010) and emphasising the importance of large reductions in rapid-acting insulin 
dose preceding exercise. Furthermore, patients were, on average within euglycaemic ranges for 
60 minutes after exercise, suggesting that this strategy exposes patients to only transient 
hyperglycaemia prior to exercise (Figure 3.2). 
As demonstrated in the present study, it is important that post-exercise rapid-acting insulin 
dose is also heavily reduced in order to minimise the risk of hypoglycaemia following the meal 
after exercise. Blood glucose was best preserved when reducing post-exercise rapid-acting 
insulin dose by 50%, protecting all patients from hypoglycaemia (≤ 3.9 mmol.l-1) during post-
meal period in the laboratory. Conversely, 45% of patients under Full, and 18% under 75% 
required carbohydrate supplementation. The exact mechanisms underpinning these findings 
are not entirely known. However, the performance of exercise at moderate-to-high intensities 
requires a contribution from muscle glycogen (Chokkalingam et al. 2007, Jenni et al. 2008) 
and replenishment of this is a high metabolic priority after exercise (Jentjens and Jeukendrup 
2003). Following exercise, glycogen synthesis is increased dramatically, thought to be driven 
primarily by depleted glycogen (Mikines et al. 1988, Nielsen et al. 2004), an up-regulation of 
insulin signalling pathways (Maarbjerg et al. 2011), and a prolonged permeability to the 
muscle cell membrane to glucose (Cartee et al. 1989). Taken together, an increased rate of 
glucose transport into the muscle, and an increased capacity to convert glucose to glycogen, 
results in a window where there is likely an increase in the potency of administered rapid-
acting insulin (Zinman et al. 1977).  
It would be naïve to suggest that the glycaemic responses of the patients under Full and 75% 
in this study are solely due to depleted muscle glycogen stores however, as large carbohydrate 
boluses (1.0 g.carbohydrate.kg
-1 
BM) were ingested before and after exercise, which would 
have helped supplement glycogen reserves (Jentjens and Jeukendrup 2003). It is likely that the 
administration of larger doses of rapid-acting insulin (under the Full and 75% conditions) 
created a milieu of relative hyperinsulinaemia, in turn supressing hepatic glucose production 
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and enhancing glucose uptake (Zinman et al. 1977), potentially into non-exercised tissue 
(Chokkalingam et al. 2007); if the destination of glucose was the liver, this may reduce the risk 
of hypoglycaemia later in the day (Chokkalingam et al. 2007). Indeed if this were true, the risk 
of developing hypoglycaemia during this initial period would be increased significantly if 
carbohydrate intake were not increased to match glucose disposal. Interestingly, blood glucose 
under 75% and Full continued to decline beyond the action time of that typically expected for 
rapid-acting insulin analogues (Homko et al. 2003) with patients under these conditions 
requiring multiple boluses of carbohydrate supplementation. This is likely to explain a lack of 
statistical significance between the 50% and 75% conditions at 120 and 180 minutes.  
Irrelevant of the exact mechanisms at play, these findings demonstrate an increased risk of 
early and late post-exercise hypoglycaemia when post-exercise rapid-acting dose is not 
adjusted. Furthermore, these data indicate that a 50% reduction is necessary to prevent falls in 
blood glucose early after exercise and prevent hypoglycaemia, which is greater than the ~30% 
reduction current opinion would suggest (Lumb and Gallen 2009).  
Unfortunately 75% of patients under the 50% condition were exposed to hyperglycaemia (≥ 
8.0 mmol.l-1) following the post-exercise meal. Whereas the majority of these patients 
experienced only mild hyperglycaemia during the post-exercise post-prandial period, peak 
blood glucose ranged between 8.8 and 21.8 mmol.l-1, with one patient averaging a blood 
glucose concentration of 19.3 mmol.l-1 throughout this time. The finding that some patients 
may be exposed to periods of severe hyperglycaemia following reductions to post-exercise 
rapid-acting insulin highlights that patients differ in their sensitivity to insulin following 
exercise, and may therefore require a smaller reduction in post-exercise rapid-acting insulin 
dose. As such, clinicians and patients should be made aware that when heavily reducing pre- 
and post-exercise rapid-acting insulin dose there is potential for hyperglycaemia following the 
post-exercise meal. It is noteworthy that hyperglycaemia sustained in the present study 
occurred without employing currently recommended reductions to basal insulin (Lumb and 
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Gallen 2009, Maahs et al. 2009), which if applied, could exacerbate post-prandial 
hyperglycaemia.  
Interstitial glucose concentrations revealed a preservation of glycaemia under 50% for a 
further 4 hours after leaving the laboratory, meaning patients had been protected against 
hypoglycaemia for a total of 8 hours post-exercise. In comparison, glycaemia during the 
evening (between 4 and 8 hours post-exercise; Figure 3.3) was significantly lower under both 
Full and 75% conditions, with patients under these conditions experiencing further 
hypoglycaemic episodes. However, at ~7 hours post-exercise, there was a decline in interstitial 
glucose concentrations under 50%, such that at ~8 hours post-exercise glycaemia were similar 
between conditions. The decline in interstitial glucose was consistent across trials (Figure 3.3) 
and was coincidental with patients consuming their evening meal. Type 1 diabetes patients 
face particular difficulty in avoiding hypoglycaemia 7-11 hours post-exercise, as the 
requirement for glucose to maintain euglycaemia is increased (Mcmahon et al. 2007, 
Tamborlane 2007). Therefore, patients may need to make further adjustments to their rapid-
acting insulin dose. However, this strategy is largely dependent upon time of exercise; if 
exercise is performed in the evening, falls in glycaemia will likely occur nocturnally. 
Therefore it may be prudent to implement a more specific feeding strategy following evening 
exercise. Considering that increased insulin sensitivity may persist for more than 48 hours after 
exercise, an additional strategy could be to reduce basal insulin dose.  
So that it was possible to determine the impact of mealtime adjustments on glycaemia 
independent of basal insulin, basal insulin regimen was unaltered and standardised across 
trials. Reducing basal insulin dose requires planning exercise in advance, and may offer little 
flexibility if the timing of a reduction is not considered; if unforeseen circumstances prevent 
planned exercise from taking place, the patient may be exposed to prolonged and / or severe 
periods of hyperglycaemia (Lumb 2012), especially if patients display pre-existing post-
prandial hyperglycaemia following the post-exercise rapid-acting insulin reduction. There are 
however no recommendations regarding dose or timing of basal dose adjustment for exercising 
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patients with type 1 diabetes. Moreover, it would be unwise to promote a reduction in basal 
dose in the setting of this present strategy without knowledge of the deeper metabolic, 
hormonal or inflammatory implications. 
Of the total number of hypoglycaemic episodes experienced across all trials during the post-
laboratory period, 82% occurred nocturnally. Therefore, sleep may be a contributing factor to 
the increased incidence of hypoglycaemia during the night (Macdonald 1987). As well as 
recent exercise (Sandoval et al. 2006, Briscoe et al. 2007), antecedent hypoglycaemia (Cryer 
2008) may blunt symptomatic and autonomic responses to hypoglycaemia later in the day, 
particularly during sleep (Cryer and Childs 2002). This is important as those patients who 
experienced hypoglycaemia in the laboratory eliciting blood glucose concentrations less than 3 
mmol.l-1, also experienced hypoglycaemia again during sleep. These data suggest that if 
patients experience hypoglycaemia early after exercise, there is potential that they are at an 
increased risk of blood glucose falling again during the night. Although only 18% of patients 
experienced nocturnal hypoglycaemia under 50%, the late fall in glycaemia means that the 
risk, albeit less, may still be present for patients despite large reductions in pre- and post-
exercise rapid-acting insulin dose. Experiencing hypoglycaemia during sleep is a real fear for 
type 1 diabetes patients (Cryer and Childs 2002). This risk is likely to be exacerbated when 
exercise is performed during the afternoon or evening. Therefore, there is a need to further 
refine current exercise recommendations for type 1 diabetes patients, such that patients can 
engage in regular exercise with a reduced risk and fear of post-exercise nocturnal 
hypoglycaemia. 
The aim of this study was to assess the acute and 24 hour glycaemic effects of reducing post-
exercise rapid-acting insulin dose whilst employing current recommendations for reducing pre-
exercise rapid-acting insulin dose. The results suggest that a 50% reduction in post-exercise 
rapid-acting insulin dose, under conditions of a large pre-exercise rapid-acting insulin 
reduction, preserves glycaemia and prevents hypoglycaemia for ~8 hours after exercise. 
However, patients may experience periods of post-prandial hyperglycaemia following the post-
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exercise rapid-acting insulin reduction. It is important therefore to now assess the acute 
metabolic, inflammatory, and counter-regulatory hormonal effects of reducing post-exercise 
rapid-acting insulin dose under conditions of reduced pre-exercise rapid-acting insulin dose. 
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CHAPTER 3B 
 
 
 
 
 
 
 
 
THE METABOLIC, INFLAMMATORY, AND COUNTER-
REGULATORY-HORMONAL EFFECTS OF REDUCING RAPID-
ACTING INSULIN DOSE AFTER EXERCISE 
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3.4 Introduction 
As highlighted in chapter 3A, some patients may be exposed to periods of hyperglycaemia 
when combining pre and post-exercise rapid-acting insulin dose reductions (Campbell et al. 
2013). With this is mind, it would be reasonable to speculate that low levels of circulating 
insulin combined with elevated concentrations of post-exercise counter-regulatory hormones 
may, in fact, precipitate a metabolic milieu promoting increased lipolysis (Khani and Tayek 
2001) and ketogenesis (Laffel 2000). In addition, inflammatory cytokine responses are related 
to hyperglycaemia (Targher et al. 2001, Esposito et al. 2002, De Rekeneire et al. 2006, Rosa et 
al. 2008), lipid oxidation (Febbraio and Pedersen 2005), and/or hyperketonaemia (Stouthard et 
al. 1995, Karavanaki et al. 2011, Karavanaki et al. 2012). Although regular exercise has been 
demonstrated to reduce systemic inflammation, thus strengthening its therapeutic utility for 
patients with type 1 diabetes (Petersen and Pedersen 2005), somewhat paradoxically, these 
long-term adaptations occur despite opposing acute effects in which there is a pronounced 
increase in inflammatory markers early after exercise (Sprenger et al. 1992, Drenth et al. 1995, 
Nehlsen-Cannarella et al. 1997, Ostrowski et al. 1999, Pedersen and Hoffman-Goetz 2000, 
Nemet et al. 2002).  
Potentially, performing exercise under conditions of concurrent or prior hyperglycaemia and/or 
hypoinsulinaemia might result in an inappropriately elevated level of inflammation after 
exercise. Additionally, metabolic disturbances could negate the over-all health benefits of 
exercise and accelerate the progression of diabetes related complications. Indeed, this may 
offer some explanation towards conflicting opinion regarding the efficacy of aerobic or 
endurance-based exercise for improvements in glycaemic control (for review see Tonoli et al 
(2012).  
It is a well-established recommendation that patients reduce their pre-exercise rapid-acting 
insulin dose to prevent exercise-induced hypoglycaemia (West et al. 2010, West et al. 2011, 
West et al. 2011, Campbell et al. 2013) as the metabolic implications of this are well known 
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(Bracken et al. 2011). Having now demonstrated that a reduction in post-exercise rapid-acting 
insulin dose is also necessary to avoid early post-exercise hypoglycaemia, in the setting of 
post-prandial hyperglycaemia (Campbell et al. 2013; chapter 3A) it is important to investigate 
the deeper metabolic, hormonal and inflammatory consequences of this strategy to determine 
its efficacy. Therefore, a second arm of analysis was applied to chapter 3A to determine 
whether reducing pre- and also post-exercise rapid-acting insulin dose, as a strategy for 
preventing post-exercise hypoglycaemia in type 1 diabetes patients, causes metabolic or 
hormonal disturbances, influences ketonaemia, or alters inflammatory cytokine concentrations.  
3.5 Methods 
A second arm of analysis was performed on all patients from Full and 50% trials from chapter 
3A. Full and 50% trials were chosen to illustrate both extremes of the intervention (normal 
dose versus large reduction). Blood lactate, serum cortisol, non-esterified-fatty-acids, -
hydroxybutyrate, and plasma glucagon, adrenaline, noradrenaline, IL-6 and TNF-α were 
measured for 180 minutes post-meal (Figure 3.4).  
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
 
 
 
 
 
 
3.6 Results 
3.6.1 Counter-regulatory hormone and metabolite responses 
There were no conditional differences in counter-regulatory hormones or metabolites (Table 
3.2) up to 60 minutes post-exercise (p > 0.05). A significant interaction of condition and time 
(F(11,77) = 5.611, p = 0.006, partial-eta
2 = 0.445), and a significant effect of time (F(1,77) = 71.424, 
p < 0.001, partial-eta2 = 0.691) and condition (F(1,7) = 13.070, p = 0.009, partial-eta
2 = 0.651) 
was found when examining plasma glucagon concentrations during the trials (Table 3.2). 
Plasma glucagon concentrations following the post-exercise meal were significantly elevated 
from pre-meal values under both conditions, but were greater under Full (Table 3.2). There 
was no effect of insulin dose on plasma adrenaline, noradrenaline, serum cortisol, blood 
Plasma   
TNF-α 
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Figure 3.4. Schematic of experimental trial design. Note: Bold text indicates post-exercise 
intervention period. 
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lactate, serum NEFA (Table 3.2) or -hydroxybutyrate following the post-exercise meal 
(Figure 3.5).  
Mean post-exercise postprandial glucagon concentrations were positively related to 
corresponding mean noradrenaline concentrations under both conditions (Full r = 0.929, p = 
0.027; 50% r = 0.788, p = 0.020). During this time, there was a transient decline in -
hydroxybutyrate with concentrations similar to rest under 50%, and lower than rest under Full 
(Figure 3.5). There was positive correlation observed between mean -hydroxybutyrate 
concentrations and NEFA under both conditions (Full r = 0.671, p = 0.024; 50% r = 0.790, p 
= 0.001), as well as mean blood glucose under 50% (r = 0.716, p = 0.013), but not under Full 
(r = 0.257, p = 0.446). Moreover, mean NEFA concentrations were associated with greater 
blood glucose concentrations under 50% (50% r = 0.761, p = 0.007; Full r = 0.198, p = 
0.559) whereas NEFA were inversely related to mean circulating insulin concentrations under 
Full (Full r = -0.746, p = 0.034; 50% r = -0.291, p = 0.484).  
3.6.2 Inflammatory cytokine responses 
The IL-6 and TNF-α responses are presented in Figure 3.5. Resting concentrations of IL-6 and 
TNF-α were positively related to length of diabetes (IL-6: r = 0.701, p = 0.033; TNF-α: r = 
0.632, p = 0.042) and inversely related to HbA1c (IL-6: r = -0.699, p = 0.020; TNF-α: r = -
0.698, p = 0.039), but not V̇O2peak (IL-6: r = -0.463, p = 0.528; TNF-α: r = -0.327, p = 0.356). 
Both plasma IL-6 and TNF-α concentrations were significantly raised from rest at 15 minutes 
post-exercise (IL-6: Full Δ+2.02  1.01 (125 %) pg.ml-1; p = 0.032, 50% Δ+1.34  0.98 (116 
%) pg.ml-1; p = 0.030; TNF-α: Full Δ+2.83  0.86 (147 %) pg.ml-1; p = 0.025, 50% Δ+2.99  
0.74 (144 %) pg.ml-1; p = 0.021). Following the post-exercise meal, IL-6 concentrations were 
significantly greater under 50% (Figure 3.5), although TNF-α was similar between conditions. 
Despite this, both cytokines under 50% remained similar to pre-meal and resting measures (p 
> 0.05; Figure 3.5). Under 50% mean IL-6 concentrations over the post-exercise period were 
positively related to mean TNF-α concentrations (r = 0.676, p < 0.001) and serum insulin 
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concentrations were inversely related to IL-6 (r = -0.484, p = 0.017), but not TNF-α (r = -
0.169, p = 0.430). No significant relationships existed between mean blood glucose and IL-6 (r 
= 0.299, p = 0.155) or TNF-α (r = 0.005, p = 0.980) over the post-meal period under 50%. No 
relationships were found between any other measures under Full. 
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Table 3.2. Metabolic and counter-regulatory hormone responses to reductions in pre- and post-exercise rapid-acting insulin dose  
 
     ANOVA p 
 Rest 60 E 0 15 30 Pre-Meal 30 60 90 120 150 180 T T*C 
 
Plasma 
Glucagon  
(pg.ml-1) 
Full 76070 69781  115299† 83283† 69861 71069 101579†‡ 1597116†‡ 1590102†‡ 140294†‡ 1332137†‡ 1099124†‡ <0.001 =0.006 
50% 78985 62885†*  1067128† 854127 81589 60998† 97582†‡ 135096†*‡ 125197†*‡ 117790†*‡ 108586†*‡ 88982*‡   
 
Plasma 
Adrenaline 
(nmol.l-1) 
Full 0.29±0.05 0.12±0.03†  0.56±0.09† 0.40±0.10 0.31±0.07 0.21±0.05 0.20±0.05 0.18±0.07 0.12±0.04† 0.15±0.05 0.18±0.06 0.13±0.04†‡ =0.029 =0.577 
50% 0.27±0.05 0.19±0.04 
 0.59±0.07† 0.29±0.04 0.20±0.04 0.15±0.03 0.15±0.04 0.14±0.03 0.15±0.04 0.15±0.04 0.15±0.02 0.12±0.03   
 
Plasma 
Noradrenaline 
(nmol.l-1) 
Full 2.13±0.24 1.76±0.20 
 11.75±1.37† 4.30±0.56† 2.87±0.30† 2.49±0.27 2.51±0.25 2.86±0.33 2.53±0.29 2.61±0.40 2.37±0.31 2.36±0.32 <0.001 =0.537 
50% 2.51±0.28 2.42±0.29 
 
12.68±1.38† 4.09±0.27† 3.35±0.21† 2.74±0.27 2.79±0.39 2.97±0.44 2.70±0.37 2.90±0.52 2.82±0.49 2.80±0.44   
 
Serum 
Cortisol 
(µmol.l-1) 
Full 0.22±0.03 0.21±0.03 
 
0.19±0.02 0.23±0.03 0.20±0.03 0.17±0.01† 0.16±0.02† 0.15±0.03† 0.12±0.02†‡ 0.11±0.02†‡ 0.10±0.01†‡ 0.10±0.01†‡ <0.001 =0.256 
50% 0.23±0.03 0.19±0.03 
 
0.20±0.03 0.23±0.04 0.22±0.03 0.17±0.02†‡ 0.14±0.02†‡ 0.12±0.02†‡ 0.11±0.02†‡ 0.10±0.02†‡ 0.08±0.01†‡ 0.07±0.01†‡   
Blood Lactate 
(mmol.l-1) 
Full 0.49±0.12 0.82±0.13 
 3.63±0.61† 1.49±0.25† 1.07±0.16† 0.79±0.10 0.62±0.10 0.74±0.17 0.66±0.19 0.56±0.16 0.51±0.13‡ 0.50±0.13‡ <0.001 =0.789 
50% 0.53±0.17 0.80±0.10 
 3.68±0.48† 1.64±0.29† 0.96±0.19† 0.74±0.15 0.68±0.19 0.69±0.11 0.59±0.13 0.54±0.12‡ 0.55±0.1‡2 0.50±0.12‡   
Serum NEFA 
(mmol.l-1) 
Full 0.48±0.08 0.23±0.04†  0.24±0.04 0.42±0.11 0.34±0.06 0.35±0.07 0.30±0.06† 0.18±0.04†‡ 0.17±0.04†‡ 0.27±0.04† 0.25±0.03† 0.25±0.02† =0.012 =0.448 
50% 0.40±0.06 0.24±0.07†  0.31±0.11 0.46±0.16 0.32±0.14 0.38±0.14 0.33±0.08 0.21±0.06† 0.24±0.05† 0.37±0.05 0.44±0.07 0.51±0.07   
Note: Data presented as mean  SEM. 75% trial was omitted from analysis. Test meal and insulin were administered immediately following rest and pre-meal sample points. * indicates 
significantly different from Full (p ≤ 0.05). † indicates significantly different from rest. ‡ indicates significantly different from pre-meal. Exercise commenced 60 minutes after rest. T = 
Time, C = Condition, E = Exercise. 
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Figure 3.5 A-C. Time-course changes in (A) plasma IL-6, (B) plasma TNF-α, and (C) serum β-
hydroxybutyrate from rest. Data presented as mean ± SEM. IL-6 and TNF-α (n = 8). Black squares = 
Full, red diamonds = 50%. Transparent sample point within a condition indicates a significant 
difference from pre-meal concentrations (p ≤ 0.05). * indicates significantly different from Full (p ≤ 
0.05). Thatched area indicates exercise. Vertical dashed line break indicates carbohydrate meal and 
insulin administration. Note: Test meal and insulin were administered immediately following 60 
minutes post-exercise sample point. 
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3.7 Discussion 
This study demonstrates that reducing pre- and also post-exercise rapid-acting insulin dose, as 
a strategy for preventing early-onset post-exercise hypoglycaemia, does not cause adverse 
metabolic, counter-regulatory-hormonal or inflammatory disturbances. Specifically, the data 
indicates that large reductions in rapid-acting insulin dose administered before and also after 
intensive running does not augment ketonaemia, nor cause significant elevations in 
inflammatory cytokines IL-6 and TNF-α above fasting concentrations, despite periods of 
postprandial hyperglycaemia following the post-exercise meal, in patients with type 1 diabetes. 
Completing the exercise protocol caused a significant metabolic stress to patients, inducing 
large increases in blood lactate (~392 %) and catecholamines (adrenaline ~287 %, 
noradrenaline ~591 %), and large decreases in blood glucose (Δ~7.6 mmol.l-1; chapter 3A). As 
described in chapter 3A, all patients under 50% were protected from hypoglycaemia 
throughout their laboratory stay despite reductions in glycaemia following exercise and the 
administration of a second dose of rapid-acting insulin 60 minutes later. However, as a 
consequence of preventing hypoglycaemia, the majority of patients following the 50% 
reduction (82 %) were exposed to periods of hyperglycaemia following the post-exercise meal. 
Hyperglycaemia plays a central pathophysiological role in the development of long-term 
diabetes related complications (Nathan et al. 2005, Ceriello et al. 2013), but is also of 
immediate concern because hypoinsulinaemic hyperglycaemia is associated with an acute 
increase in lipolysis and ketogenesis (Laffel 2000, Wallace and Matthews 2004). Indeed, the 
present study revealed a positive association between increased blood glucose and NEFA, and 
increased blood glucose and β-hydroxybutyrate appearance. Although temporal changes in 
both NEFA and β-hydroxybutyrate concentrations were evident following the post-exercise 
meal under 50%, concentrations remained similar between both conditions, and by 180 
minutes both metabolites were similar to fasting rested concentrations. From a clinical 
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perspective, concentrations in these ranges are not deemed significant (< 1.0 mmol.l-1) (Laffel 
2000).  
Although a large reduction in rapid-acting insulin dose was applied, serum insulin 
concentrations were elevated above resting and pre-meal measures under 50% (chapter 3A). 
Despite unexplained differences in glucagon concentrations, the administration of even small 
amounts of rapid-acting insulin, under conditions of unchanged basal insulin dose, is likely to 
have raised circulating insulin concentrations whereby lipolysis is inhibited (through 
dephosphorlyation of hormone-sensitive lipase) and lipogenesis is increased (via activation of 
acetyl CoA carboxylase). Thus, reducing the capacity for β-oxidation of NEFA and ultimately 
limiting substrate availability for ketogenesis (Mcgarry 1996), and potentially promoting 
peripheral ketone body disposal (Balasse and Féry 1989). Moreover, temporal changes in 
catecholamine concentrations, the main lipolytic stimulus (Kalra and Tigas 2002), and cortisol 
(Fowler 2008) were not statistically significant between conditions. The consumption of a 
large carbohydrate based meal would have helped supplement muscle and liver glycogen, 
reducing the energy deficit created by exercise, and limiting the appearance of catecholamines 
and cortisol.  
A logical extension of the results from chapter 3A was to question whether post-exercise 
hyperglycaemia would exacerbate the appearance of inflammatory cytokines in the patients in 
this investigation, as this would likely be further increased if patients experienced 
hyperketonaemia. Increased markers of inflammation are strongly related to glycaemic 
management and the pathogenesis of diabetes related complications (Targher et al. 2001, 
Fowler 2008). Patients with type 1 diabetes exhibit chronically elevated levels of inflammatory 
markers at rest (Targher et al. 2001, Esposito et al. 2002, De Rekeneire et al. 2006, Galassetti 
et al. 2006, Rosa et al. 2008). Indeed, a positive relationship was observed between resting 
inflammatory cytokine concentrations, and diabetes duration, which was inversely related to 
HbA1c. It is worthy to note however, that baseline measures in this study were elevated above 
some of those previously reported (Galassetti et al. 2006, Galassetti et al. 2006, Rosa et al. 
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2008, 2010, Rosa et al. 2011). However it would be naïve to think that this was not influenced 
by the overnight fast or low circulating concentrations of insulin. Furthermore, most studies 
implement glucose and/or insulin clamp procedures and recruit children or adolescents who 
are usually recently diagnosed (Galassetti et al. 2006, Galassetti et al. 2006, Rosa et al. 2008, 
2010, Rosa et al. 2011). This study population consisted of a relatively young (~24 years) 
group of individuals all in good glycaemic control (~7.7 % / 61 mmol/mol); exposure to 
inflammatory stimuli is likely to be much greater in the general diabetes population who are 
older, have a longer duration of diabetes, and in those with excess adiposity (De Rekeneire et 
al. 2006). 
Only modest increases in IL-6 (~22%) and TNF-α (~45%) were observed following exercise, 
which is likely due to the consumption of the pre-exercise meal and concomitant insulin 
administration. The large carbohydrate bolus (1.0 g.carbohydrate.kg-1 BM) would have helped 
supplement glycogen reserves (Jentjens and Jeukendrup 2003), which may have attenuated the 
exercise-induced increases in IL-6 (Stouthard et al. 1995, Pedersen and Febbraio 2008) and 
even completely inhibited IL-6 release from contracting skeletal muscle (Pedersen and 
Febbraio 2008). In addition, insulin carries anti-inflammatory properties (Viardot et al. 2007), 
of which its administration, even in small doses, may have partially combatted the pro-
inflammatory effects of TNF-α. Indeed, IL-6 concentrations were inversely related to 
circulating insulin concentrations. IL-6 has anti- as well as pro-inflammatory properties 
(Ostrowski et al. 1999, Petersen and Pedersen 2006), with some studies demonstrating IL-6 to 
exert inhibitory effects on TNF-α (Petersen and Pedersen 2006). In the present study there was 
a positive correlation between IL-6 and TNF-α; although a relationship does not necessarily 
indicate cause-effect, speculatively, increases in IL-6 may indeed have been in direct response 
to reductions in TNF-α (see section 1.5). Regardless of the underpinning mechanisms, data 
presented herein indicates that reductions in rapid-acting insulin after exercise do not 
significantly elevate the pro-inflammatory cytokine TNF-α, and that both TNF-α and IL-6 are 
not elevated above fasting concentrations. 
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IL-6 and TNF-α were selected, in part, because both display the greatest quantitative change in 
individuals with and without type 1 diabetes (Pedersen and Febbraio 2008), and therefore have 
a likelihood to yield distinct differences between study conditions (Ostrowski et al. 1999, 
Pedersen and Hoffman-Goetz 2000, Galassetti et al. 2006, Rosa et al. 2011). There is however, 
a known and marked inherent variability of many inflammatory markers (Rosa et al. 2008, 
Rosa et al. 2011), which reflects the remarkable metabolic complexity of the patient with type 
1 diabetes, in which permutations in inflammation status are variable across patients and also 
within the same individuals over time (Rosa et al. 2008). Some of this variability can be 
attributed to antecedent hyperglycaemia (Sprenger et al. 1992, Drenth et al. 1995, Nehlsen-
Cannarella et al. 1997, Ostrowski et al. 1999, Pedersen and Hoffman-Goetz 2000, Nemet et al. 
2002, Galassetti et al. 2006, Rosa et al. 2008, 2010), however, it is important to note that 
patients in this study were kept under free-living conditions before experimentation and 
without correction using euglycaemic clamp procedures. Patients outside of this study are 
therefore likely to closely experience the responses in day-to-day life that were found in this 
study. 
An interesting, if not surprising, finding was that plasma glucagon concentrations following 
the post-exercise meal were elevated under both Full and 50%, but were significantly greater 
under Full. Although the majority of patients under this condition experienced hypoglycaemia 
(blood glucose ≤ 3.9 mmol.l-1; Full n = 5, 50% n = 0; chapter 3A), patients were treated with a 
corrective bolus of carbohydrate such that blood glucose levels (group mean blood glucose 
~6.6 mmol.l-1; chapter 3A) remained above the glycaemic threshold for plasma glucagon 
release (blood glucose ~ < 3.0 mmol.l-1; Cryer 2008). Even if an appropriate glycaemic 
threshold was achieved to stimulate glucagon release, it would remain a surprise to find any 
increase in glucagon concentrations in these patients (length of diagnosis: range 4-31 years) as 
its secretion under hypoglycaemic conditions is largely attenuated in long-standing type 1 
diabetes (Cryer 2008). One possible explanation for the increase in glucagon concentrations 
could be the consumption of a mixed-meal. Brown et al (2008) observed increased glucagon 
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concentrations in response to a mixed-meal in type 1 diabetes patients, as have other studies 
(Müller et al. 1970, Gerich et al. 1975, Ternand et al. 1982, Porksen et al. 2007), suggestive 
that the α-cell secretory reserve may be unaffected by the progression of the autoimmune 
process (Brown et al. 2008). If this were true, increases in glucagon may be attributed to neural 
stimulation, increased α-cell stimuli such as gastric inhibitory polypeptide (GIP) or a lack of 
glucagon-like peptide (GLP) which would otherwise promote postprandial endogenous 
glucagon secretion, although this is purely speculative. Whereas GLP usually inhibits glucagon 
secretion in non-diabetes patients, GLP is largely deficient in those with type 1 diabetes 
(Aronoff et al. 2004). Casual factors underpinning this are yet to be elucidated, although some 
authors suggest that this is consequential of lower intra-islet insulin levels, rather than systemic 
insulin concentrations per se (Greenbaum et al. 2002). Of note, the meal administered in the 
study by Brown et al (2008), was similar in nutritional content to the post-exercise meal given 
to patients in this study (Carbohydrate: 56 vs. 53 %, Protein: 21 vs. 25 %,  Fat: 21 vs. 22 %), 
although smaller (~1.7 vs. ~2.8 MJ). In the present study, glucagon increased under both 
conditions, but was significantly greater following Full; as meals were identical in 
composition and weight, this may suggest a conditional effect following changes in rapid-
acting insulin dose, however glucagon failed to correlate with changes in insulin 
concentrations, similarly to Brown et al (2008) and Potter and colleagues (1989). Interestingly, 
there was a positive association between glucagon and noradrenaline concentrations over the 
post-exercise post-prandial period. In individuals without diabetes, a sustained rise (≤ 120 
minutes) in plasma noradrenaline has previously been demonstrated following a carbohydrate-
rich mixed meal (Potter et al. 1989) with some initial mechanistic data indicating a complex 
synergy between glucagon and norepinephrine in appetite hormone regulation (Gagnon and 
Anini 2013). However, this has never been demonstrated in type 1 diabetes patients. Temporal 
rises in mean noradrenaline were evident at 60 minutes following the post-exercise meal under 
both conditions in this study, although changes from pre-meal concentrations were very small 
(~0.4 nmol.l-1) and did not reach statistical significance.  
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The aim of this study was to assess the acute metabolic, inflammatory, and counter-regulatory 
hormonal effects of reducing post-exercise rapid-acting insulin dose under conditions of 
reduced pre-exercise rapid-acting insulin dose. The results from this study indicate that heavily 
reducing the dose of pre- and post-exercise rapid-acting insulin, as a measure to combat post-
exercise hypoglycaemia, does not induce hyperketonaemia, increase the inflammatory 
cytokines IL-6 or TNF-α above fasting concentrations, or cause other metabolic or hormonal 
disturbances in type 1 diabetes patients. With this, diabetes care staff can have confidence that 
the only adverse effect of this strategy is hyperglycaemia. There is now a need to normalise 
post-exercise post-prandial glycaemia through modifications to dietary intake whilst under 
conditions of reduced rapid-acting insulin dose.  
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CHAPTER 4A 
 
 
 
 
 
 
 
 
THE GLYCAEMIC RESPONSES TO MANIPULATING THE 
GLYCAEMIC INDEX OF CARBOHYDRATES CONSUMED 
FOLLOWING EVENING EXERCISE IN TYPE 1 DIABETES 
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4.0 Introduction 
In chapter 3 it was demonstrated that meal time insulin adjustment, specifically reducing the 
dose of rapid-acting insulin before and after exercise is vital to minimise the risk of post-
exercise hypoglycaemia (Campbell et al. 2013), although, this may cause post-prandial 
hyperglycaemia. However, there is currently little advice on optimal carbohydrate type for 
exercising patients with type 1 diabetes (Chu et al. 2011). Current recommendations place 
more focus on the quantity rather than the composition of the carbohydrate to be consumed 
following exercise (Bantle et al. 2008, Evert et al. 2014). Consumption of ~5.0g 
carbohydrate.kg-1 BM is typically recommended for moderate intensity exercise (Riddell and 
Perkins 2006, Perry and Gallen 2009), however, food composition is also an important 
consideration, as the type of carbohydrate can exert a major influence on post-prandial 
glycaemia in diabetes patients (Parillo and Riccardi 1995). Meals containing identical 
macronutrient compositions are digested and absorbed at varying rates producing a range of 
glycaemic responses (Jenkins et al. 1981), with carbohydrate foodstuffs with a low GI eliciting 
a more gradual rise and fall in blood glucose compared to their high GI equivalents. 
Resultantly, more favourable post-prandial glycaemic profiles have been shown following 
ingestion of low GI foods in patients with type 1 diabetes (Nansel et al. 2008, Parillo et al. 
2011).  
It may thus be possible to optimise post-exercise glycaemia by manipulating the composition 
of foods consumed during this time. The protracted absorption rates of low GI foods may be 
beneficial for reducing post-prandial hyperglycaemia. However, slower delivery of 
carbohydrate to post-exercise musculature, and potentially slower rates of muscle glycogen 
replenishment following exercise (Jentjens and Jeukendrup 2003, Jensen and Richter 2012), 
may increase the risk of post-exercise hypoglycaemia (Macdonald 1987, Riddell and Perkins 
2006). Inversely, consuming high GI foods may promote accelerated muscle glycogen 
restoration (Jentjens and Jeukendrup 2003, Jensen and Richter 2012), reducing the incidence 
of post-exercise hypoglycaemia (Macdonald 1987, Riddell and Perkins 2006). However, the 
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need to reduce the insulin-to-carbohydrate ratio may be associated with post-prandial 
hyperglycaemia following ingestion of high GI carbohydrates (Nansel et al. 2008, Parillo et al. 
2011).  
In addition, studies have traditionally employed morning time exercise, whereas many 
individuals prefer to exercise in the evening. Considering that patients experience a delayed 
risk of hypoglycaemia 7-11 hours after exercise (Mcmahon et al. 2007), falls in glycaemia 
following evening time exercise are likely to occur nocturnally (Taplin et al. 2010). As such, 
patients are recommended to consume a bedtime snack (Hernandez et al. 2000) to ensure 
adequate carbohydrate availability during the night, avoiding nocturnal hypoglycaemia. 
Unfortunately however, there is currently no information regarding the optimum composition 
of this snack, nor whether a snack is required at all if adjustments in post-exercise rapid-acting 
insulin and meal composition are made.  Therefore, the aim of this study was to examine the 
influence of the glycaemic index of the meal and subsequent bedtime snack consumed after 
evening-time exercise on post-prandial glycaemia and nocturnal glycaemic control in type 1 
diabetes patients. 
4.1 Methods 
Patient demographic information is presented in Table 4.0. A schematic of the trial design is 
presented in Figure 4.0; this study was a randomised, counterbalanced, cross-over design. 
Patients arrived to the exercise laboratory on two separate evenings (~17:00 PM) having 
consumed a prescribed lunch meal (see 2.2.5.2, Table 2.3, MEAL 2) ~4 hours before arrival. 
Following a resting sample, patients self-administered a 75% reduced dose of rapid-acting 
insulin (2.0 ± 0.1 IU, see 2.2.6) into the abdomen (West et al. 2010, Campbell et al. 2013). 
Patients consumed a pre-exercise carbohydrate bolus equating to 1.0 g.carbohydrate.kg-1 BM 
(1.8 ± 0.2 MJ, see 2.2.5.6, Table 2.3, MEAL 3) within a 5 minute period. Patients remained at 
rest for 60 minutes following consumption of the pre-exercise carbohydrate bolus / rapid-
acting insulin injection with blood samples at 60 minutes. Immediately after the 60 minute 
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blood draw, patients commenced 45 minutes of treadmill running at a speed calculated to elicit 
70% of their �̇O2peak. Immediately following exercise, a blood sample was taken, with further 
interval samples at 15, 30, and 60 minutes post-exercise. At 60 minutes, patients administered 
a 50% rapid-acting insulin dose (4.0 ± 0.2 IU; see 2.2.6) (determined from the results of 
chapter 3) and consumed one of two isoenergetic meals similar in macronutrient content 
equating to 1.0 g.carbohydrate.kg-1 BM but differing in glycaemic index (GI). The meals were 
of either a low (GI = 37; 1.7 ± 0.1 MJ, MEAL 5) or high GI (GI = 92; 1.7 ± 0.1, MEAL 6) (see 
2.2.5.8, Table 2.3). Patients remained at rest for a further 180 minutes with periodic blood 
samples every 30 minutes. Fifteen minutes before the consumption of the post-exercise meal, 
and at 45, 105, and 165 minutes following the post-exercise meal, expired gases were collected 
for calculation of substrate oxidation rates (see 2.8). At 180 minutes post-exercise, patients 
consumed one of two isoenergetic bedtime snacks matched for macronutrient content and 
equating to 0.4 g.carbohydrate.kg-1 BM but differing in GI (low versus high) (Low: GI = 38, 
0.9 ±0.3 MJ, MEAL 8; High: GI = 86, 0.9 ± 0.3 MJ, MEAL 9) (see 2.2.5.9, Table 2.3), 
corresponding to the GI of the post-exercise meal. As such, patients completed two trials in a 
randomised and counter-balanced fashion: a low GI (LOW) and a high GI trial (HIGH). 
Following the consumption of the bedtime snack, patients were discharged from the laboratory 
and returned home. Transport was provided to patients on their journey home to control travel 
across trials. Patients were instructed to replicate sleeping patterns as best possible over the 
course of the study. Continuous glucose monitoring captured interstitial glucose for a further 
21 hours post-laboratory, and patients self-recorded β-hydroxybutyrate.  
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Table 4.0 Patients demographic information  
  Patient ID  
  1 2 3 4 5 6 7 8 9 10 11 MeanSEM 
Insulin 
(IU) 
Basal 38GM 20
D
B 22
G
M 26
D
B 34
G
E 18
D
B 20
G
E 31
G
M 24
G
M 30
G
E - 26  2 
Bolus 1L 1A 1A 1A 1A 0.8A 1A 1 A 1A 1A - 1.0  0.0 
HbA1c                      
(%) 
6.6 6.4 6.9 6.4 6.3 6.9 7.0 6.4 7.1 7.2 - 6.7  0.7 
BMI                    
(kg.m2) 
26.7 24.5 25.4 23.1 25.4 24.5 26.9 26.1 25.4 27.2 - 25.5  0.9 
Diabetes duration 
(years) 
15 16 16 14 15 4 26 14 16 15 - 15  2 
�̇O2peak         
(ml.kg.min-1) 
50.1 54.3 53.1 56.3 53.2 54.3 49.1 54.3 45.3 48.1 - 51.9  1.2 
Age 
(years) 
30 24 27 35 24 25 38 19 26 21 - 27  5 
Note: G = Glargine, D = Detemir, A = Aspart, L = Lispro, M = once daily (morning), E = once daily evening , B = 
bi-daily; bolus insulin calculated per 10g CHO. 
 
 
 
Rest Exercise 60 30 150 30 0 15 60 60 90 120 180 -24hr +21hr 
CGM 
Bolus insulin 
 
Bolus food 
 
Blood glucose 
HR and respiration 
Diet 
Activity 
Figure 4.0. Schematic of experimental trial. Note: Bold text indicates post-exercise intervention 
period. 
Self-recorded       
β-hydroxybutyrate 
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4.2 Results 
4.2.1 Pre-laboratory phase 
4.2.1.1 Pre-laboratory glycaemia 
Glycaemic control was comparable over the 24 hours prior to patients’ arrival at the laboratory 
for both experimental trials (CGM mean glucose: HIGH 7.9 ± 0.7, LOW 7.9 ± 0.7 mmol.l-1; p 
= 0.465; and total interstitial glucose area under the curve: HIGH 11277 ± 1069, LOW 10971 
± 1126 mmol.l-1.min-1; p = 0.215).  
4.2.1.2 Pre-laboratory dietary intake, insulin administration and activity 
There were no differences in total energy consumed (HIGH 9.0 ± 0.8, LOW 9.9 ± 0.8 MJ; p = 
0.508), with similar contribution from carbohydrate (HIGH 51 ± 3, LOW 46 ± 3 %; p = 
0.869), fat (HIGH 30 ± 3, LOW 32 ± 4 %; p = 0.301) and protein (HIGH 20 ± 2, LOW 22 ± 
3 %; p = 0.556). The total amount of rapid-acting insulin administered (HIGH 26 ± 4, LOW 
26 ± 4 IU; p = 0.609) and levels of activity (HIGH 6949 ± 105, LOW 7041 ± 118 steps; p = 
0.372) were comparable over the 24 hours before each trial. 
4.2.2 Laboratory phase 
The absolute blood glucose responses are presented in Figure 4.1. There was a significant 
condition*time interaction (F(11,99) = 15.972, p < 0.001, partial eta
2 = 0.666), and a significant 
time (F(11,99) = 39.827, p < 0.001, partial eta
2 = 0.833) and condition effect (F(1,9) = 15.049, p = 
0.005, partial eta2 = 0.653) for absolute blood glucose responses. Baseline blood glucose 
concentrations were similar (HIGH 6.5 ± 0.3, LOW 6.2 ± 0.7 mmol.l-1; p = 0.715), as were 
those immediately before exercise (HIGH 12.1 ± 1.0, LOW 12.1 ± 0.5 mmol.l-1; p = 0.762). 
4.2.2.1 Exercise and recovery period 
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Patients ran at an average speed of 10.1  0.3 km.hr-1, completing 7.6  0.2 km and expending 
3.0  0.2 MJ. Patients exercised at a similar intensity across trials (HIGH 77 ± 0, LOW 74 ± 0 
%�̇O2peak; p = 0.352; HIGH 80 ± 2, LOW 79 ± 3 %HRpeak; p = 0.631) inducing comparable 
falls in blood glucose (HIGH -5.4 ± 0.7, LOW -6.8 ± 0.5 mmol.l-1; p = 0.733; Figure 4.1) such 
that immediately following the cessation of exercise, blood glucose were comparable to 
baseline under both conditions (p > 0.05; Figure 4.1). There were no incidences of 
hypoglycaemia during exercise or throughout the 60 minutes recovery period, with blood 
glucose concentrations, on average, in euglycaemic ranges up to the administration of the post-
exercise meal (HIGH 6.4 ± 0.9, LOW 5.5 ± 0.7 mmol.l-1; p = 0.389; Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Time-course changes in blood glucose following the post-exercise meal intervention. Data 
presented as mean ± SEM. Black diamonds = HIGH, red circles = LOW. Transparent sample point 
within a condition indicates a significant difference from pre-meal concentrations (p ≤ 0.05). * 
indicates a significant different between HIGH and LOW (p ≤ 0.05). Vertical dashed line break 
indicates carbohydrate meal and insulin administration. Thatched area indicates exercise. Note: Test 
meal and insulin were administered immediately following 60 minutes post-exercise sample point. 
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4.2.2.2 Post-exercise intervention period 
Both meal types induced an increase in blood glucose concentrations over the subsequent 180 
minutes, although this rise was significantly attenuated following LOW, compared HIGH (p < 
0.05; Figure 4.1). Despite clear differences in glycaemia, all patients were protected from 
hypoglycaemia during this time, regardless of meal GI. However, all patients were exposed to 
hyperglycaemia following HIGH, whereas fewer patients experienced hyperglycaemia 
following LOW (n = 4). Moreover, hyperglycaemia was less pronounced (mean peak blood 
glucose: LOW 8.8 ± 1.0 vs. HIGH 15.9 ± 1.2 mmol.l-1; p = 0.005) and tended to be only 
transient (time spent hyperglycaemic: LOW 81 ± 26 vs. HIGH 165 ± 15 minutes; p < 0.001) 
following LOW. As such, immediately before the consumption of the bedtime snack, blood 
glucose concentrations were significantly greater following HIGH (HIGH 12.7 ± 1.5 vs. 
LOW 7.5 ± 2.6 mmol.l-1; p = 0.004; Figure 4.1), resulting in more patients leaving the 
laboratory hyperglycaemic (HIGH n = 9 vs. LOW n = 4). 
4.2.2.3 Substrate oxidation responses  
There were no differences in substrate oxidation responses during the post-exercise post-
prandial period, with average carbohydrate (HIGH 14.5 ± 2.6, LOW 14.7 ± 2.7 
g.carbohydrate.hr-1; p = 0.927) and lipid (HIGH 3.0 ± 0.9, LOW 3.1 ± 0.9 g.lipid.hr-1; p = 
0.809) oxidation rates similar.  
4.2.3 Post-laboratory phase 
4.2.3.1 Late evening glycaemic responses 
Following discharge from the laboratory and having consumed the bedtime snack, glycaemia 
during the late evening was significantly greater under HIGH (mean interstitial glucose: 
HIGH 13.2 ± 1.6 vs. LOW 9.3 ± 0.9 mmol.l-1; p = 0.011; Figure 4.2), with greater 
individualised mean peak interstitial glucose (HIGH 18.3 ± 1.1 vs. LOW 13.9 ± 0.8 mmol.l-1; 
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p = 0.009) and more patients in hyperglycaemic ranges before sleep (HIGH n = 9 vs. LOW n 
= 5). All patients under all conditions were protected from hypoglycaemia during this time. 
4.2.3.2 Nocturnal glycaemia  
During sleep, falling glucose levels were evident under both conditions, such that 
concentrations became comparable ~8 hours after exercise (p > 0.05; Figure 4.2). As such, 
mean interstitial glucose (HIGH 10.8 ± 1.4, LOW 8.4 ± 1.2 mmol.l-1; p = 0.262; Figure 4.2) 
and total interstitial glucose area under the curve (HIGH 5876 ± 738, LOW 4562 ± 672 
mmol.l
-1
.min
-1
; p = 0.236) during the night were similar between conditions. During the night, 
patients were exposed to hypoglycaemia under both conditions (HIGH n = 5, LOW n = 5), 
with similar time of onset (~8 hours post-exercise; Figure 4.2) and similar individualised 
interstitial glucose nadir (HIGH 3.6 ± 0.4, LOW 3.4 ± 0.3 mmol.l-1; p = 0.650). Despite some 
patients experiencing multiple bouts of hypoglycaemia (total number of episodes: HIGH 10, 
LOW n = 8), total time spent in hypoglycaemic ranges (HIGH 237 ± 55, LOW 176 ± 32 
minutes; p = 0.569) were similar between conditions, despite a tendency for fewer 
hypoglycaemic episodes and less times spent hypoglycaemic under LOW. There were no 
differences in time spent in euglycaemic (HIGH 202 ± 55, LOW 282 ± 55 minutes; p = 0.705) 
or hyperglycaemic ranges (HIGH 101 ± 44, LOW 81 ± 43 minutes; p = 0.765). As such, 
interstitial glucose concentrations immediately upon awakening were similar (HIGH 8.5 ± 0.9, 
LOW 8.3 ± 0.9 mmol.l-1; p = 0.614). Glycaemia remained similar between conditions for the 
remainder of the 24 hours post-exercise window (p > 0.05; Figure 4.2). 
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4.2.3.3 Post-laboratory dietary intake, insulin administration, activity, and self-recorded β-
hydroxybutyrate 
Self-recorded β-hydroxybutryate concentrations were undetectable in all patients throughout 
the post-laboratory period. During this time, total energy consumed (HIGH 3.0 ± 0.1, LOW 
2.9 ± 0.2 MJ; p = 0.774) with contribution from carbohydrate (HIGH 72 ± 5, LOW 64 ± 8 %; 
p = 0.767), fat (HIGH 20 ± 5, LOW 22 ± 7 %; p = 0.834) and protein (HIGH 8 ± 3, LOW 14 
± 6 %; p = 0.548) was similar between all conditions, despite more carbohydrate consumed to 
correct blood glucose (HIGH 32 ± 7, LOW 6.0 ± 4 g; p = 0.002). The total amount of rapid-
acting insulin administered (HIGH 17 ± 2, LOW 18 ± 2 IU; p = 0.967), and levels of activity 
(HIGH 6087 ± 94, LOW 6489 ± 118 steps; p = 0.369) were comparable during this time. 
Figure 4.2. Time-course changes in interstitial glucose concentrations throughout the post-laboratory 
period. Data presented as mean ± SEM. Black solid trace = HIGH, red broken trace = LOW. ** 
indicates a significant difference in interstitial glucose area under the curve between HIGH and LOW 
(p ≤ 0.05). Open circles represent hypoglycaemic episodes, as determined from CGM data Vertical 
dashed line break indicates nocturnal and daytime periods.  
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4.3 Discussion 
The aim of this study was to determine whether manipulating the glycaemic index of 
carbohydrates consumed following evening-time exercise could modulate post-prandial 
glycaemia and metabolism, to provide protection from post-exercise, post-prandial 
hyperglycaemia and late-onset hypoglycaemia in patients with type 1 diabetes. This study 
demonstrates for the first time that consumption of low glycaemic index carbohydrates, under 
conditions of reduced rapid-acting insulin dose following evening exercise, improves post-
prandial glycaemia, by reducing hyperglycaemia and offering protection from hypoglycaemia 
for approximately 8 hours after exercise. However, beyond this time risk of late-onset 
nocturnal hypoglycaemia persists regardless of the glycaemic index of the post-exercise meal 
and bedtime snack.  
Chapter 3A demonstrated the importance of reducing rapid-acting insulin dose administered 
with the meal after, as well as before exercise to extend the period of protection from post-
exercise hypoglycaemia (Campbell et al. 2013). This study now demonstrates that under these 
conditions, the composition of the post-exercise meal has an important role for modulating 
post-prandial glycaemia. Blood glucose concentrations following the high GI post-exercise 
meal were significantly greater than that with the low GI meal, consequently exposing all 
patients in the former condition to hyperglycaemia during the laboratory observation period. 
Conversely, the incidence of hyperglycaemia was reduced by 60% after the low GI meal 
(LOW = 40% vs. HIGH = 100%). Indeed, in those patients affected, hyperglycaemia was less 
pronounced and tended to be only transient and short lasting after the low GI meal. Despite 
clear post-prandial differences in glycaemia between the high and low GI meals, all patients 
remained protected from hypoglycaemia during their time in the laboratory. Presently, there 
are relatively few dietary guidelines to assist individuals with type 1 diabetes in managing 
post-exercise glycaemia. This study shows that by consuming a low glycaemic index post-
exercise meal, post-prandial hyperglycaemia can be reduced, without exposure to 
hypoglycaemia. This is an important observation because the aim of diabetes management is to 
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normalise blood glucose concentrations (Thomas et al. 2007), especially when incorporating 
exercise into the lives of patients (Chu et al. 2011).  
When exercise is performed in the evening, consumption of a carbohydrate-based snack before 
bed is recommended for type 1 diabetes patients (Hernandez et al. 2000). Blood glucose was 
typically within the euglycaemic ranges prior to the consumption of the bedtime snack 
following the low GI post-exercise meal, whereas following consumption of the high GI meal 
and snack, patients tended to stay in hyperglycaemic ranges over the entire duration of the 
post-exercise post-prandial period (LOW ~7.5 vs. HIGH ~12.2 mmol.l-1). Outside of formal 
studies, patients within normal blood glucose ranges before bed often choose to raise 
glycaemia by consuming a carbohydrate-based snack (Hernandez et al. 2000) due to fear of 
nocturnal hypoglycaemia (Cryer and Childs 2002). However, patients who are severely 
hyperglycaemic before bed (such as those under HIGH) may be tempted to administer 
corrective insulin units, which, in an exercise-induced insulin sensitised state (Mikines et al. 
1988, Maarbjerg et al. 2011) is likely to cause a rapid fall in glucose during the night. 
Avoidance of the bedtime snack, and hence missing a valuable source of carbohydrate before 
sleep, is likely to exacerbate the risk of nocturnal hypoglycaemia. Despite wide differences in 
blood glucose concentrations before sleep under all conditions, declines occurred irrelevant of 
post-exercise meal and snack composition, such that conditions became comparable 3 hours 
after consuming the bedtime snacks and with similar rates of nocturnal hypoglycaemia 
thereafter. This indicates that patients are at risk of late-onset nocturnal hypoglycaemia with 
predicted nadir more than 8 hours post-exercise (Mcmahon et al. 2007, Campbell et al. 2013) 
(chapter 3A) despite the consumption of a bedtime snack, regardless of GI, or blood glucose 
levels before bed. Thus, it would seem that elevating blood glucose before sleep through 
consumption of high GI carbohydrates in the post-exercise period confers no glycaemic benefit 
for avoiding nocturnal hypoglycaemia. 
So that it was possible to investigate the impact of the GI of the evening carbohydrates, 
patients consumed enough carbohydrate (consuming 2.6 g.carbohydrate.kg-1 BM during the 
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evening) to cover the cost of the exercise bout, with patients utilising ~1.7 g.carbohydrate.kg-1 
BM in total during exercise, and with total daily carbohydrate intake matching current 
recommendations of ~5.0 g.carbohydrate.kg-1BM  (Riddell and Perkins 2006, Perry and Gallen 
2009), thus establishing a positive carbohydrate balance. Despite consuming sufficient 
carbohydrate for the recovery of muscle glycogen post-exercise, and perhaps consuming more 
carbohydrate than is typical, hypoglycaemia was still encountered late after exercise in the 
early hours of the morning. Indeed this study shows that acute alterations in insulin dosage and 
carbohydrate feeding both before and after evening exercise are not enough to prevent late-
onset hypoglycaemia in all patients. These findings direct attention towards the role of basal 
insulin administration in avoiding nocturnal hypoglycaemia after evening exercise. 
Considering once daily insulin Glargine administration is associated with a glucose nadir 4-14 
hours after administration (Ashwell et al. 2006, Thomas et al. 2007), not only basal insulin 
dose but also the timing of administration may be of particular importance.  
The aim of this study was to assess the acute and 24 hour glycaemic effects of manipulating 
the glycaemic index of carbohydrates consumed following evening exercise, under conditions 
of reduced pre- and post-exercise rapid-acting insulin dose. This study shows for the first time 
that consuming low glycaemic index carbohydrates in tandem with a reduced rapid-acting 
insulin dose following evening exercise can play an important role in normalising glycaemia, 
preventing post-prandial hyperglycaemia whilst protecting patients from hypoglycaemia for up 
to 8 hours after exercise. The clinical utility of these findings is clear, as carbohydrates which 
are part of a patients habitual diet can be easily exchanged with those that offer the same 
macronutrient content but are of a low GI (e.g. substituting particular types of breads, strains 
of rice, pastas and potatoes, or sports drinks with different carbohydrate compositions) 
facilitating more desirable post-prandial glycaemic responses. However, it does not seem that 
carbohydrate type, nor total carbohydrate intake alone, are factors in the development of late-
onset hypoglycaemia, as patients may still be exposed to nocturnal hypoglycaemia following 
evening-time exercise. There is now a need to firstly: determine whether this strategy is 
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associated with adverse hormonal, metabolic, counter-regulatory disturbances, and whether 
there is an effect on appetite regulation, and secondly: to focus on basal insulin adjustment to 
determine whether late-onset nocturnal hypoglycaemia following evening-time exercise can be 
avoided, whilst harnessing improved post-prandial profiles following the consumption of low 
GI carbohydrates with a reduced rapid-acting insulin dose, during the post-exercise period.  
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CHAPTER 4B 
 
 
 
 
 
 
 
 
THE METABOLIC, INFLAMMATORY, AND COUNTER-
REGULATORY HORMONAL RESPONSES FOLLOWING 
MANIPULATION OF THE GLYCAEMIC INDEX OF 
CARBOHYDRATES CONSUMED AFTER EVENING EXERCISE 
IN TYPE 1 DIABETES 
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4.4 Introduction 
Chapter 4A demonstrated that under conditions of reduced rapid-acting insulin dose, the 
consumption of low glycaemic index carbohydrates following evening exercise modulates 
post-prandial glycaemia such that hyperglycaemia is reduced without increased risk of early-
onset post-exercise hypoglycaemia (Campbell et al. 2014). Whereas there is a clear glycaemic 
benefit for altering the composition of post-exercise meals following exercise whilst under 
conditions of reduced rapid-acting insulin dose, it remains unknown whether this strategy 
carries implications for hormonal, metabolic, or inflammatory parameters. Thus, the efficacy 
of manipulating post-exercise carbohydrates is yet to be determined. Considering the wide 
glycaemic variation attributed to differences in GI, it is likely that hormonal, metabolic and / or 
inflammatory measures could differ significantly between two meals with contrasting GI 
values.  
It is known that hyperglycaemia is associated with an inflammatory cytokine response 
(Targher et al. 2001, Esposito et al. 2002, De Rekeneire et al. 2006, Rosa et al. 2008), and 
hypoinsulinaemic hyperglycaemia is associated with increased lipolysis and ketogenesis 
(Laffel 2000, Wallace and Matthews 2004). This was demonstrated in chapter 3B, in which a 
positive association between increased blood glucose and NEFA, and increased blood glucose 
and β-hydroxybutyrate appearance were evident. Although a clinically-meaningful difference 
in β-hydroxybutyrate concentrations was not established, nor were there clear differences 
observed in the pro-inflammatory cytokine TNF-α, patients were on average in only mildly 
hyperglycaemic ranges in chapter 3A (average blood glucose ~9.9 mmol.l-1) compared to those 
observed in chapter 4A following the high GI post-exercise meals (average blood glucose 
~13.2 mmol.l-1). Furthermore, on average patients displayed a greater mean peak blood 
glucose (chapter 3A ~11.5, chapter 4A ~14.3 mmol.l-1). With this in mind, there may be 
greater potential for wider differences in hormonal, metabolic and inflammatory parameters 
following the consumption of a high GI post-exercise meal. Whether normalisation of 
glycaemic profiles (Daneman 2006) through consumption of a low GI post-exercise meal can 
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avoid such disturbances is yet to be determined. Accordingly, the aim of this study was to 
investigate the influence of manipulating the GI of the meal consumed following evening 
exercise on hormonal, metabolic and inflammatory parameters in type 1 diabetes patients. 
4.5 Methods 
A second arm of analysis was performed on all patients from HIGH and LOW trials from 
chapter 4A. Blood lactate, serum cortisol, non-esterified-fatty-acids, -hydroxybutyrate, and 
plasma glucagon, adrenaline, glycerol, IL-6 and TNF-α were measured for 180 minutes post-
meal (Figure 4.3). 
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Figure 4.3. Schematic of experimental trial. Note: Bold text indicates post-exercise intervention period. 
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4.6 Results 
4.6.1 Serum insulin, counter-regulatory hormone and metabolite responses 
The serum insulin responses are presented in Figure 4.4. There was a significant time effect 
(F(11,99) = 13.232, p < 0.001, partial-eta
2 = 0.343), but not a time*condition interaction (F(1,9) = 
13.002, p < 0.001, partial-eta2 = 0.652) when examining insulin concentrations. Serum insulin 
concentrations peaked similarly at 60 minutes following the post-exercise meal / 
administration of rapid-acting insulin dose, before returning to pre-meal and resting 
concentrations under both conditions (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Time-course changes in serum insulin from rest. Data presented as mean ± SEM. Black 
diamonds = HIGH, red circles = LOW. Transparent sample point within a condition indicates a 
significant difference from pre-meal concentrations (p ≤ 0.05). * indicates significantly different from 
HIGH (p ≤ 0.05). Thatched area indicates exercise. Vertical dashed line break indicates carbohydrate 
meal and insulin administration. Note: Test meal and insulin were administered immediately following 
60 minutes post-exercise sample point. 
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Hormonal and metabolite responses are presented in Table 4.1. There were no conditional 
differences in counter-regulatory hormones or metabolites up to 60 minutes post-exercise (p > 
0.05; Table 4.1). There were no conditional differences in absolute concentrations of plasma 
glucagon, adrenaline, or serum cortisol (Table 4.1). Plasma glucagon concentrations peaked 
similarly 30 minutes following the post-exercise meals. Over the course of the remaining post-
prandial period concentrations declined under HIGH such that at 150 and 180 minutes, 
concentrations were lower to those elicited at pre-meal, whereas under LOW this decline was 
largely attenuated (Table 4.1). Serum cortisol declined similarly such that concentrations under 
both conditions were lower than those observed pre-meal (Table 4.1).  
Blood lactate was, on average, greater under LOW over the course of the post-exercise post-
prandial period, although this failed to reach statistical significance between conditions and by 
150 and 180 minutes concentrations were similar to resting and pre-meal concentrations (Table 
4.1). Plasma glycerol concentrations were significantly lower following the LOW meal, with 
measures declining below pre-meal concentrations (p < 0.05; Table 4.1). No differences were 
observed in serum NEFA (Table 4.1) or β-hydroxybutyrate (Figure 4.5), with concentrations 
similar to pre-meal and rest at 180 minutes post-meal. 
4.6.2 Inflammatory cytokine responses 
The inflammatory cytokine responses are presented in Figure 4.5. There was a significant 
time*condition interaction (F(11,99) = 12.567, p < 0.001, partial-eta
2 = 0.583), and a significant 
effect of time (F(11,99) = 11.792, p < 0.001, partial-eta
2 = 0.567) and condition (F(1,9) = 9.664, p = 
0.013, partial-eta2 = 0.518) when examining plasma IL-6 concentrations. There was also a 
significant time*condition interaction (F(11,99) = 17.027, p < 0.001, partial-eta
2 = 0.654), and a 
significant effect of time (F(11,99) = 8.996, p < 0.001, partial-eta
2 = 0.500) and condition (F(1,9) = 
16.341, p = 0.03, partial-eta2 = 0.645) when examining plasma TNF-α concentrations. 
Resting concentrations of IL-6 and TNF-α were positively related to length of diabetes (IL-6: r 
= 0.762, p = 0.010; TNF-α: r = 0.786, p = 0.007) and inversely related to HbA1c (IL-6: r = -
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0.708, p = 0.022; TNF-α: r = -0.600, p = 0.049), but not �̇O2peak (IL-6: r = -0.374, p = 0.288; 
TNF-α: r = -0.165, p = 0.650). Length of diagnosis and HbA1c were negatively correlated (r = -
0.942, p <0.001). 
Both plasma IL-6 and TNF-α concentrations were significantly raised 15 minutes post-exercise 
(Figure 4.5) but returned to resting concentrations immediately before the administration of the 
post-exercise meals. Following HIGH post-prandial IL-6 and TNF-α significantly increased 
above pre-meal and resting concentrations (Figure 4.5), whereas IL-6 and TNF-α was 
attenuated following LOW. As such, at 180 minutes post-meal IL-6 and TNF-α decreased 
below resting measures under LOW, whereas concentrations remained elevated under HIGH. 
Average IL-6 and TNF-α concentrations over the post-exercise post-prandial period were 
positively correlated with average blood glucose concentrations (IL-6: r = 0.425, p = 0.049; 
TNF-α: r = 0.425, p = 0.049). No other relationships were found between any other measures.  
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Figure 4.5 A-C. Time-course changes in (A) plasma IL-6, (B) plasma TNF-α and (C) serum β-
hydroxybutyrate throughout the laboratory period. Data presented as mean ± SEM. Black diamonds = 
HIGH, red circles = LOW. Transparent sample point within a condition indicates a significant 
difference from pre-meal concentrations (p ≤ 0.05). * indicates significantly different from HIGH (p ≤ 
0.05). Thatched area indicates exercise. Vertical dashed line break indicates carbohydrate meal and 
insulin administration. Thatched area indicates exercise. Note: Test meal and insulin were administered 
immediately following 60 minutes post-exercise sample point. 
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Table 4.1. Metabolic and counter-regulatory hormone responses to post-exercise meals of differing glycaemic index  
 
 
ANOVA p 
 Rest 60 E 0 15 30 Pre-Meal 30 60 90 120 150 180 T T*C 
Plasma 
Glucagon 
(pg.ml-1) 
HIGH 730±99 591±72†  682±68 760±83 768±94 833±117 953±155† 922±154† 872±145† 798±141 690±100‡ 669±101‡ <0.001 =0.306 
LOW 733±130 611±75†  658±68 792±82 818±100 816±125 947±170†‡ 937±159†‡ 907±149† 862±141 806±120 840±139   
Plasma 
Adrenaline       
(nmol.l-1) 
HIGH 0.09±0.01 0.15±0.03 
 0.55±0.10† 0.35±0.11† 0.15±0.03 0.15±0.04 0.17±0.02 0.16±0.03 0.11±0.04 0.09±0.02 0.11±0.03 0.08±0.02 =0.013 =0.497 
LOW 0.08±0.02 0.15±0.02 
 0.54±0.12† 0.28±0.10† 0.14±0.04 0.14±0.04 0.15±0.02 0.13±0.03 0.11±0.02 0.11±0.02 0.10±0.02 0.07±0.02   
Serum 
Cortisol       
(µmol.l-1) 
HIGH 0.17±0.03 0.18±0.02 
 0.28±0.02† 0.33±0.04† 0.24±0.03† 0.19±0.02 0.14±0.02 0.14±0.02 0.13±0.02‡ 0.11±0.01†‡ 0.08±0.01†‡ 0.08±0.01†‡ <0.001 =0.099 
LOW 0.17±0.03 0.15±0.02 
 0.24±0.03† 0.32±0.05† 0.23±0.04† 0.18±0.03 0.13±0.02‡ 0.12±0.02‡ 0.10±0.01†‡ 0.10±0.01‡ 0.10±0.01‡ 0.09±0.01‡   
Blood 
Lactate 
(mmol.l-1) 
HIGH 1.0±0.2 1.1±0.3 
 4.1±0.8† 2.1±0.5† 1.3±0.3 1.0±0.3 0.7±0.2 0.9±0.2 0.8±0.1 0.7±0.2 0.5±0.1 0.4±0.1† =0.001 =0.129 
LOW 0.9±0.2 1.0±0.2 
 4.2±0.5† 1.7±0.3 1.2±0.3 1.±0.2 0.8±0.2† 1.0±0.2 1.1±0.2 1.2±0.2‡ 0.6±0.2 0.5±0.2   
Serum 
NEFA 
(mmol.l-1) 
HIGH 0.18±0.05 0.12±0.03 
 
0.25±0.06 0.35±0.06† 0.43±0.11† 0.53±0.15† 0.37±0.07 0.24±0.06‡ 0.24±0.07‡ 0.27±0.11‡ 0.27±0.09‡ 0.35±0.13 =0.011 =0.514 
LOW 0.27±0.07 0.18±0.03 
 
0.27±0.07 0.34±0.07† 0.33±0.07 0.39±0.10† 0.39±0.10† 0.27±0.07 0.24±0.05 0.24±0.05 0.27±0.05 0.30±0.05   
Plasma 
Glycerol 
(mmol.l-1) 
HIGH 4.23±0.58 4.35±1.23 
 
6.83±1.51 5.02±1.13 5.69±1.31 7.21±1.83 7.52±1.78 9.50±2.23† 10.03±2.84† 8.99±2.99 8.36±2.21 6.15±1.80 =0.316 =0.032 
LOW 4.35±0.54 4.47±1.28 
 
6.49±1.54 5.05±1.07 5.55±1.06 6.92±1.61 5.78±1.72* 5.42±1.61* 3.63±0.85*‡ 2.96±0.69*‡ 4.07±0.82*‡ 2.89±0.85*‡   
Note: Data presented as mean  SEM. Test meal and insulin were administered immediately following rest and pre-meal sample points. * indicates significantly different from 
HIGH (p ≤ 0.05). † indicates significantly different from rest. ‡ indicates significantly different from pre-meal. Exercise commenced 60 minutes after rest. T = Time, C = Condition, 
E = Exercise. 
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4.7 Discussion 
The aim of this study was to determine whether manipulating the glycaemic index of foods 
consumed following evening-time exercise influence hormonal, metabolic or inflammatory 
parameters and appetite responses in patients with type 1 diabetes. This study demonstrates 
that consumption of a low glycaemic index post-exercise meal administered in tandem with 
reduced rapid-acting insulin dose reduces circulating inflammatory markers, whereas these 
inflammatory markers are significantly elevated following substitution for a high GI meal. 
Other hormonal and metabolic measures remain unaffected. 
The clinical utility of consuming meals with a low GI around the time of exercise is clear; 
specifically, low GI meals after exercise offer more favourable postprandial glycaemic 
profiles, without an increased risk of post-exercise hypoglycaemia in type 1 diabetes patients 
(West et al. 2011, West et al. 2011, Campbell et al. 2014) (chapter 4A). This is important 
because the inclusion of exercise into the lives of patients is severely hampered by difficulties 
in managing post-exercise glycaemia. Now, this study demonstrates that manipulating the 
glycaemic index of meals under conditions of a reduced rapid-acting insulin dose also carries 
important implications on inflammatory markers. This is important, as regular exposure to 
metabolic, hormonal or inflammatory disturbances could significantly influence long-term 
diabetes-related complications in regularly exercising patients (Rabasa-Lhoret et al. 2001). 
This study shows that meal GI has significant implications for post-prandial circulating 
inflammatory markers; specifically, for the first time, under non-clamp techniques and 
replicating free-living conditions, inflammatory cytokines TNF-α and IL-6 were dramatically 
increased following a high GI meal. An otherwise comparable low GI meal completely 
prevented rises in these inflammatory cytokines. The clinical relevance of these findings 
should not be underestimated, as offsetting hyperglycaemia and inflammation is important for 
preventing early pathogenetic diabetes-related complications (Rosa et al. 2011). Indeed, 
resting inflammatory cytokine concentrations were positively related to length of diabetes, 
supporting the notion that diabetes is a long-standing inflammatory disease (Devaraj et al. 
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2007). Moreover, resting inflammatory cytokine concentrations were positively correlated with 
average blood glucose concentrations and inversely related to HbA1c, strengthening the 
hypotheses of hyperglycaemia as a mediator of inflammation (Devaraj et al. 2005, De 
Rekeneire et al. 2006, Galassetti et al. 2006) and that the normalisation of glycaemic profiles 
through tight diabetes management reduces inflammatory disturbances. Moreover, anti-IL-6 
therapy has demonstrable effects for reducing HbA1c (Ogata et al. 2011) and neutralisation of 
TNF-α improves glucose metabolism (Hotamisligil et al. 1993).  
However, the pathological versus the beneficial nature of IL-6 remains to be fully understood. 
Indeed, during contraction, muscles can produce IL-6 strictly independently of TNF-α (Keller 
et al. 2006), strengthening the argument that muscular IL-6, of which is quantitatively more 
important than that released from any other tissue (Hiscock et al. 2004), plays a role in 
metabolism and not just inflammation per se. IL-6 expression is increased when intramuscular 
glycogen is low, consuming carbohydrate during exercise diminishes the exercise induced 
increases in IL-6 (Nehlsen-Cannarella et al. 1997, Nieman et al. 1998), and studies in humans 
show increased hepatic glucose output in response to injections of recombinant human IL-6 
(Stouthard et al. 1995). Taken together it would seem that IL-6 is related to hepatic glycogen 
content, plays a role in endogenous glucose production, and is involved in muscle-to-liver 
communication (Febbraio et al. 2004). This seems plausible as muscle-derived IL-6 has been 
shown to contribute to improved glycaemia following exercise (Pedersen and Febbraio 2008) 
by increasing glucose uptake (Ellingsgaard et al. 2011).  
In addition, IL-6 has been shown to mediate post-exercise increases in GLP-1 secretion (Allen 
et al. 2012) indicating a potential role for insulin-mediated glucose uptake. The incretin 
response in type 1 diabetes is known to be diminished however (Greenbaum et al. 2002, 
Aronoff et al. 2004). Data taken from mice models in which β-cells were destroyed with 
streptozotocin have failed to show any improvement in insulin secretion with exogenous 
administration of IL-6 (Allen et al. 2012), which, when considering the pathology of type 1 
diabetes, may make the role of IL-6 an unlikely antagonist for hyperglycaemia. 
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Additionally, β-hydroxybutyrate concentrations did not significantly rise under either of the 
two conditions (Figure 4.5), remaining similar to pre-meal and resting concentrations. Basal 
insulin dose remained unchanged, and despite a reduction in rapid-acting insulin dose, 
circulating insulin concentrations likely remained sufficient for suppression of β-
hydroxybutyrate production (Mcgarry 1996), potentially driving ketone body disposal (Balasse 
and Féry 1989). Concentrations during both trial conditions were well below those levels 
deemed clinically significant (> 1.0 mmol.L-1) (Laffel 2000). All other hormonal and 
metabolite measures remained similar between conditions during the post-exercise post-
prandial period.  
The aim of this study was to assess the metabolic, inflammatory, and counter-regulatory 
hormonal effects of manipulating the glycaemic index of post-exercise carbohydrates 
consumed following evening exercise, under conditions of reduced pre- and post-exercise 
rapid-acting insulin dose. This study demonstrates that consumption of a low GI post-exercise 
meal under conditions of a reduced rapid-acting insulin dose reduces markers of inflammation, 
whereas substitution for a high GI meal significantly elevates inflammatory parameters. Other 
hormonal and metabolic measures remain unaffected. There is now a need to assess the impact 
of this strategy on appetite responses. 
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CHAPTER 4C 
 
 
 
 
 
 
 
 
APPETITE RESPONSES FOLLOWING MANIPULATION OF 
THE GLYCAEMIC INDEX OF CARBOHYDRATES CONSUMED 
AFTER EVENING EXERCISE IN TYPE 1 DIABETES 
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4.8. Introduction 
Current recommendations stipulate that exercising patients consume adequate amounts of 
carbohydrate to avoid hypoglycaemia (Gallen et al. 2011). As evidenced in chapter 4A 
however, it would seem that the risk of developing hypoglycaemia late-after exercise remains 
in spite of consuming enough carbohydrate to cover the cost of exercise. Following exercise, 
over-consumption of carbohydrate (Dubé et al. 2014), and ultimately excessive energy intake 
(Robertson et al. 2009), as a preventative measure against further falls in glycaemia, may 
negate the benefits exercise offers and could potentially contribute to a deterioration in wider 
diabetes management (Kennedy et al. 2013).  
Research has shown that insufficient exercise and excessive energy intake can confer 
detrimental long-term implications for glycaemic control and cardiovascular risk in patients 
(Wadén et al. 2008; Salem et al. 2010). Conversely, elevating energy expenditure through 
regularly exercising, and thus inducing a negative energy balance could be advantageous to 
glycaemic control; reduced energy and carbohydrate intake may assist in the prevention of 
adiposity accumulation and the associated insulin resistance which occurs following diagnosis 
of type 1 diabetes (de Vries et al. 2013). However, even in people without diabetes there is a 
risk of over-compensation of energy intake in response to energy expenditure (King et al. 
2012), potentially due to increased appetite (King et al. 2012). Nonetheless, a negative energy 
balance can be induced further when combined with a dietary strategy (Shaw et al. 2006). 
Indeed, modulating post-exercise appetite through nutritional strategies could be advantageous 
for type 1 diabetes patients, thus, appetite regulation following exercise is emerging as an 
important component of diabetes care (Specht et al. 2013, Dubé et al. 2014).  
The composition of the foods consumed following exercise is of importance to type 1 diabetes 
patients. Chapter 4A illustrated improved glycaemia in the acute post-exercise period when 
LGI carbohydrates are consumed after exercise, compared HGI. This is important, as patients 
with type 1 diabetes are faced with particular difficulty in normalising glycaemia around the 
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time of exercise and more so following exercise (chapter 3A and 4A), repeated exposure to 
severe glycaemic variability on a regular basis may indeed negate the benefits that exercise 
offers (Chimen et al. 2012, Kennedy et al. 2013). However, the impact of food composition on 
appetite in type 1 diabetes is less well understood.  
In people without type 1 diabetes, diets that contain LGI carbohydrates are associated with 
reductions in appetite (Stevenson et al. 2009), however this may not be the case when fibre 
content is matched (Gonzalez and Stevenson 2012). The acute impact of glycaemic index on 
appetite in a healthy population may be largely driven by insulinaemia rather than glycaemia, 
as postprandial insulin concentrations are inversely related to hunger, whereas postprandial 
glycaemia does not (Flint et al. 2006). Another potential factor in the appetite response to HGI 
vs. LGI meals is the gastrointestinal peptide glucagon-like peptide-1 (GLP-1), which 
suppresses appetite and energy intake (Verdich et al. 2001). GLP-1 is secreted by 
enteroendocrine cells in response to nutrient exposure and displays a differential response 
following ingestion of carbohydrates that differ in their rate of appearance into the circulation 
(Wachters-Hagedoorn et al. 2006). Whether these assumptions can be applied to patients with 
type 1 diabetes remains to be established, as differences in post-prandial glucose and GLP-1 
excursions are vastly different to those witnessed in people without diabetes (Kamoi et al. 
2011). In addition, studying appetite responses following HGI and LGI meals in type 1 
diabetes patients offers a unique insight into the impact of meal glycaemic index, whereby 
insulin-induced satiety is not confounded by dissimilar insulinaemia (Air et al. 2002), as 
administration of insulin dose is typically based on carbohydrate amount and not type. 
Accordingly, this study had two main aims: 1) to investigate the appetite and GLP-1 response 
to HGI and LGI post-exercise meals in type 1 diabetes patients, thereby reflecting a typical 
daily situation in which exercise recommendations for minimising the risk of hypoglycemia 
are adhered; 2) to examine the influence of the glycaemic index on appetite independent of 
insulinaemia and fibre content.  
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4.9. Methods 
HIGH and LOW trials from chapter 4A were repeated in a randomised and counterbalanced 
fashion. Such that, the same cohort of patients performed HIGH and LOW trials twice, to 
avoid repetition of data. Blood glucose, serum insulin, plasma glucagon, and total GLP-1, and 
subjective appetite scores (via visual analogue scales) were measured for 180 minutes post-
meal (Figure 4.6). 
 
 
 
 
 
 
 
 
 
4.10. Results 
4.10.1 Pre-intervention phase 
There were no differences in glycaemia, serum insulin, plasma glucagon concentrations or 
appetite scores prior to the consumption of the post-exercise test meals (p > 0.05), such that 
immediately before administration, patients displayed similar blood glucose (HIGH 6.2 ± 0.7 
vs. LOW 5.8 ± 0.5 mmol.l-1, p = 0.169; Figure 4.7), serum insulin (HIGH 106 ± 15 vs. LOW 
Visual 
analogue scales 
Rest Exercise 60 150 30 60 60 90 120 180 
Bolus insulin 
Bolus food 
 
Blood 
glucose 
 Serum   
insulin 
 Plasma    
glucagon 
Plasma      
total GLP-1 
Figure 4.6. Schematic of experimental trial. Note: Bold text indicates post-exercise intervention 
period. 
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102 ± 14 pmol.l-1, p = 0.986; Figure 4.7), plasma glucagon (HIGH 732 ± 99 vs. LOW 735 ± 
103 pg.ml-1, p = 0.884; Figure 4.8), and total GLP-1 (HIGH 1.95 ± 0.21 vs. LOW 2.47 ± 0.87 
pmol.l-1, p = 0.620; Figure 4.8). At this time, sensations of hunger (HIGH 68 ± 3 vs. LOW 67 
± 2, p = 0.925) and fullness (HIGH 60 ± 2 vs. LOW 61 ± 2, p =0.791) were similar between 
conditions. 
4.10.2 Post-intervention phase 
Following administration of rapid-acting insulin and test meals, serum insulin peaked similarly 
at 60 minutes under both conditions (HIGH 181 ± 26 vs. LOW 175 ± 30 pmol.l-1, p = 0.773; 
Figure 4.7). Blood glucose increased from periprandial concentrations over the postprandial 
period under both conditions, but elevations were significantly more pronounced under HIGH, 
with greater mean peaks (HIGH +10.2 ± 0.5 vs. LOW +3.2 ± 0.6 mmol.l-1, p < 0.001; Figure 
4.7). Temporal changes in serum insulin remained similar beyond this time (p > 0.05; Figure 
4.7), with concentrations returning to periprandial measures at 180 minutes (p > 0.05; Figure 
4.7). Moreover, total insulin AUC were similar between conditions over the postprandial 
period (HIGH 49576 ± 6786 vs. LOW 43924 ± 6196 pmol.l-1.min-1, p = 0.332). Total blood 
glucose AUC was significantly greater under HIGH (HIGH 2205 ± 90 vs. LOW 1437 ± 107 
mmol.l-1.min-1, p = 0.002), displaying a significantly greater average change in absolute blood 
glucose concentrations over the post-meal period (HIGH +6.6 ± 0.9 vs. LOW +1.7 ± 0.4 
mmol.l-1, p < 0.001). As such, patients under HIGH were, on average, hyperglycaemic (HIGH 
12.8 ± 0.5 mmol.l-1; Figure 4.7), whereas patients under LOW typically remained within 
euglycaemic ranges (LOW 7.6 ± 0.6 mmol.l-1, p = 0.002; Figure 4.7).  
Glucagon concentrations were significantly increased following the administration of both 
meals peaking similarly 30 minutes after consumption (Figure 4.8). Following this, 
concentrations declined under HIGH such that at 150 and 180 minutes concentrations were 
lower than pre-meal, whereas the decline under LOW was largely attenuated (Figure 4.8). 
However, total glucagon AUC was not statistically different between conditions (LOW 
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264150 ± 98209 vs. HIGH 247054 ± 79042 pg.ml-1.min-1; p = 0.141). Temporal increases in 
total GLP-1 at 60 minutes following the meal were not statistically significant (p = 0.223), 
with concentrations similar between conditions and baseline over the course of the post-
prandial period (Figure 4.8). 
Sensations of hunger peaked at 60 minutes under both conditions, which was matched with 
suppression in feelings of fullness (Figure 4.9). Over the remaining 120 minutes hunger 
sensations decreased under HIGH, whereas there was an increase in fullness. Inversely, under 
LOW increases in hunger and decreases in fullness were largely attenuated. Total AUC for 
feelings of hunger and fullness were significantly greater (LGI 7619 ± 1130 vs. HIGH 6961 ± 
1050 mm.min-1, p < 0.001), and lower (LOW 2669 ± 421 vs. HIGH 3345 ± 561 mm.min-1, p 
< 0.001) under LOW, respectively. 
Under LOW, a negative relationship was observed between total post-meal blood glucose 
AUC and hunger AUC (r = 0.840, p = 0.039), but not fullness AUC (r = 0.006, p = 0.910) or 
serum insulin AUC (r < 0.001, p = 0.977), plasma total GLP-1 (r = 0.018, p = 0.543). Neither 
hunger (r = 0.004, p = 0.900) nor fullness (r = 0.040, p = 0.699) were associated with changes 
in serum insulin AUC. Neither glucagon AUC nor total GLP-1 were associated with any other 
variable under LOW. No other correlations were observed between measures under HIGH (p 
> 0.05). 
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Figure 4.7 A-B. Time-course changes in (A) serum insulin and (B) blood glucose. Data presented 
as mean ± SEM. Black diamonds = HIGH, red circles = LOW. Transparent sample point within a 
condition indicates a significant difference from pre-meal concentrations (p ≤ 0.05). * indicates 
significantly different from HIGH (p ≤ 0.05). Thatched area indicates exercise. Vertical dashed 
line break indicates post-exercise intervention. Note: Test meal and insulin were administered 
immediately following 60 minutes post-exercise sample point. 
A 
B 
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Figure 4.8 A-B. Time-course changes in (A) plasma glucagon and (B) plasma GLP-1 total. 
Data presented as mean ± SEM. Black diamonds = HIGH, red circles = LOW. Transparent 
sample point within a condition indicates a significant difference from pre-meal 
concentrations (p ≤ 0.05). Thatched area indicates exercise. Vertical dashed line break 
indicates post-exercise intervention. Note: Test meal and insulin were administered 
immediately following 60 minutes post-exercise sample point. 
B 
A 
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Figure 4.9 A-B. Time-course changes from pre-meal in (A) hunger, and (B) fullness. Data 
presented as mean ± SEM. Black diamonds = HIGH, red circles = LOW. Transparent sample 
point within a condition indicates a significant difference from pre-meal concentrations (p ≤ 0.05). 
* indicates significantly different from HIGH (p ≤ 0.05). Post-exercise meal and insulin 
administration at 0 minutes sample point. Positive change on Y axis denotes an increase in hunger 
(A), and fullness (B), negative change denotes a decrease. 
A 
B 
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4.11. Discussion 
The aim of this study was to investigate the influence of manipulating the GI of the meal 
consumed following exercise on appetite responses in type 1 diabetes patients. This study 
shows for the first time that high GI carbohydrates consumed following exercise, elevates 
subjective feelings of fullness and supresses sensations of hunger in patients with type 1 
diabetes. It is important to note that these responses were observed under comparable 
insulinaemia and when meals were matched for macronutrient composition and fibre content. 
Consuming meals with a low GI before and after exercise offer more favourable postprandial 
glycaemic profiles without increasing the risk of post-exercise hypoglycaemia in type 1 
diabetes patients (West et al. 2011, West et al. 2011, Campbell et al. 2014)(chapter 4A). This 
is important because the inclusion of exercise into the lives of patients is severely hampered by 
difficulties in managing post-exercise glycaemia. The present study now reveals that meals 
with a low GI may be less satiating in the post-exercise recovery period in patients with type 1 
diabetes, as determined via visual analogues scales. Although it would be naïve to infer these 
findings to longer-term observations, our data may indicate likelihood for increased calorie 
intake following exercise due to increased appetite, rather than avoidance of hypoglycaemia 
per se, as commonly reported (Tonoli et al. 2012, Kennedy et al. 2013). This may have 
important implications for long-term weight management in this population, and may contrast 
data in non-diabetes individuals which demonstrate an improvement in weight management 
following low GI consumption (Larsen et al. 2010).  
It has previously been demonstrated that with fibre-matched meals, a higher glycaemic 
response is associated with greater postprandial feelings of fullness (Gonzalez and Stevenson 
2012). Based on strong positive correlations of fullness and postprandial insulinemia in 
humans (Flint et al. 2006), taken in concert with the acute induction of satiety in animal 
models (Air et al. 2002), it would be reasonable to speculate that insulin was a major 
confounding factor in the appetite response observed. However, insulin concentrations were 
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controlled manually in this study, under non-clamp procedures and from matched insulin 
administration. Accordingly, insulin concentrations were similar at every time point in the 
postprandial period (Figure 4.7), whereas marked increases in postprandial glucose 
concentrations were evident with HIGH vs. LOW (Figure 4.8) as expected. Therefore these 
results indicate that high GI meals induce greater satiety independent of the insulin response 
that is typical of these meals (Stevenson et al. 2006).  
These findings are consistent with previous infusion studies in people with and without type 1 
diabetes, whereby hyperglycaemic (~14 and ~10 mmol.l-1) intravenous infusion reduced 
hunger sensations compared to euglycaemia (~6 mmol.l-1) (Chapman et al. 1998, Russell et al. 
2001). Interestingly, these effects are more apparent in the postprandial state (Russell et al. 
2001), suggesting an interaction with the gastrointestinal tract. Another potential mechanism to 
explain the reduced hunger sensations with HIGH versus LOW could be through portal vein 
signalling (Mithieux et al. 2005). With HIGH, high concentrations of glucose would likely be 
present in the portal vein. Animal models have shown decreased food consumption following 
portal glucose infusions (Mithieux et al. 2005), suggesting that portal glucose is associated 
with appetite suppression. Furthermore, this response is attenuated by portal vein denervation 
(Mithieux et al. 2005), demonstrating the importance of this pathway for glucose sensing and 
appetite. However, it is worthy to note that circulating insulin concentrations in the present 
study resulted from subcutaneous administration opposed to insulin release into the portal vein 
from the pancreas. Even under conditions of peripheral circulating hyperinsulinaemia, normal 
postprandial portal venous insulin patterns are not fully reproduced (Rizza et al. 1980), leading 
to an impaired assimilation of splanchnic glucose (Felig et al. 1978), and an inability to 
supress glucagon through a paracrine effect thus favouring the release of hepatic glucose 
(Baron et al. 1987). Whilst glucagon displays anorectic properties (Chan et al. 1984), it is 
improbable that this influences the appetite response observed in this study, since glucagon 
concentrations did not significantly differ between trials and in fact, were on average, greater 
with LOW. 
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In addition, appetite responses may be mediated by the release of incretins such as GLP-1 
(Wachters-Hagedoorn et al. 2006, Krog-Mikkelsen et al. 2011). Although the evidence for a 
differential GLP-1 response to HIGH vs. LOW mixed-meals is equivocal (Stevenson et al. 
2009). The present study demonstrates no difference in the GLP-1 response to HIGH vs. 
LOW meals consumed following exercise in type 1 diabetes patients. This indicates that the 
appetite responses observed were independent of both insulinaemia and plasma GLP-1 
concentrations. 
The difference in fibre content between the HIGH and LOW meals was 0.5 g. Meta-analyses 
indicate that fibre does reduce subjective appetite sensations and subsequent energy intake 
(Wanders et al. 2011). The difference between meals in this study however is not likely to 
have played a role in the response observed, as a 1 g increase in fibre intake suppresses 
appetite by ~0.18% (Wanders et al. 2011). In the current investigation a ~9 % and ~25 % 
difference was observed in the postprandial AUC for hunger and fullness, respectively. Given 
the ~0.5 g difference in fibre would influence these responses by at least 2 orders of magnitude 
less (~0.09 %) it can be considered a negligible difference. 
The aim of this study was to assess the appetite responses following the manipulation of the 
glycaemic index of carbohydrates consumed following evening exercise, under conditions of 
reduced pre- and post-exercise rapid-acting insulin dose. The findings of this study should be 
considered in the context of more global diabetes care, as low GI post-exercise meals produce 
more suitable glycaemic responses than otherwise comparable high GI meals (chapter 4A) 
(Campbell et al. 2014). However, this study demonstrates that a post-exercise high GI meal 
produces greater fullness and less hunger, independent of insulin, in patients with type 1 
diabetes. It is worthy to note that this is the first study to assess post-prandial appetite 
responses in exercising type 1 diabetes patients. With this in mind, the clinical application of 
these findings should not be underestimated; interventions were carried out in the evening, in a 
non-fasted state, thereby facilitating greater translation to daily life (Gonzalez and Stevenson 
2013). Further work is needed to clarify the mechanisms of this effect in patients and to 
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establish the long-term implications of this response in patients regularly participating in 
exercise as VAS measures do not necessarily translate to changes in behaviour. In conclusion, 
this is the first study to demonstrate that high GI post-exercise meals induce greater 
postprandial feelings of fullness and lower postprandial hunger sensations in type 1 diabetes 
patients, independent of insulinaemia. There is now a need to assess the acute and 24 hour 
glycaemic effects of a combined basal-bolus insulin reduction and carbohydrate feeding 
strategy for preventing hypoglycaemia following evening exercise. 
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CHAPTER 5A 
 
 
 
 
 
 
 
 
THE EFFECTS OF REDUCING BASAL INSULIN DOSE ON 
GLYCAEMIA AFTER EVENING EXERCISE IN TYPE 1 
DIABETES 
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5.0 Introduction 
Making meal-time adjustments, in both rapid-acting insulin dose (chapter 3) and food 
composition (chapter 4), is a pragmatic and effective strategy to achieve euglycaemia in the 
early hours following exercise for patients with type 1 diabetes (chapters 3 and 4). More 
specifically, consuming post-exercise carbohydrates with a low GI, whilst under conditions of 
reduced pre- and post-exercise rapid-acting insulin dose, offers protection from early-onset 
post-exercise hypoglycaemia (~8 hours) whilst reducing exposure to post-prandial 
hyperglycaemia and inflammation (chapters 3 and 4). 
Unfortunately, these acute prandial adjustments do not offer complete protection; falls in 
glycaemia are likely to occur beyond ~8 hours post-exercise, particularly during the hours of 
sleep if exercise is performed in the evening (chapter 4) (Campbell et al. 2014). Exposure to 
late-onset nocturnal hypoglycaemia would suggest that acute prandial modifications to rapid-
acting insulin dosage and carbohydrate intake are inadequate in preventing late falls in 
glycaemia following evening exercise, indicating a more long-lasting intervention may be 
required to extend this window of protection considering the prolonged period of heightened 
insulin sensitivity after exercise. 
Under non-exercise conditions, there is typically a glucose nadir 4-14 hours after 
administration of basal insulin (Ashwell et al. 2006, Thomas et al. 2007). Considering late 
falls in glycaemia following exercise typically coincide at this time, application of a basal dose 
reduction could be a potential strategy to combat the risk of late-onset hypoglycaemia. 
Moreover, adjustments to both meal composition and rapid-acting insulin dose leaves basal 
dose open to modification. Unfortunately, there is currently a lack of evidence to support such 
advice with accompanying acute strategies, in spite of widespread recommendation in current 
clinical practice (Gallen 2012). Within the literature, alterations to the basal component of a 
patients’ regimen have been predominantly trialled in individuals treated with continuous 
subcutaneous insulin infusion therapy (CSII) with demonstrable success (Edelmann et al. 
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1986, Sonnenberg et al. 1990, Admon et al. 2005, Tsalikian et al. 2006). For example, 
Tsalikian and colleagues (2006) found hypoglycaemia was reduced by a factor of two thirds 
when basal insulin was suspended. This form of treatment involves continuous infusion of 
rapid-acting insulin delivered subcutaneously at a variable rate controlled via an electronically 
controlled pump. However, UK based patients are predominantly treated using an injectable 
basal-bolus regimen, whereby the basal component consists of a slowly-absorbed long-acting 
insulin analogue (insulin Glargine [Lantus], sanofi-aventis, USA; Determir [Levemir], Novo 
Nordisk, Denmark) that is self-administered once or twice per day. This is a far less flexible 
method of insulin delivery than CSII meaning it would be inappropriate to infer findings from 
these studies across different treatment regimens. Furthermore, there is currently no literature 
examining the effects of reducing basal insulin when employing acute prandial adjustments to 
diet and rapid-acting insulin. Potentially, reducing basal dose could spare glucose in the hours 
following exercise protecting patients from late-onset hypoglycaemia. Conversely, reducing 
basal insulin when large reductions to pre- and post-exercise rapid-acting insulin dose are also 
applied may induce periods of sustained hyperglycaemia which could potentially be 
detrimental to glycaemic control (Gallen 2012). 
Therefore, the aim of this study was to examine the effects of reducing basal insulin dose when 
employing acute prandial recommendations (chapters 3 and 4) on glycaemic control for 24 
hours after exercise in patients with type 1 diabetes. 
5.1 Methods 
Details of patients and patents’ insulin regimen are presented in Table 5.0. A schematic of the 
experimental design in presented in Figure 5.0; this study was a randomised counterbalanced 
cross-over design. Patients completed two experimental arms, in which basal insulin dose was 
maintained (100%) or reduced by 20% (80%) over the course of one day where exercise was 
performed in the evening. Timing of basal dose (changed / unchanged) was maintained 
between trials and performed as per each patient’s individual regimen. On the morning of each 
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trial (~08:00 AM) patients arrived to the laboratory, having fasted overnight, for a resting 
venous blood sample before consuming a standardised breakfast meal equating to 1.3 
g.carbohydrate.kg-1BM (534 ± 27 kcal; 2.2 ± 0.11 MJ, MEAL 1, see 2.2.5.3, Table 2.3). 
Patients returned in the evening at (~17:00 PM) having consumed a prescribed lunch meal 
equating to 1.3 g.carbohydrate.kg-1 BM (4.0 ± 0.11 MJ, MEAL 2, see 2.2.5.4, Table 2.3), ~4 
hours before arrival. Following a resting sample, patients self-administered a 75% reduced 
dose of rapid-acting insulin (2 ± 0.5 IU, see 2.2.6.1) into the abdomen (West et al. 2010, 
Campbell et al. 2013, Campbell et al. 2014). Patients consumed a pre-exercise carbohydrate 
bolus equating to 1.0 g.carbohydrate.kg-1 BM (1.7 ± 0.03, MEAL 3, see 2.2.5.6, Table 2.3) 
within a 5 minute period. Patients remained at rest for 60 minutes following consumption of 
the pre-exercise carbohydrate bolus / rapid-acting insulin injection with blood samples at 60 
minutes (Figure 5.0). Immediately after the 60 minute blood draw, patients commenced 45 
minutes of treadmill running at a speed calculated to elicit 70% of their �̇O2peak. Immediately 
following exercise, a blood sample was taken, with further interval samples at 15, 30, and 60 
minutes post-exercise. At 60 minutes, patients administered a 50% rapid-acting insulin dose (4 
± 0.3 IU, see 2.2.6.1), as determined from chapter 3, and consumed a low glycaemic index 
(GI) meal equating to 1.0 g.carbohydrate.kg-1 BM (1.7 ± 0.1 MJ, MEAL 7, see 2.2.5.8, Table 
2.3), as determined from chapter 4, before being discharged. Patients were provided with a 
standardised low GI bed-time snack equating to 0.4 g.carbohydrate.kg-1 BM (0.9 ± 0.04 MJ, 
MEAL 10, see 2.2.5.10) which was consumed 180 minutes after the post-exercise meal (before 
sleep at 22:45 PM); patients were contacted at 180 minutes post-exercise meal to ensure 
compliance. Patients were instructed to replicate sleeping patterns as best possible over the 
course of the study. Over the course of this day, patients either maintained their regular basal 
insulin dose (100%; 32 ± 4 IU), or performed a global basal insulin reduction, so that total 
daily amount of basal insulin administered was reduced by 20% (80%; 26 ± 3 IU) (see 
2.2.6.1). The following morning, patients returned to the laboratory, having fasted overnight, 
for a further resting blood sample and a breakfast meal (MEAL 11, see 2.2.5.11, Table 2.3). 
Blood glucose and serum insulin were measured on the morning before and after each 
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laboratory visit, and throughout each laboratory visit. CGM was used to capture interstitial 
glucose concentrations for 24 hours post-exercise (see 2.2.3.2). 
 
Table 5.0 Patients demographic information  
  Patient ID  
  1 2 3 4 5 6 7 8 9 10 11 MeanSEM 
Insulin 
(IU) 
Basal 38GM 20
D
B 22
G
M 26
D
B 34
G
E 18
D
B 20
G
E 31
G
M 24
G
M 30
G
E - 26  2 
Bolus 1L 1A 1A 1A 1A 0.8A 1A 1 A 1A 1A - 1.0  0.0 
HbA1c                      
(%) 
6.9 6.7 6.8 6.8 6.6 7.1 6.1 6.2 6.2 7.7 - 6.9  0.2 
BMI                    
(kg.m2) 
22.9 24.2 26.3 25.1 25.4 25.8 22.9 26.1 27.1 27.2 - 25.0  0.8 
Diabetes duration 
(years) 
11 14 11 14 7 6 22 12 13 8 - 12  2 
�̇O2peak         
(ml.kg.min-1) 
56.3 53.2 54.3 49.1 53.2 54.3 45.3 48.8 46.3 51.2 - 51.3  2.1 
Age 
(years) 
30 24 26 26 26 34 38 24 26 26 - 27  2 
Note: G = Glargine, D = Detemir, A = Aspart, L = Lispro, M = once daily (morning), E = once daily evening , B = 
bi-daily; bolus insulin calculated per 10g CHO. 
 
 
 
180 Morning Rest Exercise 60 30 0 15 60 -24hr +21hr 
CGM 
Bolus insulin 
 
Bolus food 
 
Blood glucose 
HR and respiration 
Diet 
Activity 
Figure 5.0. Schematic of experimental trial.  
Morning 
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5.2 Results 
5.2.1 Pre-laboratory phase 
5.2.1.1 Pre-laboratory glycaemia 
Over the course of the 24 hours prior to patients’ arrival to the laboratory, glycaemic control 
was comparable between both experimental trials (CGM mean interstitial glucose: 100% 8.1 ± 
0.3, 80% 8.2 ± 0.4 mmol.l-1; p = 0.962; and total interstitial glucose area under the curve: 
100% 11593 ± 547, 80% 12024 ± 949 mmol.l-1.min-1; p = 0.876). Moreover, resting, fasted 
pre-trial morning blood glucose concentrations were similar between trials (100% 5.9 ± 0.5, 
80% 6.1 ± 0.7 mmol.l-1; p = 0.459; Figure 5.1). In addition, fasting serum insulin was also 
similar between conditions (100% 111 ± 23, 80% 112 ± 23 mmol.l-1; p = 0.933) 
5.2.1.2 Pre-laboratory dietary intake, insulin administration and activity 
No differences were observed in total energy consumed (100% 9.8 ± 0.7, 80% 9.9 ± 0.8 MJ; p 
= 0.982), with contribution from carbohydrate (100% 53 ± 3, 80% 53 ± 3 %; p = 0.998), fat 
(100% 28 ± 3, 80% 28 ± 3 %; p = 0.998) and protein (100% 19 ± 2, 80% 19 ± 1 %; p = 
0.991) similar. In addition, total rapid-acting insulin units administered (100% 30 ± 3, 80% 30 
± 3 IU; p = 0.922) as well as levels of activity (100% 5721 ± 96, 80% 5703 ± 101 steps; p = 
0.901) were comparable over the 24 hours before each trial. 
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5.2.2 Laboratory phase 
Patients displayed similar serum insulin (100% 132 ± 19, 80% 129 ± 18 mmol.l-1; p = 0.936) 
and blood glucose concentrations upon arrival to the laboratory (100% 6.1 ± 0.3, 80% 6.7 ± 
0.6 mmol.l-1; p = 0.290; Figure 5.1). Blood glucose increased similarly following the pre-
exercise bolus and reduced rapid-acting insulin dose, such that concentrations immediately 
before exercise were similar (100% 10.9 ± 0.6, 80% 11.1 ± 0.7 mmol.l-1; p = 0.772). Serum 
insulin concentrations during this time remained similar between conditions (p > 0.05). 
 
 
Figure 5.1. Time-course changes in morning time fasted, and daytime rested blood glucose 
concentrations. Data presented as mean ± SEM. Black diamonds = 100%, red circles = 80%. * 
indicates a significant difference in blood glucose between 100% and 80% (p ≤ 0.05).  
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5.2.2.1 Exercise and recovery period 
Patients ran at an average speed of 9.7  0.4 km.hr-1, completing 7.3  0.3 km and expending 
3.1  0.2 MJ. Patients exercised at a similar intensity across trials (100% 74 ± 0.1, 80% 73 ± 
0.1 %V̇O2peak; p = 0.993; 100% 78 ± 1, 80% 78 ± 2 %HRpeak; p = 0.991) inducing comparable 
falls in blood glucose (100% Δ -6.4 ± 0.4, 80% Δ-5.9 ± 0.6 mmol.l-1; p = 0.688), such that 
immediately following the cessation of exercise, blood glucose were lower than baseline under 
both conditions (p < 0.05). However, blood glucose remained within euglycaemic ranges up to 
the administration of the post-exercise meal (100% 6.3 ± 0.2, 80% 6.9 ± 0.1 mmol.l-1; p = 
0.180), with all patients remaining protected from hypoglycaemia. 
5.2.3 Post-laboratory phase 
5.2.3.1 Late evening glycaemic responses 
There was a significant condition*time interaction (F(44,440) = 4.021, p = 0.002, partial-eta
2 = 
0.287), and a significant time effect (F(22,220) = 18.054, p < 0.001, partial-eta
2 = 0.659) for 
interstitial glucose concentrations over the course of the entire post-laboratory period. 
Following discharge from the laboratory, glycaemia remained similar throughout the late 
evening (1-5 hours post-exercise; 19:30-00:30 PM; Figure 5.2) with interstitial glucose, under 
free-living conditions, typically in euglycaemic ranges prior to the consumption of the bedtime 
snack (mean interstitial glucose: 100% 5.7 ± 0.5, 80% 5.8 ± 0.6 mmol.l-1; p = 0.817;  
Figure 5.2). Furthermore, interstitial glucose concentrations were comparable immediately 
before sleep (100% 7.2 ± 1.0, 80% 8.0 ± 0.7 mmol.l-1; p = 0.217; Figure 5.2), and all patients 
under both conditions were protected from hypoglycaemia during this time.  
5.2.3.2 Nocturnal glycaemia  
Under the 100% condition glucose levels fell at ~6 hours post-exercise with the first 
hypoglycaemic episode occurring at 8 hours post-exercise, and mean interstitial glucose nadir 
occurring at ~8-12 hours post-exercise and during hours of sleep (mean interstitial nadir: 
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100% 2.6 ± 0.2 mmol.l-1; Figure 5.2). Conversely, glycaemia was preserved throughout the 
night under 80% (mean interstitial glucose: 80% 8.7 ± 0.6 vs. 100% 7.0 ± 0.9,  mmol.l-1; p = 
0.032; total interstitial glucose area under the curve: 100% 2574 ± 246, 80% 3657 ± 190 
mmol.l
-1
.min
-1
; p = 0.021; Figure 5.1). As such, all patients under 80% were protected from 
nocturnal hypoglycaemia, whereas, 9 patients (90 %) experienced nocturnal hypoglycaemia 
under 100% with 3 of those patients encountering 2 or more nocturnal hypoglycaemic 
episodes (total of 14 individual hypoglycaemic episodes). Moreover, total time spent in 
hypoglycaemic ranges was significantly less under 80% (80% 0 ± 0, 100% 286 ± 35 minutes; 
p < 0.001), with a significantly greater amount of time spent euglycaemic (80% 397 ± 56, 
100% 122 ± 28 minutes; p < 0.001), but not hyperglycaemic (80% 143 ± 56, 100% 132 ± 52 
minutes; p = 0.188).   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Time-course changes in interstitial glucose concentrations throughout the post-laboratory 
period. Data presented as mean ± SEM. Black solid trace = 100%, red broken trace = 80%. ** indicates a 
significant difference in interstitial glucose area under the curve between 100% and 80% (p ≤ 0.05). 
Open circles represent hypoglycaemic episodes, as determined from CGM data. Vertical dashed line 
break indicates nocturnal and daytime periods.  
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5.2.3.3 Next-day glycaemia 
Immediately upon awakening (~13 hours post-exercise; 07:30 AM; Figure 5.2), interstitial 
glucose was significantly less under 100% with patients typically in hypoglycaemic ranges 
(100% 5.3 ± 0.6, 80% 8.1 ± 0.6 mmol.l-1; p = 0.008; Figure 5.1). Fasted, resting blood glucose 
was significantly lower under 100% (100% 3.7 ± 0.3, 80% 7.7 ± 0.9 mmol.l-1; p < 0.001; 
Figure 5.1), and significantly less than those concentrations measured on the morning before 
exercise (p < 0.001). In comparison, patients under 80% were typically in euglycaemic ranges 
upon awakening, and displayed similar blood glucose concentrations to those measures on the 
morning before exercise (p > 0.05).  
After this time, patients under 100% spent more time in hypoglycaemic (100% 264 ± 22 vs. 
80% 5 ± 6 minutes; p < 0.001) and hyperglycaemic (100% 123 ± 21 vs. 80% 67 ± 16 
minutes; p = 0.004)  ranges, and less time in euglycaemia (100% 643 ± 54 vs. 80% 1048 ± 71 
minutes; p = 0.007) than those under the 80% condition. In addition, patients under 80% also 
tended to elicit less glycaemic variability during this time, although a significant difference 
between measures of glycaemic variability was not observed (Table 5.1). 
Table 5.1. Estimates of next day glycaemic variability 
 Median Mean SD CV% MAGE CONGA MODD Mr J-Index 
100% 7.5 7.7 2.4 30.4 35.1 2.12 5.0 6.4 0.1 
80% 7.1 7.4 1.7 23.4 32.2 1.8 5.2 6.4 0.01 
p value =0.654 =0.631 =0.320 =0.284 =0.634 =0.367 =0.472 =0.994 =0.351 
Note: MAGE = mean amplitude of glycaemic excursions; Mr = weighted average of glucose values; 
CONGA = continuous overall net glycaemic action; MODD = mean of daily differences.  
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5.2.3.4 Post-laboratory dietary intake, insulin administration and activity 
Over the course of the next day, total energy consumed was significantly greater under 100% 
(100% 4.8 ± 0.2, 80% 3.0 ± 0.2 MJ; p < 0.001), with increased contribution from 
carbohydrate (100% 76 ± 3, 80% 69 ± 3 %; p = 0.004). All patients under 100% required 
carbohydrate bolus’ to correct blood glucose, whereas this was avoided under 80% (100% 
26.8 ± 19.9, 80% 0 ± 0 g; p < 0.001). Total meal-time carbohydrate (excluding carbohydrate 
consumed to correct blood glucose), was greater (100% 117.6 ± 12.3, 80% 46.6 ± 3.3 g; p < 
0.001) as was fat (100% 17.2 ± 2.7, 80% 13.7 ± 2.8 g; p = 0.014) and protein (100% 16.08 ± 
4, 80% 11.6 ± 3.3 g; p = 0.023) consumption under 100%. As such, patients administered 
significantly less meal-time rapid-acting insulin under 80% (80% 12.5 ± 1.2, 100% 6.7 ± 0.8 
IU; p = 0.001), although insulin administered to correct blood glucose was greater (80% 2.1 ± 
2.5, 100% 1.0 ± 2.0 IU; p = 0.040). Levels of activity were similar between conditions with 
total amount of steps comparable (100% 4231 ± 102, 80% 4301 ± 132 steps; p = 0.602). 
5.3 Discussion 
The aim of this study was to examine the effects of reducing basal dose under conditions acute 
prandial adjustments to rapid-acting insulin and meal composition on glycaemia for 24 hours 
after performing evening exercise in patients with type 1 diabetes. This study demonstrates for 
the first time that a combined basal-bolus insulin reduction and carbohydrate feeding strategy 
provides full protection from exercise-induced hypoglycaemia for 24 hours after exercise. 
Notably, when basal dose was reduced by 20% a clear preservation of glycaemia during the 
night was observed, completely abating the risk of nocturnal hypoglycaemia. In addition, it 
would seem patients tend to experience fewer glycaemic fluctuations, with more time spent in 
euglycaemic ranges across the following day. 
An inability to manage blood glucose following exercise has, until now, proved great 
tribulation to patients wishing to engage in exercise (Brazeau et al. 2008). Indeed, the 
connection between poor rates of exercise participation and adherence in this population has a 
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tenable link with the risk and fear of developing exercise-induced hypoglycaemia (Bernardini 
et al. 2004, Brazeau et al. 2008). As such, hypoglycaemia remains the primary obstacle to 
exercise (Brazeau et al. 2008). Heretofore, protection from exercise induced-hypoglycaemia 
was limited to a narrow window after exercise (~8 hours; chapter 4A). Indeed, 90 % of patients 
under the non-reduction trial encountered hypoglycaemia beyond 8 hours post-exercise. It is 
therefore clear that prandial adjustments to rapid-acting insulin, and carbohydrate feeding 
carry only acute protective effects and do not influence late-onset nocturnal hypoglycaemia 
risk following evening exercise (Campbell et al. 2014) (chapter 4A).  
Late falls in glycaemia appear coincidental with reported glucose nadirs on non-exercise days 
occurring 4-14 hours after basal insulin administration (Ashwell et al. 2006, Mcmahon et al. 
2007, Thomas et al. 2007). It is noteworthy that these findings were observed in insulin 
Glargine users (Porcellati et al. 2007, Heller et al. 2009). Insulin Glargine reaches a metabolic 
plateau after 3-6 hours after injection (Heinemann et al. 2000, Lepore et al. 2000, Rave et al. 
2003, Klein et al. 2007), and remains in steady state activity close to 100% for 24 hours after 
administration (Porcellati et al. 2007). The majority of patients in this study were treated with 
basal insulin Glargine (Glargine n = 8 vs. Detemir n = 2), all of whom encountered nocturnal 
hypoglycaemia on the non-reduction trial. Insulin Detemir shares similar action-time profiles 
to that of insulin Glargine over the first 12 hours, but beyond this time, Detemir exhibits a 
progressive decrease in activity to ~55% by 24 hours post-administration (Porcellati et al. 
2007). The aim of this study was not to determine the optimal basal insulin regimen (insulin 
type or timing) per se, but to establish the effectiveness of a global reduction in basal dose. 
Considering the relatively small sample size in this study it would be in appropriate to draw 
comparisons against different regimens. Future work should be directed towards this aim 
however, considering the differences in pharmacokinetic and pharmacodynamic effects of 
insulin Glargine and Detemir and the future release of ultra-long-acting insulin Degludec. 
Irrelevant of basal insulin (Glargine versus Detemir), time of administration (morning versus 
evening) or frequency of injection (once versus twice daily), the results of this study show, for 
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the first time, that when total daily basal insulin dose is reduced by 20% on the day of evening 
exercise, in concert with acute prandial adjustments, patients are protected from 
hypoglycaemia for a total of 24 hours after exercise.  
To maximise applicability to everyday diabetes management, the experimental design was 
conceived trying to reproduce real life conditions, capturing events of the intervention on the 
proceeding day after exercise, and under free living conditions. It is important to understand 
whether strategies which adapt patients’ treatment regimens influence their ability to manage 
glycaemia on subsequent non-exercise days as glycaemic dysregulation could offset the 
beneficial effects exercise carries. The results of this study indicate that patients adopting the 
basal reduction tend to experience tighter glucose control compared to those administering 
their full basal dose. Patients under 80% spent significantly more time in euglycaemic ranges, 
and less time in hypoglycaemic and hyperglycaemic ranges. Measures of glycaemic variability 
revealed that there was a propensity for fewer and less severe fluctuations in glucose under 
80%, although this was not statistically significant. Lower basal insulin concentrations may 
have a direct effect on next-day glycaemia considering the duration of basal insulin action may 
be longer than 24 hours (Lepore et al. 2000). However, reductions in basal dose may carry 
indirect effects also; patients under 80% consumed significantly less food ad libitum, in 
particular, consuming less carbohydrates and administering significantly fewer units of insulin, 
which in a state of continued insulin sensitivity (Mikines et al. 1988) may lend some 
explanation to differences in glycaemia during this time. Patients were instructed to continue 
habitual food consumption, with patients not required to replicate diet, over the course of day 
following the exercise trials. Potentially, reductions in basal dose may carry prospective effects 
on appetite regulation and energy balance, although a more longitudinal study would be 
required to confirm this hypothesis. In light of the above, it would seem that reducing basal 
dose carries important implications for next day glycaemic control. In addition, glycaemia was 
similar between conditions over the course of exercise day, with differences establishing after 
6 hours post-exercise and during sleep. This would indicate that reducing basal dose on the day 
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of exercise does not significantly disrupt glycaemic control in the time preceding exercise. 
This is an important observation because the aim of diabetes management is to normalise 
blood glucose concentrations (Thomas et al. 2007), especially when incorporating exercise 
into the lives of patients (Chu et al. 2011). 
The aim of this study was to assess the acute and 24 hour glycaemic effects of a combined 
basal-bolus insulin reduction and carbohydrate feeding strategy for preventing hypoglycaemia 
following evening exercise. This is the first study to demonstrate that a combined basal-bolus 
insulin reduction and carbohydrate feeding strategy provides full protection from exercise-
induced hypoglycaemia for 24 hours after exercise. The clinical importance of these findings is 
self-evident, as patients adopting this strategy can now participate in exercise without fear of 
exercise-induced hypoglycaemia. However, these findings may not be directly transferable to 
patients treated on different regimens, and the optimum regimen (insulin type and timing) are 
yet to be determined. There is now a need to establish whether this strategy is associated with 
wider metabolic, hormonal, and inflammatory implications which could, if repeated on a 
regular basis affect longer-term diabetes management. 
 
 
 
 
 
 
151 
 
CHAPTER 5B 
 
 
 
 
 
 
 
THE METABOLIC, INFLAMMATORY, AND COUNTER-
REGULATORY HORMONAL RESPONSES FOLLOWING 
EVENING EXERCISE IN TYPE 1 DIABETES PATIENTS UNDER 
CONDITIONS OF REDUCED BASAL INSULIN DOSE 
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5.4 Introduction 
Reducing basal dose whilst employing a reduced pre- and post-exercise rapid-acting insulin 
and low GI carbohydrate feeding strategy protects type 1 diabetes patients from 
hypoglycaemia for 24 hours following exercise (chapter 5A). However, there is now a need to 
determine the hormonal, metabolic and inflammatory implications of this strategy.  
Whereas hypoinsulinaemia augments lipolysis and ketogenesis (Laffel 2000, Wallace and 
Matthews 2004) and concomitant exposure to hyperglycaemia increases the appearance of 
circulating inflammatory cytokines (Targher et al. 2001, Esposito et al. 2002, De Rekeneire et 
al. 2006, Rosa et al. 2008), heavily reducing pre- and post-exercise rapid-acting insulin dose 
does not cause clinically meaningful increases in β-hydroxybutyrate (> 1.0 mmol.L-1) (chapter 
3B). Moreover, when these reductions are applied in concert with the consumption of a low GI 
meal, the appearance of IL-6 and TNF- α are also reduced (chapter 4B). Thus, it would appear 
that: 1) despite a large reduction in insulin dose, circulating concentrations remain great 
enough to supress ketone body production (Balasse and Féry 1989, Mcgarry 1996), and 2) that 
normalisation of glycaemia via modification of post-exercise food composition can reduce 
inflammatory disturbances. Whether the application of a basal dose reduction in combination 
with rapid-acting insulin adjustments would affect counter-regulatory hormonal, metabolic and 
inflammatory parameters is yet to be established.  
Accordingly, the aim of the study was to examine the counter-regulatory hormonal, metabolic, 
and inflammatory responses of reducing basal insulin dose when evening exercise is 
performed in patients with type 1 diabetes adopting acute prandial recommendations. 
5.5 Methods 
A second arm of analysis was performed on both trials from chapter 5A. Blood lactate, serum 
cortisol, non-esterified-fatty-acids, -hydroxybutyrate, and plasma glucagon, adrenaline, IL-6 
and TNF-α were measured for 60 minutes post-meal (Figure 5.3). 
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5.6 Results 
5.6.1 Pre-laboratory phase 
5.6.1.1 Counter-regulatory hormone and metabolite responses 
The counter-regulatory hormone and metabolite responses are presented in Table 5.2. There 
were no conditional differences in fasted, resting morning-time concentrations in any 
measures. 
5.6.1.2 Inflammatory cytokine responses 
The inflammatory cytokine responses are presented in Figure 5.4. There were no conditional 
differences in IL-6 or TNF-α concentrations in fasted, resting pre-trial morning concentrations 
in either measure. Concentrations of IL-6 and TNF-α were positively related to length of 
Plasma   
TNF-α 
Plasma      
IL-6 
Serum               
β-OH 
Serum     
NEFA 
Rest Exercise 60 30 150 30 0 15 60 60 90 120 180 
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Blood     
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Figure 5.3. Schematic of study trial design.  
Morning  Morning  
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diabetes (IL-6: r = 0.811, p = 0.008; TNF-α: r = 0.799, p = 0.003) and inversely related to 
HbA1c (IL-6: r = -0.722, p = 0.032; TNF-α: r = -0.771, p = 0.034), but not �̇O2peak (IL-6: r = -
0.322, p = 0.257; TNF-α: r = -0.102, p = 0.893). Length of diagnosis and HbA1c were 
negatively correlated (r = -0.799, p < 0.029). 
5.6.2 Laboratory phase 
5.6.2.1 Counter-regulatory hormone and metabolite responses 
There were no conditional differences in counter-regulatory hormone or metabolite responses 
during the laboratory phase. Serum cortisol was lower than pre-trial morning concentrations 
under both conditions at rest, and throughout the trial period. All other resting measures were 
similar to those observed on the pre-trial morning, with temporal changes remaining similar 
between conditions (Table 5.2). 
5.6.2.2 Inflammatory cytokine responses 
Trial resting concentrations in both IL-6 and TNF-α were similar to those elicited on the pre-
trial morning (Figure 5.4) and remained similar in the 60 minutes before exercise. Following 
exercise, TNF-α was significantly raised from both rest and pre-trial morning concentrations 
under both conditions before returning to trial resting and morning concentrations immediately 
before the post-exercise meal at 60 minutes post-exercise (Figure 5.4). There were no 
conditional differences in TNF-α during this time (p > 0.05). Temporal changes in IL-6 were 
evident during the post-exercise period whereby concentrations peaked similarly at 15 minutes 
post-exercise (Figure 5.4). IL-6 decreased under both conditions following this point, however 
the decline was significantly attenuated under 80%. Conversely, IL-6 under 100% decreased 
such that concentrations were significantly lower than both resting and pre-trial morning 
concentrations (Figure 5.4). 
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5.6.3 Post-laboratory phase 
5.6.3.1 Counter-regulatory hormone and metabolite responses 
Plasma adrenaline was significantly lower under both conditions than the pre-trial morning and 
trial resting sample (Table 5.2). Blood lactate, and serum NEFA and β-hydroxybutyrate (Table 
5.2) were significantly increased under both conditions. Serum cortisol, was increased from 
rested concentrations, but remained similar to those measured on the pre-trial morning under 
both conditions (Table 5.2). All other hormones and metabolites remained unchanged (Table 
5.2). 
5.6.3.2 Inflammatory cytokine responses 
Both conditions displayed similarly raised TNF-α concentrations compared to the pre-trial 
morning sample, although these were similar to resting concentrations elicited during the main 
trials. Conversely, IL-6 under 100% was significantly lower than both pre-trial morning and 
trial resting measures (Figure 5.4). Concentrations under 80% remained similar to both pre-
trial morning and trial resting samples (Figure 5.4). 
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Table 5.2 Metabolic and counter-regulatory hormone responses during manipulation to basal-bolus insulin 
 
          ANOVA p 
 Morning 1 Rest E 60 0 15 30 Pre-Meal Morning 2 T T*C 
Plasma 
Glucagon 
(pg.ml-1) 
100% 637±148 549±115 
 396±80#† 526±94 573±125 555±118 576±136 634±147 =0.049 =0.663 
80% 595±118 532±111 
 397±77#† 501±84 593±138 540±128 536±121 611±106   
Plasma 
Adrenaline       
(nmol.l-1) 
100% 0.22±0.04 0.14±0.03 
 
0.10±0.04# 0.47±0.10#† 0.26±0.08 0.12±0.03 0.12±0.04 0.13±0.03# =0.017 =0.322 
80% 0.29±0.06 0.14±0.04 
 
0.11±0.03# 0.45±0.12† 0.29±0.11 0.13±0.05 0.13±0.03 0.08±0.02#   
Serum 
Cortisol       
(µmol.l-1) 
100% 0.65±0.06 0.32±0.06# 
 
0.20±0.37# 0.37±0.10# 0.41±0.12 0.42±0.12 0.30±0.08# 0.61±0.08† = 0.042 = 0.654 
80% 0.71±0.06 0.28±0.04# 
 
0.24±0.04# 0.29±0.09# 0.42±0.14 0.36±0.13 0.27±0.09# 0.68±0.07†   
Blood  
Lactate 
(mmol.l-1) 
100% 0.01±0.01 0.44±0.21 
 0.95±0.15#† 3.27±0.58#† 1.83±0.29#† 0.77±0.22# 1.41±0.93#† 0.27±0.15# <0.019 =0.798 
80% 0.11±0.11 0.53±0.19 
 1.18±0.23#† 3.40±0.66#† 1.77±0.34#† 0.86±0.30# 0.64±0.17# 0.40±0.18#   
Serum  
NEFA 
(mmol.l-1) 
100% 0.39±0.06 0.26±0.05 
 
0.19±0.03# 0.16±0.02# 0.24±0.04 0.20±0.02# 0.29±0.06 0.65±0.15#† =0.049 =0.663 
80% 0.36±0.05 0.30±0.10 
 
0.35±0.13# 0.25±0.04# 0.38±0.09 0.31±0.08 0.33±0.08 0.52±0.07#†   
Note: Data presented as mean ± SEM. Test meal and insulin were administered immediately following rest and pre-meal sample points. * indicates significantly different from 100% (p ≤ 0.05). 
# indicates significantly different to morning 1. † indicates significantly different from rest.  Morning 1 = pre-trial morning sample, Morning 2 = post-trial morning visit sample, T = Time, C = 
Condition, E = Exercise. 
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Figure 5.4 A-C. Time-course changes in (A) plasma IL-6, (B) plasma TNF-α and (C) serum β-
hydroxybutyrate. Data presented as mean ± SEM. Black diamonds = 100%, red circles = 80%. 
Transparent sample point within a condition indicates a significant difference from pre-meal 
concentrations (p ≤ 0.05). * indicates significantly different from 100% (p ≤ 0.05). Thatched area 
indicates exercise. Vertical dashed line break indicates carbohydrate meal and insulin 
administration. Thatched area indicates exercise. Note: Basal insulin dose was administered as per 
individual patient regimen. 
 
158 
 
5.7 Discussion 
The main findings in this study were that a reduction in basal insulin dose, in concert with acute 
prandial adjustments, does not significantly augment ketonaemia to clinically meaningful 
concentrations. Alike, elevations in the inflammatory marker TNF-α were similar between 
conditions, with concentrations on the morning after exercise greater than those on the morning 
before, but similar to resting pre-exercise measures. IL-6 concentrations were not significantly 
raised from morning or pre-exercise measures under the reduction trial, and there were no other 
hormonal or metabolic disturbances associated with this strategy. 
Exercise-induced hypoglycaemia is avoidable for type 1 diabetes patients by applying acute 
prandial adjustments with a reduction in basal insulin dose (chapter 5A). The importance of a 
strategy which achieves this cannot be underestimated as hypoglycaemia remains the primary 
obstacle to patients wishing to engage in exercise (Brazeau et al. 2008). Now, this study 
demonstrates that this strategy does not significantly raise ketonaemia. Decrements in insulin and 
elevations in counter-regulatory hormones combine to stimulate lipolysis in adipose tissue, and 
ketogenesis in the liver (Nosadini et al. 1994, Delaney et al. 2000). Under such conditions, lipases 
are activated increasing circulating NEFA and impairing their re-esterification, catalysing their 
transport into the mitochondria (Mcgarry and Foster 1980, Kruszynska 1997), and subsequently 
converting them into ketone bodies (Keller et al. 2009).  
Rapid-acting insulin was omitted with the bedtime snack, and there were no reported occasions of 
rapid-acting insulin being administered to correct blood glucose through the late evening and 
night, meaning rapid-acting insulin administration was matched over the course of the laboratory 
period and throughout the night (1-13 hours post-exercise) between the two trials (chapter 5A). As 
the rapid-acting analogue insulin Aspart is 100% cross-reactive with insulin Glargine (Pennartz et 
al. 2011), any changes in serum concentrations can be considered a result of manipulating basal 
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dose. However, serum insulin concentrations remained similar between conditions across the 
exercise trial and post-laboratory period, meaning differences in circulating basal insulin were 
undetectable at the specified time points. Similarly, adrenaline and cortisol, the main lipolytic 
stimulators (Keller et al. 2009), returned to pre-exercise concentrations under both conditions by 
60 minutes post-exercise, and by the following morning were lower than those obtained on the 
preceding morning. Although increases in NEFA concentrations were apparent under the 80% 
condition on the morning after exercise, the rise was comparable to 100%, indicating that the 
reduction in basal dose was not great enough to significantly elevate lipolysis. Furthermore, it 
would appear that this metabolic milieu was insufficient to augment ketonaemia, as β-
hydroxybutyrate was alike between conditions. Moreover, concentrations were less than those 
considered clinically meaningful (> 1.0 mmol.l-1; Laffel (2000)).  
Blood lactate concentrations represent a balance between lactate production and utalisation. Small 
elevations in blood lactate would support a notion for increased glycolysis, probably in exercised 
musculature as this tissue is the major component of production and use (Gladden 2008), and 
maybe the liver too although to a lesser extent (Connor and Woods 1982); subsequent production 
of pyruvate, the precursor for oxaloacetate, and its condensation with acetyl CoA prevents its 
diversion from the citric acid cycle to ketogenesis (Jain et al. 1998, Jain et al. 1999, Jain et al. 
2006), hence low levels of β-hydroxybutyrate. Indeed, lactate forms from the reduction of 
pyruvate by lactate dehydrogenase, which if oxidised in the citric acid cycle would increase lactate 
production. Post-trial morning elevations in blood lactate were comparable between conditions 
suggesting no conditional effect of insulinaemia on this metabolite. Indeed, acute regulation of 
endogenous glucose production by insulin is demonstrated to occur mainly via changes in 
glycogenolysis rather than gluconeogenesis in type 1 diabetes patients (Boden et al. 2003). 
However, depleted glycogen stores following exercise, and their subsequent restoration in the 
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post-exercise period, may have promoted an increased contribution from gluconeogenesis to 
endogenous glucose production. 
An important observation was the response in inflammatory cytokines following the intervention 
as the avoidance of inflammation is important for preventing the early-onset of diabetes related 
complications (Rosa et al. 2011). This study shows that the inflammatory cytokine TNF-α is not 
affected by reductions in basal insulin dose when acute prandial adjustments are also made for 
evening exercise. In addition, IL-6 is not significantly increased from fasted, rested morning-time 
concentrations, although concentrations are significantly lower when a basal dose reduction is not 
applied. At 1 hour post-exercise, IL-6 concentrations under 100% were significantly lower than 
those on the pre-morning trial and trial resting sample point, and would have likely remained 
stable, at least in the early hours following the post-exercise meal (chapter 4B). Conversely, 
concentrations under 80% were significantly greater than 100% immediately prior to the post-
exercise meal and on the post-exercise morning. Insulin carries anti-inflammatory properties 
(Viardot et al. 2007). Indeed an inverse relationship between circulating insulin and IL-6 found in 
chapter 3B would support findings herein. However, insulin concentrations at the post-trial 
morning sample point were comparable (chapter 5A). It is possible that differences in insulin 
concentrations occurred during the night and were simply not captured due to sampling frequency. 
If this were the case, it may lend some explanation as to why post-trial morning IL-6 
concentrations differed between conditions; as concentrations were lower under the 100% 
condition, potentially, higher insulin concentrations through the night may have supressed IL-6 or 
increased IL-6 clearance. However, with no visible differences in other metabolic parameters at 
this time point, and considering the multiple roles IL-6 plays (e.g. anti- versus pro-inflammatory 
effects, molecular signalling and metabolic cross-tissue communicator; see Ellingsgaard et al. 
(2011)), it would be inappropriate to speculate on the exact mechanisms underpinning this finding.  
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In support of the findings in chapter 4B, resting inflammatory cytokine concentrations were 
positively related to length of diabetes and inversely related to HbA1c in this study, strengthening 
the premise of diabetes as a long-standing inflammatory disease (Devaraj et al. 2007), and the 
association between intensive diabetes management and reduced inflammatory disturbances 
(Devaraj et al. 2005, De Rekeneire et al. 2006, Galassetti et al. 2006). All other hormonal and 
metabolite measures remained similar between conditions during the post-exercise post-prandial 
period.  
The aim of this study was to assess the metabolic, counter-regulatory hormonal, and inflammatory 
responses following a combined basal-bolus insulin reduction and carbohydrate feeding strategy 
for evening exercise. In summary, this study demonstrates that a reduction in basal insulin dose, in 
concert with acute prandial adjustments to rapid-acting insulin and diet, following evening 
exercise in type 1 diabetes does not significantly alter ketone body formation or increase IL-6 
above fasted, rested morning-time concentrations, and that TNF-α is not increased above day-time 
pre-exercise levels. Future work would benefit from a more detailed profiling of inflammatory and 
ketogenic markers to better capture potential changes in these parameters in the post-exercise 
period. In addition, it is suggested that future thought be given to the impact of different insulin 
species and treatment regimens. 
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CHAPTER 6 
 
 
 
 
 
 
 
 
GENERAL DISCUSSION 
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6.0 Introduction 
The research presented in this thesis has examined the impact of alterations in insulin 
administration and carbohydrate feeding on acute and 24 hour post-exercise glycaemic control. In 
addition, acute metabolic, counter-regulatory hormonal and inflammatory parameters were 
investigated to understand the deeper underlying physiological consequences of the interventions 
employed. This chapter will collate and consider the findings of chapters 3 to 5.  A schematic is 
provided in Figure 6.0 which summarises and incorporates these findings into a workable strategy 
which can be applied in clinical practice. 
6.1 Acute glycaemic control and avoidance of early-onset hypoglycaemia 
Patients are recommended to reduce the amount of rapid-acting insulin administered before 
exercise, to prevent hypoglycaemia during and immediately after exercise (Rabasa-Lhoret et al. 
2001, Mauvais-Jarvis et al. 2003, West et al. 2010, West et al. 2011, West et al. 2011). Across all 
chapters, patients heavily reduced the amount of rapid-acting insulin dose administered 60 minutes 
before exercise. Despite the performance of an intensive bout of aerobic exercise during a time of 
peak insulin absorption (Plank et al. 2002), there were no incidences of hypoglycaemia during 
exercise, and all patients remained protected for up to one hour post-exercise without further 
feeding. In addition, patients were, on average, within euglycaemic ranges over the duration of the 
60 minute post-exercise period (chapters 3, 4, and 5). This emphasises the importance of large 
reductions in pre-exercise rapid-acting insulin dose for protecting patients from hypoglycaemia 
during, and immediately after exercise, and highlights that this strategy exposes patients to only 
transient hyperglycaemia in the period before exercise. It is worthy to note however, that such 
large reductions in pre-exercise rapid-acting insulin may not necessary if the exercise modality is 
altered. For example, performing resistance exercise or including intermittent high-intensity 
periods throughout aerobic exercise, is likely to increase acute counter-regulatory hormones which 
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may assist in the preservation of glycaemia acutely after exercise (<1 hour post-exercise) 
(Campbell et al. 2014). 
Chapter 3 demonstrated that it is also important to reduce the dose of rapid-acting insulin 
administered with the meal after exercise to extend this window of protection. A 50 % reduction in 
post-exercise rapid-acting insulin was necessary to prevent falls in glycaemia, and protect all 
patients from hypoglycaemia for a further 7 hours (8 hours post-exercise). This contrasts to current 
opinion which advocates a reduction of only ~30 % (Lumb and Gallen 2009). In addition, it can be 
advised that post-exercise rapid-acting insulin reductions should be applied irrelevant of exercise 
modality, although alterations in dose should be tailored to individual exercise preferences. 
GI heavily influences post-prandial glycaemia in type 1 diabetes (Nansel et al. 2008, Parillo et al. 
2011). Now, it is clear that the GI of meals consumed following exercise carry important 
implications for post-exercise glycaemia. Evidenced by chapter 3, hyperglycaemia is a likely 
consequence for the majority of patients reducing post-exercise rapid-acting insulin dose; the 
incidence of hyperglycaemia was greater than double when a 50 % dose was implemented, with 
individual peak blood glucose as great as 21.8 mmol.l-1 and one patient averaging blood glucose 
concentrations of 19.3 mmol.l-1 across the post-meal period (chapter 3). Notably, the post-exercise 
meal in this study elicited a moderate GI (GI = 57), and in chapter 4, a high GI (GI = 92) also 
induced severe hyperglycaemia in the majority of patients. However, when an otherwise similar 
meal identical in macronutrient composition but of a low GI (GI = 37), the incidence of post-
prandial hyperglycaemia was reduced by 60 % and in those patients affected, hyperglycaemia 
tended to be shorter-lasting and less pronounced. Currently, there are relatively few dietary 
guidelines to assist patients in managing their blood glucose after exercise (Chu et al. 2011). Now 
however, it is clear that the composition of post-exercise carbohydrate is an important 
consideration for patients with type 1 diabetes. Specifically, low GI carbohydrate consumption 
facilitates more desirable post-prandial glycaemia responses by normalising blood glucose. This is 
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an important contribution to the literature as current recommendations place more focus on the 
quantity rather than the composition of the carbohydrate to be consumed following exercise 
(Bantle et al. 2008, Evert et al. 2014).  
6.2 Avoidance of late-onset hypoglycaemia 
Chapters 3 and 4 illustrate that acute prandial adjustments to rapid-acting insulin and carbohydrate 
feeding carry only short-lasting protective effects from exercise-induced hypoglycaemia. Patients 
in both chapters were exposed to hypoglycaemia 8 hours after exercise, irrelevant of the dose 
administered with the post-exercise meal (chapter 3), or post-exercise meal composition (chapter 
4). It would not seem that carbohydrate intake alone is sufficient for preventing late falls in 
glycaemia, as patients across chapters consumed adequate carbohydrate to cover the energy 
expended during exercise and establish a positive energy balance across the course of the day. 
Notably, when exercise is performed in the evening, late falls in glycaemia occur nocturnally 
(chapter 4 and 5), meaning it would be impractical for patients to consume carbohydrate at this 
time. Moreover, hypoglycaemia occurred despite the consumption of a bedtime snack, irrespective 
of its composition, and notwithstanding ambient glucose levels before sleep. Typically, patients 
within normal blood glucose ranges before sleep often choose to raise glycaemia before bed. 
However, the findings from chapter 4 and 5 would suggest that simply elevating glycaemia before 
sleep does not confer any glycaemic benefit for avoiding late-onset nocturnal hypoglycaemia. 
It was important to assess whether late-onset hypoglycaemia could be acutely managed, as 
adjusting basal dose may be daunting for patients. In addition, there is no data regarding the 
deeper, metabolic, hormonal and inflammatory implications of adjusting basal insulin dose. 
However, the findings of chapter 4 direct attention towards the need for a longer-lasting 
intervention. Late falls in glycaemia appear coincidental with reported glucose nadirs on non-
exercise days occurring 4-14 hours after basal insulin administration (Ashwell et al. 2006, 
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Mcmahon et al. 2007, Thomas et al. 2007). Chapter 5 has somewhat confirmed this; reducing the 
total amount of basal insulin administered over the course of the exercise day by 20 % prevented 
falls in glycaemia late after exercise, completely abating the risk of hypoglycaemia for a total of 
24 hours after exercise. This is the first strategy to date that has provided complete 24 hour 
protection from exercise-induced hypoglycaemia in patients with type 1 diabetes. This is 
particularly pertinent considering the intensive nature of exercise employed compared to that in 
other studies. 
In addition, it would seem that a reduction in basal dose of this magnitude does not significantly 
alter glycaemic control in the time preceding exercise, as differences in glycaemia were not 
established until 6 hours after exercise and during sleep (chapter 5). Moreover, it would seem that 
glycaemic control over the course of the next day is improved with this strategy, with fewer and 
less severe fluctuations in glucose following a reduction in basal insulin. It is important to 
understand whether strategies that adapt patients’ treatments regimens influence their ability to 
manage glycaemia on subsequent non-exercise days as glycaemic dysregulation in the time 
following exercise could offset the beneficial effects that exercise carries. Moreover, it would 
seem that when comparing post-prandial glycaemia, there are only minimal, if any differences 
between chapters 4 and 5, suggesting the influence of basal dose adjustment on acute fluctuations 
is negligible. 
6.3 Implications for ketonaemia and counter-regulatory hormones 
As hypoinsulinaemic hyperglycaemia is associated with acute increases in lipolysis and 
ketogenesis (Laffel 2000, Keller et al. 2009) manipulating insulin administration and carbohydrate 
feeding may promote ketonaemia. In support of this, chapter 3 revealed a positive association 
between increased blood glucose and NEFA, and increased blood glucose and β-hydroxybutyrate 
following reductions to rapid-acting insulin after exercise. Despite large reductions in pre-exercise 
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rapid-acting insulin dose and exposure to transient hyperglycaemia however, ketonaemia was not 
significantly elevated immediately before exercise. During exercise, patients demonstrated an 
average respiratory exchange ratio of ~0.97 which reflects the utilisation of carbohydrate as the 
predominant fuel source; low levels of lipolysis would have limited substrate availability for 
ketogenesis. As with previous literature, β-hydroxybutyrate was not significantly increased over 
the course of the post-exercise period (Bracken et al. 2011). Following the post-exercise meal, β-
hydroxybutyrate did not rise significantly under any of the interventions indicating that the 
administration of even small amounts of rapid-acting insulin was enough to maintain circulating 
concentrations to a level whereby lipolysis was inhibited, and lipogenesis increased, thus reducing 
the capacity for β-oxidation of NEFA and ultimately limiting substrate availability for ketogenesis 
(Keller et al. 2009). In chapter 5, a rested morning sample was taken on the day after exercise. 
Comparable NEFA and β-hydroxybutyrate concentrations would imply that the application of a 20 
% basal dose reduction was insufficient to significantly increase lipolysis or ketonaemia. This is 
important considering that the role of basal dose is to restrict excessive hepatic glucose output, and 
prevent ketoacidosis. Indeed, altering basal dose may be daunting for patients, especially as there 
is no experimental data pertaining to the implications of basal dose adjustment for exercise. 
However, it would seem that ketonaemia is not significantly affected despite acute alterations in 
rapid-acting insulin, diet, and now also basal dose. 
In addition, catecholamines and cortisol, the main lipolytic stimulus, remained unchanged between 
conditions across chapters. Importantly, β-hydroxybutyrate concentrations across chapters 
remained well below those levels deemed clinically significant (> 1.0 mmol.l-1) (Laffel 2000). 
Consumption of carbohydrate would have reduced the energy deficit created by exercise thereby 
limiting the appearance of catecholamines and cortisol.  
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6.4 Inflammatory cytokine responses  
Given the tight interplay between insulin, glycaemia, and inflammation, a logical extension of the 
interventions employed in this thesis was to investigate their influence on the appearance of 
inflammatory markers. Increased markers of inflammation are strongly related to glycaemic 
management and the pathogenesis of diabetes related complications (Targher et al. 2001, Fowler 
2008). All patients recruited in this thesis exhibited chronically elevated levels of inflammatory 
markers at baseline, although concentrations of IL-6 and TNF-α were typically greater than those 
previously observed (Galassetti et al. 2006, Rosa et al. 2008, 2010, Rosa et al. 2011). The majority 
of previous studies have recruited children or adolescents recently diagnosed, which differs to the 
patients in this series of studies who were older and had a longer diabetes duration. Across 
chapters, a positive relationship was observed between inflammatory cytokine concentrations and 
diabetes duration, which was inversely related to HbA1c. Therefore, concentrations reported herein 
are more likely to be reflective of an exercising adult population with type 1 diabetes. Exercise has 
the capacity to increase inflammation (Ostrowski et al. 1999, Nemet et al. 2002, Petersen and 
Pedersen 2005), which could be exacerbated under conditions of hypoinsulinaemia (Fishel et al. 
2005, Viardot et al. 2007) and hyperglycaemia (De Rekeneire et al. 2006, Devaraj et al. 2007). 
However, only modest increases in IL-6 and TNF-α were observed following exercise.  
Whereas it would seem that reductions in rapid-acting insulin alone are not sufficient to induce a 
significant increase in the inflammatory markers IL-6 and TNF-α above those at rest (chapter 3), 
these inflammatory cytokines are dramatically increased following a high GI meal (chapter 4). 
Conversely, consumption of a low GI meal completed prevented these rises. This strengthens 
current opinion that hyperglycaemia is a mediator of inflammation, but more importantly, 
normalisation of glycaemia via acute prandial adjustments in rapid-acting insulin and carbohydrate 
feeding can abate this inflammatory response. Moreover, IL-6 was supressed following a full dose 
of post-exercise rapid-acting insulin in chapter 3, which further highlights the capacity of insulin 
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to act as a potent anti-inflammatory (Viardot et al. 2007). In addition to these findings, chapter 5 
illustrates that TNF-α is not affected by a reduction in basal insulin dose when these acute 
adjustments are applied, and that IL-6 is not significantly increased from fasted, resting morning-
time concentrations. Collectively, this data would indicate that a combined basal-bolus reduction 
and post-exercise carbohydrate feeding strategy does not significantly increase the inflammatory 
markers IL-6 and TNF-α. 
6.5 Appetite responses 
The appetite responses to specific post-exercise dietary interventions in type 1 diabetes patients is 
an important consideration as excessive energy intake relative to energy expenditure can confer 
detrimental long-term implications for glycaemic control and cardiovascular risk in patients 
(Wadén et al. 2008; Salem et al. 2010). Over-consumption of carbohydrates as a compensatory 
strategy to prevent hypoglycaemia is fairly typical in type 1 diabetes patients (Dubé et al. 2014). 
However, even in those without type 1 diabetes, excessive energy intake may occur due to 
increased appetite (Kamoi et al. 2011). Thus, it was important to establish whether normalising 
glycaemia would improve or adversely affect satiety in patients. Chapter 4 revealed that 
consumption of carbohydrate based foods, match for macronutrient composition and fibre, but 
differing in GI significantly influence subjective sensations of appetite. Specifically, a high GI 
meal acutely induces greater fullness and less hunger than an otherwise equivalent low GI meal. 
Notably, these findings occurred under matched insulin administration, and similar plasma 
glucagon and GLP-1 concentrations, suggesting that ambient blood glucose concentrations play a 
large role in regulating appetite responses. Readers must consider however, that these findings are 
based on acute observations only; whereas it is possible that patients may increase calorie intake 
due to increased appetite rather than the avoidance of hypoglycaemia per se, further studies should 
be conducted to determine whether the strategies implemented within this thesis carry important 
implications for long-term weight management in this population. 
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6.6 Limitation and future directions 
Specific limitations are addressed in respective experimental chapters. The findings in this thesis 
are based upon a series of acute, relatively short-term studies, which require careful interpretation 
if translated directly into clinical practice. It is important to consider that any short-term effect of 
an intervention needs to be maintained over a longer period of time, and thus this body of work 
would benefit from longer observational studies assessing the impact of the strategies employed 
under true free-living conditions and without experimental control parameters. It is suggested that 
the recommendations generated from this thesis be advertised in-clinic and promoted to type 1 
diabetes patients with further follow-up assessment to determine whether such recommendations 
are effective within a real-world setting, and to establish whether these recommendations impact 
upon exercise participation, adherence, and improvements in glycaemic control. 
Although typical of the vast majority of applied, laboratory-based exercise studies in type 1 
diabetes (Bussau et al. 2006, Bussau et al. 2007, West et al. 2010, West et al. 2011, West et al. 
2011, Yardley et al. 2012, Davey et al. 2013, Turner et al. 2013, Yardley et al. 2013, Turner et al. 
2014, Turner et al. 2014), the sample size employed across chapters was relatively small. 
However, a power assessment revealed that the number of patients recruited in chapter 3 was 
sufficient to achieve a statistical power of 80 %, with chapters 4 and 5 achieving a statistical power 
of 73 %. In addition, this study recruited relatively young, male patients, all in excellent glycaemic 
control and who were already actively engaged in regular exercise. Caution should be taken when 
inferring results obtained from this series of studies to the wider diabetes community who may be 
older, less well controlled, less accustomed to exercise, and treated on different insulin regimens 
than those employed herein. Indeed, reduced compliance in some patients may make these 
recommendations difficult to translate and implement. A further limitation is that the strategies 
employed within this thesis are based upon one exercise model. The glycaemic, metabolic, 
hormonal and inflammatory responses in type 1 diabetes patients contrast greatly across exercise 
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modalities and intensities, and it would therefore be inappropriate to apply these findings to a 
range of different exercises. Nevertheless, these limitations should not detract from the clinical 
importance of these findings as patients and clinicians can tailor these strategies based on 
individual glycaemic responses, treatment regimens, and exercise preferences.  
It would be advantageous to follow on from this body of work by investigating wider markers of 
glycaemic control and diabetes management. Although a fairly broad ranging and comprehensive 
assessment of the deeper implications arising from these interventions was conducted, due to 
financial resources, it was only possible to measure two inflammatory cytokines, with a limited 
number of hormones and metabolites. It would be of great interest, and of potential importance, to 
determine the deeper physiological mechanisms behind these findings, with an investigation into 
liver and muscle to determine specific effects on both glucose output and storage, as well as the 
interplay between these tissues in their role for late-onset hypoglycaemia. To strengthen the 
clinical application of these strategies it would be beneficial to investigate more global 
pathological markers for cardiovascular health, such as lipoproteins, hypertension, and endothelial 
progenitor cells.  
6.7 Conclusions 
The findings in this thesis have demonstrated: 
1. Reducing the dose of rapid-acting insulin administered after exercise, whilst under 
conditions of heavily reduced pre-exercise rapid-acting insulin dose protects patients for a 
total of 8 hours after exercise. During this time, patients may experience periods of post-
prandial hyperglycaemia, but are not exposed to other metabolic, counter-regulatory 
hormonal or inflammatory disturbances. Beyond this time, risk of late-onset 
hypoglycaemia remains. This fully addresses aims 1 and 2 (section 1.10). 
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2. The composition of foods consumed after evening exercise carry important implications 
for type 1 diabetes patients. Specifically, consuming foods that elicit a low GI in the post-
exercise period, whilst employing reductions in pre- and post-exercise rapid-acting insulin, 
reduces post-prandial hyperglycaemia whilst maintaining protection from early-onset 
hypoglycaemia for a total of 8 hours after exercise. During this time, a high GI meal was 
shown to increase inflammatory markers, whereas a low GI meal completely prevented 
this rise and was not associated with any other metabolic or counter-regulatory 
disturbance. Beyond this time, risk of late-onset nocturnal hypoglycaemia remains. In 
addition, acute prandial adjustments to rapid-acting insulin and food composition carry 
implications for appetite, whereby a low GI post-exercise meal induces greater sensations 
of hunger and lower feelings of satiety early into the post-prandial period. This fully 
addresses aims 3, 4, and 5 (section 1.10). 
3. Combining acute prandial adjustments in rapid-acting insulin and food composition with a 
reduction in the amount of basal dose administered over the course of an exercise day 
offers complete protection from hypoglycaemia for a total of 24 hours after exercise. In 
addition, this strategy does not augment ketonaemia, does not raise inflammatory markers 
IL-6 and TNF-α above fasted rested concentrations, and is not associated with any other 
hormonal or metabolic disturbances. In addition, this strategy carries important 
implications for next day glycaemic control and appetite regulation. This fully addresses 
aims 6 and 7 (section 1.10). 
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Aerobic exercise (~45 
minutes of moderate-to-
vigorous intensity) 
Figure 6.0. Schematic of recommended course of action for preventing exercise-induced hypoglycaemia. 
Breakfast: carbohydrate-
based meal 
(1.3g.carbohydrate.kg-1) 
Lunch: carbohydrate-based 
meal 
(1.3g.carbohydrate.kg-1) 
60 minutes pre-exercise: 
carbohydrate-based meal 
(1.0g.carbohydrate.kg-1) 
60 minutes post-exercise: 
carbohydrate-based meal 
(1.0g.carbohydrate.kg-1) 
Reduced pre-exercise: 
rapid-acting insulin 
analogue (~25% dose) 
Reduced post-exercise 
rapid-acting insulin 
analogue (50% dose) 
Omit rapid-acting insulin 
analogue 
240 minutes post-exercise: 
carbohydrate-based bedtime 
snack (0.3g.carbohydrate.kg-1) 
Full dose of rapid-acting 
insulin analogue 
Full dose of rapid-acting 
insulin analogue 
Reduced total basal insulin 
administration (~80% dose) 
Breakfast: carbohydrate-
based meal 
(1.3g.carbohydrate.kg-1) 
Full dose of rapid-acting 
insulin analogue 
Resume normal basal 
insulin administration 
(~100% dose) 
Sleep 
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Appendix A. Local National Health Service Ethics Committee favourable opinion 
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Appendix A2. Chapter 4 A-C 
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Appendix A3. Chapter 5 A-B 
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Appendix A4. Written informed consent form 
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Appendix B. Assessment for impaired awareness of hypoglycaemia (Clarke et al. 1995) 
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 Appendix C. Reliability and validity of GlucoMen LX, Medtronic Ipro2 CGM, and Medtronic 
Paradigm Real Time CGM 
Sample  
MeanSD CV 
(%) 
Validity against venous blood 
1 2 3 Mean bias  SD LOA ICC r2 p value 
Glucomen LX: blood glucose    
1.3 1.3 1.2 1.30.04 5.6 
0.40.37 -0.37 – 1.06 0.723 0.701 0.625 3.2 3.2 3.1 3.20.04 2.2 7.4 7.6 7.9 7.60.18 2.8 
13.1 13.2 12.9 13.10.11 1.6 
19.2 19.4 19.9 19.50.25 1.8 
      
Glucomen LX: blood ketone     
0.3 0.4 0.3 0.30.06 17.3 
- - - - - 
0.6 0.5 0.7 0.60.10 16.7 
0.9 1.1 1.1 1.00.12 11.2 
1.4 1.2 1.3 1.30.10 7.8 
1.1 1.5 1.3 1.30.20 15.4 
      
The Medtronic IPro 2 CGM    
2.2 2.3 2.1 2.20.01 3.24 
0.30.59 -0.85 – 1.47 0.802 0.801 0.401 5.9 5.8 6.2 6.00.01 5.00 9.9 10.2 10.2 10.10.01 2.72 
14.1 14.3 14.2 14.20.01 1.79 
19.0 19.2 19.3 19.20.1 1.12 
 
   
The Medtronic Paradigm Veo Real Time    
1.33 1.27 1.25 1.90.00 4.5 
0.230.60 -0.93 – 1.39 0.822 0.788 0.567 14.70 14.32 14.92 4.20.01 3.5 17.01 16.96 16.67 8.40.01 1.7 
20.09 20.46 19.76 14.90.3 0.7 
24.46 24.17 23.92 22.00.01 0.8 
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Appendix D. Patient dietary and insulin administration recording record 
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Appendix E. Reliability of the Omron pedometer: Quantification of pre-and post-
laboratory activity levels 
Trial Unit 1 Unit 2 Unit 3 
1 100 101 102 
2 100 102 102 
3 101 101 101 
4 101 101 101 
5 100 100 100 
6 100 100 101 
7 101 101 100 
8 101 102 101 
9 101 100 101 
10 100 100 101 
Mean  SEM 100.50.17 100.80.25 101.00.21 
CV (%) 0.52 0.78 0.66 
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Appendix F. Blood glucose reliability testing  
Sample 
MeanSEM 
(mmol.l-1) 
CV (%) 
1 2 3 
1.33 1.27 1.25 1.280.02 3.24 
2.34 2.36 2.27 2.320.03 2.03 
3.20 3.01 2.90 3.040.09 5.00 
4.35 4.12 4.23 4.230.07 2.72 
7.04 7.14 6.89 7.020.07 1.79 
9.68 9.52 9.41 9.540.08 1.42 
11.78 11.60 11.89 11.760.08 1.25 
12.23 12.01 12.45 12.230.13 1.80 
14.70 14.32 14.92 14.650.18 2.07 
17.01 16.96 16.67 16.880.11 1.09 
20.09 20.46 19.76 20.100.20 1.74 
24.46 24.17 23.92 24.180.16 1.12 
Note: Samples were taken from venous whole blood of a male Type 1 Diabetes patient during 
experimental protocol. 
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Appendix G. Blood lactate reliability testing  
Sample 
MeanSEM 
(mmol.l-1) 
CV (%) 
1 2 3 
0.65 0.6 0.59 0.610.02 5.24 
1.54 1.42 1.39 1.450.05 5.47 
2.87 2.85 2.61 2.780.08 5.21 
3.32 3.26 3.22 3.270.03 1.54 
4.01 3.99 3.95 3.980.02 0.77 
4.89 4.84 4.88 4.870.03 0.54 
5.43 5.32 5.35 5.370.03 1.06 
6.01 6.35 5.96 6.110.12 3.48 
6.74 6.53 6.59 6.620.06 1.63 
7.43 7.54 7.42 7.420.04 0.89 
8.67 8.59 8.49 8.580.05 1.05 
9.01 9 8.91 8.970.03 0.61 
Note: Samples were taken from venous whole blood of a male Type 1 Diabetes patient during 
experimental protocol. 
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Appendix H. Calculation of plasma volume shifts 
Blood volume (BV) 
  BVa = 100% 
  BVb = BVa * (haemoglobinb / haemoglobin
a) 
Red cell volume (CV) 
  CVa = BV
a
 * (haematocrit
a
 / 100) 
  CVb = BVa * (haemotcritb / 100) 
Plasma volume (PV) 
  PVa = BVa – CVa 
  PVb = AVb – CVa 
Percentage changes 
  BV % change = 100 * (BVb – BVa) / BVb 
CV % change = 100 * (CVb – CVa) / CVb 
PV % change = 100 * (PVb – PVa) / PVb 
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Appendix I. Summary of assays used for the quantification of hormones, metabolites and cytokines across studies 
Analyte Sample Method Product no. Product name Manufacturer Sensitivity Intra-assay 
reliability (%) 
Insulin Serum Quantitative sandwich 
enzyme immunoassay 
IV2-001 / 101 Invitron Invitron Ltd, 
Monmouth, UK 
0.35 mU/l 7.7% 
Glucagon Plasma Competitive Enzyme 
Immunoassay 
RAB0202 Glucagon EIA Sigma Aldrich, MD, 
USA 
0.97 pg/ml 7.2% 
Adrenaline Plasma Quantitative sandwich 
enzyme immunoassay 
RE59242 CatCombi IBL, Europe Ltd 10 pg/ml 7.1% 
Noradrenline Plasma Quantitative sandwich 
enzyme immunoassay 
RE59242 CatCombi IBL, Europe Ltd 20 pg/ml 7.4% 
Cortisol Serum Quantitative sandwich 
enzyme immunoassay 
KGE008, 
SKGE008, 
PKGE008 
Paramter Cortisol Assay R&D Systems, 
Minneapolis, USA 
0.071 
ng/ml 
6.3% 
NEFA Serum Enzymatic colourimetric 
assay 
FA115 Randox NEFA Randox Laboratories, 
UK 
0.01 
mmol.l 
1.7% 
Β-hydroxybutyrate Serum Enzymatic colourimetric 
assay 
RB1007 Randox Ǻ-hydroxybutyrate Randox Laboratories, 
UK 
0.07 
mmol.l 
1.7% 
IL-6 Plasma Quantitative sandwich 
enzyme immunoassay 
HS600B, SS600B, 
PHS600B 
Quantikine HS ELISA 
Human IL-6 Immunoassay 
R&D Systems, 
Minneapolis, USA 
1.6 pg/ml 4.9% 
TNF-α Plasma Quantitative sandwich 
enzyme immunoassay 
DTA00C, 
STA00C, 
PDTA0C 
Quantikine ELISA Human 
TNF-α Immunoassay 
R&D Systems, 
Minneapolis, USA 
1.6 pg/ml 4.9% 
GLP-1 Total Plasma Quantitative sandwich 
enzyme immunoassay 
RE53131 Glucagon-Like Peptide-1 
total Elisa 
IBL International, 
Hamburg, Germany 
0.6 pmol.l 7.7% 
Note: Sensitivity and intra-assay reliability derived from manufacturers information 
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Appendix J. Calculation and conversion of analyte concentrations 
Glucagon C153H225N43O349S 
C = 12.0107 x 153 = 1837.6371 (g.mol) 
H = 1.0794    x 225 = 226.7865 (g.mol) 
N = 14.0067 x 43 = 602.288 (g.mol) 
O = 15.9994  x 349 = 783.9706 (g.mol) 
S = 32.0655 x 1  = 32.0655 (g.mol) 
       + 
  =  3482.748    (g.mol) *    sample value = pg.ml 
 
Adrenaline C9H13NO3  
 C = 12.0107 x 9 = 108.0963 (g.mol) 
H = 1.0794    x13 = 13.1032 (g.mol) 
N = 14.0067 x 1 = 14.0067 (g.mol) 
O = 15.9994  x 3 = 47.9982 (g.mol) 
       + 
  = 183.2044    (g.mol) /     ((pg.ml) /1000) = nmol.l 
 
 
Noradrenaline C8H11NO3 
C = 12.0107 x 8 = 96.0856 (g.mol) 
H = 1.0794    x11 = 11.0873 (g.mol) 
N = 14.0067 x 1 = 14.0067 (g.mol) 
O = 15.9994 x 3 = 47.9982 (g.mol) 
       + 
  = 169.1778    (g.mol) /    ((pg.ml) /1000) = nmol.l 
 
 
Cortisol C21H30NO5 
C = 12.0107 x 21 = 252.2247 (g.mol) 
H = 1.0794    x 30 = 30.2382 (g.mol) 
O = 15.9994 x 5 = 79.9970 (g.mol) 
       + 
  = 362.4599    (g.mol) /    ((pg.ml) /1000) = nmol.l 
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Appendix K. Visual Analogue Scales (VAS) 
Appetite Visual Analogue Scale 
Time point 1: 
How hungry do you feel? 
 
 
How satisfied do you feel? 
 
 
 
 
I have never felt so hungry I have never felt so full 
I feel completely empty I cannot eat another bite 
